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ABSTRACT OF THESIS 
The chronic treatment of patients with a β-adrenoceptor antagonist is associated with 
prolongation of the atrial cell action potential duration (APD), potentially contributing to 
the ability of these drugs to prevent atrial fibrillation (AF).  The mechanisms underlying 
this APD prolongation are not fully understood but may involve pharmacological 
remodelling of atrial K+ currents and underlying ion channel subunits.  This project aimed 
to test the hypothesis that various characteristics of human atrial K+ currents, including 
voltage, time and rate dependency, differ between patients treated and not treated with a β-
blocker as a result of altered expression of ion channel pore-forming and accessory 
subunits.  
 
Human atrial myocytes were isolated enzymatically from right atrial appendage tissue 
obtained from consenting patients, in sinus rhythm, undergoing cardiac surgery.  Using 
whole cell patch clamping, K+ currents were recorded at physiological temperature.  
Treatment of patients with β-blockers for a minimum of 4 weeks duration was associated 
with a significant, 34% reduction in the transient outward K+ current (ITO) density but no 
change in the sustained outward current (IKSUS).  There was a reduction in the Ba2+-
sensitive, inwardly rectifying K+ current (IK1) but only at -120 mV and the physiological 
significance of this is unclear.  The reduction in ITO density was not secondary to changes 
in the voltage dependency of the current, as determined by Boltzmann curve fits.  There 
was no difference in the time dependent inactivation or re-activation of ITO between cells 
from non β-blocked and β-blocked patients, indicating these current characteristics were 
not contributing to β-blocker induced APD prolongation.  The density of ITO decreased 
significantly with increasing stimulation rate in cells from both patient groups but 
remained significantly reduced in β-blocked patients at all rates studied.  
 
To determine a possible mechanism underlying the reduction in ITO density, the expression 
of Kv4.3 mRNA, the pore-forming subunit responsible for this current, was compared in 
right atrial appendage tissue from non β-blocked and β-blocked patients using real-time 
RT-PCR.  mRNA levels were normalised to the expression of both 28S, a marker of total 
RNA, and the housekeeping gene GAPDH.  The levels of mRNA for the accessory 
subunits KChIP2, KChAP, Kvβ1 and 2 and Frequenin, which modify Kv4.3 expression 
and function, were also measured.  No change was found in the relative mRNA levels of 
any of these ion channel subunits in association with chronic β-blockade.  mRNA for the 
pore-forming subunits Kir 2.1 and 2.2 and Kv1.5 which are responsible for IK1 and IKSUS 
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respectively, in addition to mRNA for the pore-forming subunits underlying the L-type 
calcium current and sodium-calcium exchanger were also measured.  Again, no significant 
changes in expression were found in association with chronic β-blockade. 
 
The possibility of ion channel remodelling at a translational level was investigated by 
measuring Kv4.3 protein levels using Western blotting with a monoclonal anti-Kv4.3 
antibody.  Kv4.3 protein levels were normalised to GAPDH which was used as a loading 
control.  Chronic β-blockade did not change the ratio of the level of Kv4.3 protein relative 
to GAPDH.  
 
In conclusion, chronic treatment of patients with a β-blocker is associated with a reduction 
in atrial ITO density which may contribute to the APD prolongation reported in cells from 
these patients.  However, this cannot be explained by changes in the expression of Kv4.3 
or by changes in the expression of its regulatory accessory subunit genes.  
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CHAPTER 1 
 
GENERAL INTRODUCTION
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1.1 Cardiac electrophysiology 
1.1.1 Normal cardiac conduction 
Contraction of cardiac myocytes is triggered by electrical activity within each cell.  The 
organised spread of this electrical current through the heart allows contraction to occur in 
an effective, co-ordinated fashion, allowing the heart to efficiently pump blood around the 
body.  In the normal heart this electrical activity originates in the sinus node, a specialised 
area of spontaneously discharging cells located in the right atrium.  Electrical impulses are 
then conducted rapidly through the cardiac myocytes of both atria causing these chambers 
to contract.  These impulses reach the atrio-ventricular (AV) node which lies in the inter-
atrial septum and is usually the only site where electrical activity can be transmitted to the 
ventricles.  Electrical conduction is generally slowed through the AV node and then 
conducted rapidly again through a specialised system of fibres (the Bundle of His and 
Purkinje fibres) responsible for the spread of electrical impulses through the ventricles.  
This triggers ventricular contraction.  The spread of cardiac excitation in this fashion from 
the sinus node through the AV node to the ventricles is known as sinus rhythm (SR) (see 
figure 1-1) 
 
1.1.2  The cardiac action potential 
The cardiac action potential represents the brief fluctuation in the membrane potential, or 
voltage, of a cardiac myocyte that can spontaneously propagate as an electrical wave or 
impulse through adjacent excitable cardiac tissue. It is caused by the rapid opening and 
closing of voltage-gated ion channels and can be described in five phases which are 
illustrated in figure 1-2 (1).  
 
Phase 0 describes the initial rapid depolarisation of the cell membrane and is due to the fast 
sodium current, INa.  INa is activated at a membrane potential of -60 mV and therefore to 
initiate this current, the cell has to be partially depolarised from its resting membrane 
potential of around -90 mV.  This can be achieved by a slow intrinsic depolarising current 
in the context of pacemaker cells, by an external electrical stimulus, or by localised 
membrane currents generated by a propagating action potential.  INa is generated by the 
rapid influx of sodium ions through the open sodium channel in cell membrane and occurs 
as a result of the Na+ electrochemical gradient ie Na+ ions are attracted into the 
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Figure 1-1 The cardiac conducting system. RA = right atrium, LA = left atrium, RV = 
right ventricle, LV= left ventricle.  Adapted from images.med.cornell.edu. 
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Figure 1-2 The different phases of a human atrial action potential and the main 
contributing ion currents.  See text for further details.  Based on data (2) 
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cell because of the low intracellular Na+ concentration and negatively charged intracellular 
environment.  This depolarises the cell further and also causes more sodium channels to 
open.  The cell membrane potential, therefore, increases rapidly towards the sodium 
equilibrium potential (ENa) at which point the Na+ have equilibrated between the inside and 
outside of the cell and there is no further Na+ flux.  The upstroke of the action potential 
does not fully reach the ENa, however, because of the rapid inactivation of the sodium 
channels and the opposing influence of repolarising currents which are activated by the 
rising membrane potential.  In human atrial cells the upstroke of the action potential can 
depolarise the cells to around + 20 mV.   
 
Phase 1 of the action potential, the first stage of repolarisation preceding the plateau of the 
action potential, is largely due to the transient outward potassium current ITO.  This current 
is activated during the upstroke of the action potential and, once open, allows the efflux of 
K+ along the newly generated electrical gradient in which the inside of the cell has become 
positively charged relative to the extracellular environment.  The normally high 
concentration of intracellular K+ also helps to drive the outward flow of K+ and with this 
current repolarisation is initiated.  
 
During the plateau of the action potential, known as phase 2 repolarisation, the 
contribution of outward currents to repolarisation are balanced mainly by the inwardly 
directed L-type calcium current, ICaL.  This current is activated during membrane 
depolarisation but is much slower than INa, hence its main effects are not realised until later 
in the action potential.  It is the influx of Ca2+ during phase 2 repolarisation that triggers 
calcium release from the sarcoplasmic reticulum within the cell and activation of 
contractile proteins.  Counteracting the depolarising effects of ICaL is the delayed rectifying 
potassium current, IK.  This is not a single current but three distinct currents.  IKS, the slow 
delayed rectifier, activates very slowly following cell depolarisation and also inactivates 
slowly.  IKR, the rapid delayed rectifier, has more rapid kinetics and IKUR, the ultra-rapid 
delayed rectifier is activated extremely rapidly.  ITO contributes minimally to repolarisation 
during phase 2 of the action potential as the current inactivates rapidly.  
 
By phase 3 of the action potential, also known as terminal repolarisation, ICaL has 
inactivated in a time dependent fashion and the outflow of K+ due to the delayed rectifier 
currents returns the cell to its resting membrane potential.  Other currents also contribute to 
terminal repolarisation, particularly, the inwardly rectifying potassium current, IK1.  This 
current is predominantly inward at membrane potentials negative to EK or -90 mV but has 
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a small outward component at potentials more positive than this and so can contribute to 
repolarisation.   
 
Phase 4 of the action potential refers to the diastolic depolarisation that occurs in 
spontaneously discharging pacemaker cells but in atrial and ventricular cells the membrane 
potential usually remains stable during cardiac relaxation or diastole at around -80 to -90 
mV.  This resting membrane potential sits close to the EK and reflects the high intracellular 
concentration of K+ relative to extracellular fluid along with an equal and opposite 
distribution of electrical charge.  This is mainly determined by IK1 and the constitutively 
active Na-K pump which helps to maintain the high levels of intracellular K+ by pumping 
out Na+ in exchange for K+. 
 
1.2 Atrial fibrillation  
Atrial fibrillation (AF) is the most common disorder of cardiac rhythm and is characterised 
by rapid and chaotic activation of the atria.  This results in failure of co-ordinated atrial 
contraction predisposing to the formation of intra-atrial thrombus and embolic stroke.  
Rapid conduction through the AV node results in a rapid ventricular rate which, along with 
the loss of the contribution of atrial contraction to ventricular filling, can result in cardiac 
failure.  The morbidity and mortality associated with AF is considerable with the mortality 
rate of patients with AF approximately double that of patients in normal sinus rhythm (3).  
An estimated 4.5 million people in the European Union (EU) have paroxysmal or 
persistent AF making AF an extremely expensive public health problem costing the EU 
approximately €13.5 billion per year (3). 
 
There are numerous patient factors that predispose to, or are associated with, the 
development of AF but by far the most common are other co-existing heart diseases.  
These include ischaemic, hypertensive, congenital and valvular heart disease, particularly 
involving the mitral valve.  Heart failure can be both a consequence of, and risk factor for, 
AF.  Other risk factors or precipitating causes include drugs, sepsis, endocrine disorders, 
changes in autonomic tone, and genetic factors.  Age is another major risk factor with 8% 
of people over 80 years having AF compared to 0.4-1% of the general population (3).  This 
may reflect the increasing prevalence of other risk factors with age especially cardiac 
disease but probably also reflects age-related atrial fibrosis which is thought to be another 
important predisposing factor to the development of AF.  As the population ages the 
burden of AF is only likely to increase. 
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1.2.1  Basic mechanisms underlying AF 
The basis of the abnormal electrical activity and conduction that underlies the initiation 
and maintenance of AF is complex and not fully understood.  Re-entry and abnormal focal 
activity or ectopics are two key concepts in proposed mechanistic models of AF.   
 
Re-entry describes the situation where abnormal, potentially self perpetuating, circuits of 
electrical activity occur across different zones of tissue.  After depolarisation or phase 0 of 
the action potential, the sodium channels remain inactivated and are unable to be opened 
again until the cell repolarises to around -60 mV.  This time period, from the upstroke of 
the action potential until another action potential can fire, is called the refractory period.  If 
an electrical impulse arrives in an area of tissue which is still refractory it will not be 
conducted through that area but may find an alternative adjacent pathway through non-
refractory tissue.  If this electrical impulse arrives back at the refractory area once it has 
recovered, the impulse will be conducted and may then continue to conduct around this 
“re-entrant circuit”.  Re-entry can occur as a result of a single circuit producing regular 
rapid firing or due to multiple, unstable, co-existing circuits or waves which can produce 
more irregular activity.  The likelihood of re-entry occurring is determined by the 
conduction velocity and the duration of the refractory period which together define the 
wavelength or distance travelled by one electrical impulse in one refractory period.  Short 
refractory periods and hence short wavelengths promote re-entry (1;4).   
 
Re-entrant activity is thought to be important in the generation and maintenance of atrial 
fibrillation and several different models have been proposed.  It has been suggested that 
AF may be caused by a single, rapidly firing, re-entrant circuit which generates irregular 
activity due to variations in conduction of the electrical impulses through the rest of the 
atria.  Another theory is that AF is due to multiple independent re-entrant wavelets which 
travel in a randomly distributed fashion through the atria with some colliding and dying out 
while others self perpetuate and spawn daughter waves.  Re-entrant waves can take the 
form of spirals or rotors in which the maintenance of re-entry is dependent on the curvature 
of the spiral wavefront (4-6). 
 
Re-entrant circuits may be triggered by spontaneously active ectopic foci of electrical 
activity.  These can occur in non pacemaker cells if the normal balance of ion currents is 
disrupted, resulting in diastolic depolarisation of the membrane potential sufficient to 
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trigger sodium channels to open and cause a premature action potential to fire.  Ectopic 
foci can be triggered by large after-depolarisations which can occur in calcium overloaded 
cells.  They are caused by sodium-calcium exchanger (NCX) which generates a net inward 
current as it extrudes the excess free intracellular Ca2+ in exchange for Na+.  It has been 
suggested that AF may be caused by one or more continuously active, rapidly discharging, 
ectopic foci which may then be conducted in a non uniform fashion through the atria to 
produce the characteristic fibrillatory rhythm.  It is also possible that the arrhythmia may 
be triggered by an ectopic focus or foci leading to single or multiple re-entrant circuits 
which then maintain the arrhythmia (4-6).  Some of these ectopic foci originate in and 
around the pulmonary veins which drain into the left atrium. 
 
It is likely that all of these mechanisms play some role in the initiation and maintenance of 
AF and hence it is possible to take several different approaches when treating this 
arrhythmia.  Targeting ectopic foci and single re-entrant circuits by catheter ablation has 
proven to be one successful treatment strategy.  Another is to use anti-arrhythmic drugs to 
prolong the refractory period, which limits the number of functionally re-entrant circuits 
that can be maintained, so preventing the AF from being sustained.  
 
1.2.2 AF and electrophysiological remodelling  
Regardless of the mechanisms underlying the initiation of AF and the mode of electrical 
conduction, one key finding in both clinical and experimental models is that AF tends to 
become more persistent with time.  In the classic goat model of AF induced by rapid atrial 
pacing, the duration of AF determines the ability to restore and maintain normal sinus 
rhythm – “AF begets AF” (7).  In this model and others, a number of electrical and 
structural changes occur following initiation of AF that are thought to contribute to the 
perpetuation of the arrhythmia.  These processes have been termed electrical and structural 
remodelling (4;8). 
 
The electrical adaptations that occur in AF affect repolarisation at both a tissue and cellular 
level.  AF has been shown to cause shortening of the atrial action potential duration (APD) 
and effective refractory period (ERP).  It also results in an increased spatial heterogeneity 
of repolarisation and loss of rate adaptation (2;7;8).  Shortening of the APD and ERP 
shortens the minimum wavelength for re-entry thus promoting the occurrence and 
maintenance of multiple re-entrant circuits.  Underlying this shortening in APD and ERP 
are changes in ion currents which influence repolarisation (8).   Studies on isolated human 
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atrial myocytes have shown reductions ITO, ICaL and IKUR and an increaseIK1.  The net effect 
of these current changes is APD shortening largely mediated through reduction in ICaL and 
increase in IK1.    
 
Other electrical changes that occur with AF include changes in the proteins that contribute 
to gap junction formation and facilitate the passage of electrical activity from one myocyte 
to the next.  These proteins are called connexins and several studies have shown 
alternations in connexin expression along with changes in the pattern of their distribution 
(14;15). 
 
In addition to the electrical remodelling that occurs in AF, structural remodelling also 
occurs at both a cellular and organ level.  AF can result in the loss of contractile proteins, 
myocyte death, atrial fibrosis and dilatation (4;16).  These changes are likely to increase 
the heterogeneity of atrial refractoriness thus promoting re-entry, as well as impairing atrial 
contractile function. 
 
1.2.3 Current treatment of AF  
There are currently two main strategies used in the treatment of AF (3;17).  The first is to 
allow the continuation of the arrhythmia but to try to minimise the associated 
complications by controlling the ventricular rate and anti-coagulating the patient to prevent 
thromboembolism.  The second is to try to restore and maintain sinus rhythm.  This can be 
achieved using either electrical or pharmacological cardioversion followed by drugs which 
either prolong the refractory period (class III anti-arrhythmic drugs) or block Na+ channels 
(class I anti-arrhythmic drugs).  Another possible strategy for preventing the recurrence of 
AF is to burn or ablate any sites of ectopic foci which may be triggering the arrhythmia.  
These often occur around the origin of the pulmonary veins.  Pulmonary vein ablation can 
also be accompanied by further catheter-based ablation therapy to disrupt possible 
pathways of abnormal electrical activity through the atria.   
 
Recent large clinical studies have compared these “rate versus rhythm control” strategies 
and have found that, for many patients, remaining in AF is not an inferior treatment option 
if they are appropriately managed (18).  There are, however, a number of patients for 
whom a rhythm control strategy is preferable.  The major problem for these patients is that 
both the invasive and pharmacological treatments are not always effective and have the 
potential for significant complications or side effects.  One particular problem with some 
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of the anti-arrhythmic drugs used in the prevention of AF is that they can cause potentially 
lethal ventricular arrhythmias. 
 
1.2.4 β-blockers in AF 
Recent guidelines for the management of AF have given β-adrenergic receptor antagonists 
(β-blockers) a prominent role as anti-arrhythmic therapy for the prevention of AF (3;17).  
Traditionally β-blockers have been used to control the ventricular rate in patients with AF 
but there is increasing evidence that they can be effective in preventing the recurrence of 
AF once sinus rhythm is restored.  One of the major advantages of β-blockers over many 
other anti-arrhythmic agents is that they do not have the same dangerous pro-arrhythmic 
side effects. 
 
β-blockers are drugs that bind selectively to β-adrenoceptors (β-ARs) and competitively 
and reversibly inhibit the effects of β-adrenergic stimulation by endogenous or exogenous 
catecholamines.  Stimulation of β-ARs in the heart principally results in an increased heart 
rate, increased conduction velocity through the conducting system and increased 
contractility.  However, the effects of β-adrenergic stimulation on the heart and the rest of 
the cardiovascular system are complex and diverse and blocking these receptors has many 
potential effects.  β-blockers are used to treat a variety of cardiovascular pathologies in 
addition to arrhythmias, including ischaemic heart disease, heart failure and hypertension.  
Many of these conditions are themselves risk factors for AF.   
 
1.2.4.1 Classification of β-blockers 
β-blockers can be categorised into non-selective and selective blockers according to their 
ability to block both the two main cardiac β-ARs: β-AR1 and β-AR2.  Atenolol, bisoprolol, 
and metoprolol are all examples of β1-selective β-blockers.  Some β-blockers can also 
block α-adrenergic receptors e.g. carvedilol, while some have both weak agonist and 
antagonistic actions.  In addition to its non-selective, β-blocking activity, sotalol is noted to 
be an atypical β-blocker with well recognised class III, anti-arrhythmic effects, making it 
useful in the prevention of AF but limiting its uses in other cardiac diseases which benefit 
from “conventional” β-blockers. 
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1.2.4.2 Clinical evidence for an anti-arrhythmic action of β-blockers in AF 
Several randomised controlled trials have demonstrated a modest benefit of β-blockers in 
maintaining sinus rhythm after electrical cardioversion of atrial fibrillation (19).  
Metoprolol has been shown to be more effective than placebo in maintaining sinus rhythm 
following electrical cardioversion of persistent AF with recurrence rates of 48.7% vs 
59.9%, p<0.05 (20).  Treatment with bisoprolol following electrical cardioversion of 
persistent AF has been shown to be as effective as sotalol at maintaining sinus rhythm at 
one year (21).  In an open label, randomised, cross over study, atenolol was shown to be as 
effective as sotalol in reducing the frequency of paroxysmal AF (22).  β-blockers have also 
been shown to be effective at preventing AF after cardiac surgery (23). 
 
Heart failure is both a risk factor for, and consequence of, AF and indeed patients with 
heart failure and AF have a worse prognostic outcome (24).  Several studies examining the 
potential prognostic benefits of β-blockers in the treatment of heart failure have reported a 
reduction in the incidence of AF in patients receiving either carvedilol or metoprolol when 
compared to placebo and standard optimal medical therapy (25;26)  
 
1.2.4.3 Possible anti-arrhythmic mechanisms of β -blockers: pharmacological 
remodelling 
The mechanisms by which β-blockers exert their anti-arrhythmic effects are not fully 
understood and are likely to be multifactorial.  Different mechanisms may be more 
important in different clinical situations.  Undoubtedly, blocking excess sympathetic 
activity and endogenous catecholamines is a major contributing factor.  Excessive 
stimulation of the adrenergic system is known to cause shortening of refractory periods 
which can promote re-entry, as well as increasing the dispersion of repolarisation and 
increasing automaticity (27).  These drugs also help prevent cardiac ischaemia and 
improve left ventricular function both of which are likely to contribute to their anti-
arrhythmic activity.  However there is some evidence that β-blockers may have a direct 
anti-arrhythmic action rather than just preventing the deleterious effects of factors like 
ischaemia, cardiac failure and adrenergic over-stimulation. 
There are two studies which have shown potentially anti-arrhythmic, adaptive changes in 
atrial electrophysiology associated with chronic administration of β-blockers, given over a 
period of weeks to months (28;29).  The first study treated rabbits with propranolol, 
metoprolol or placebo for various periods of time up to 6 weeks (28).  After waiting for 
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approximately 24 hours after the last drug dose, to ensure elimination of the drug, the 
rabbit hearts underwent electrophysiological studies and those treated with β-blockers were 
shown to have prolonged repolarisation in both the atria and ventricles, as evidenced by 
prolonged APDs measured in whole tissue preparations.  The animals also had prolonged 
QT intervals on ECGs, a marker of the duration of ventricular repolarisation.  These 
changes were thought to be an adaptive response to the β-blockers which took almost 10 
days to develop and persisted for more than 10 days after cessation of therapy.  A more 
recent study examined the effects of chronic β-blockade with β1-selective blockers on 
isolated human atrial myocytes (29).  This was a retrospective analysis of ion current and 
action potential recordings from right atrial appendage tissue obtained from patients 
undergoing cardiac surgery.  It reported an increase in both atrial APD and ERP in cells 
from patients treated with β-blockers.  This effect was thought to occur in the absence of 
the drug which was presumed to be removed by the cell isolation process.  This adaptive 
and potentially anti-arrhythmic effect was termed “pharmacological remodelling”.  This 
effect has yet to be confirmed in a prospective study of chronic β-blockade and human 
atrial electrophysiology.  
1.2.4.4 How does chronic β-blockade prolong the APD? 
As described in section 1.1.2, the duration of the cardiac action potential is determined by 
the balance of inward and outward ion currents.  It is likely therefore that the mechanisms 
underlying the APD prolongation described in the two studies above involve changes in 
these ion currents.  The mechanism by which chronic treatment with β-blockers prolonged 
the rabbit atrial APD was not investigated in that study (28).  It was noted that the action 
potentials had a higher plateau and longer phase 2 which might suggest changes in the ion 
currents are responsible for early repolarisation however, ion currents were not measured.  
In the isolated human atrial myocytes, APD and ERP prolongation were associated with a 
reduction in ITO current density, a possible increase in IK1 but no change in ICaL or IKUR 
current densities (29).  These changes were measured in a relatively small group of patients 
and investigation of the currents was limited to measuring their magnitude.  This was the 
first report of chronic β-blocker therapy affecting ion currents.  The lack of effect on ICaL 
current density has subsequently been reported in another study by the same group (30)   
Given the widespread use of β-blockers it is important to fully understand any 
electrophysiological effects they may have.  If these effects further our understanding of 
the anti-arrhythmic activity of β-blockers it may allow us to expand their use or even help 
in the development of new anti-arrhythmic drugs for AF.  
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1.3 Potassium currents 
1.3.1 ITO  
The transient outward potassium current, ITO, was first described in Purkinje fibres as a 
rapidly activating and inactivating outward current (31;32).  It was identified as having two 
components.  ITO1 is a K+ current, which is not dependent on the presence of calcium for its 
activation and can be blocked by relatively high doses of the drug 4-aminopyridine (4-AP).  
ITO2 is now thought to be a Cl- current which is calcium dependent and is insensitive to 4-
AP (31;31-33).  In this thesis “ITO” is used to refer to the K+  selective ITO1. 
One of the original descriptions of ITO in isolated human atrial cells did describe the 
presence of two outward currents.  One of these was a rapidly activating, rapidly 
inactivating current which was relatively insensitive to 4-AP (at 3mM), was inhibited by 
barium, but was not calcium dependent (34).  Despite its relative insensitivity to 4-AP, 
which was not explored at higher doses, it is likely this current was indeed ITO1.  The slow 
inactivation of the second outward current, along with its sensitivity to 4-AP, suggests this 
current may actually have been the ultra-rapid delayed rectifier current IKUR which is 
discussed in more detail later in this chapter.  Other descriptions of the outward currents in  
atrial myocytes have also identified at least two outward potassium currents, one current 
consistent with ITO, an IKUR-like current and, in one study, a background, uncharacterised, 
non inactivating current which was not chloride based (35;36).  Therefore, in human atrial 
myocytes, and also in ventricular myocytes, there is only one ITO current.  In contrast to 
human studies, different types of ITO do seem to exist in animal models in addition to 
delayed rectifier currents.  Some animals seem to possess two types of rapidly activating 
potassium currents with similar sensitivities to 4-AP but with different inactivation 
kinetics.  The current which inactivates rapidly is called ITOf and has the same, or very 
similar, characteristics to human ITO.  The more slowly inactivating ITOs, present in rabbit 
atria and the ventricles of other rodents, has no human correlate and is thought to be due to 
the expression of different ion conducting proteins in the membrane of the myocytes (see 
section 1.4.1). 
ITO has been characterised in several different species but it is the properties of this current 
in humans and, particularly, in human atrial myocytes, that are of most interest in this 
study.  Human atrial ITO is a relatively large current that activates extremely rapidly at 
physiological temperatures, reaching maximal current in less than five milliseconds 
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although its activation is slowed considerably at room temperature (37).  It activates in a 
voltage dependent fashion with minimal activation at negative potentials and continues to 
activate as the cell membrane potential becomes more positive.  The inactivation of ITO is 
time and temperature dependent and the current characteristically inactivates rapidly.  
Following inactivation and a return to negative membrane potentials, ITO can be rapidly 
reactivated (35;36;38;39). 
ITO is also present in the human ventricle but the current characteristics are not identical 
(35).  The density of ventricular ITO varies across the transmural surface of the left 
ventricle being larger in epicardial and midmyocardial cells than in endocardial cells 
(40;41).  Ventricular ITO has been reported as being of a similar size to atrial ITO but this is 
clearly dependent on the type of ventricular cells studied and also the presence of other 
factors such as heart failure which can affect ITO density (35;42).  Ventricular ITO has been 
reported to have slightly different kinetics to atrial ITO with both longer and shorter 
inactivation reported along with a quicker recovery from inactivation (35;42).  Ventricular 
ITO is also reported to be more sensitive to 4-AP block (35).  Again, it is possible that these 
changes may reflect the differences between subpopulations of ventricular cells rather than 
real differences between ventricular and atrial cells.   
Following membrane depolarisation, ITO is activated along with several other ion currents 
including INa, ICaL and IKUR.  In order to study the properties of ITO in isolated atrial 
myocytes it has to be separated from these other ion currents.  This can be done by 
exploiting the different activation and inactivation properties of these other currents as well 
as using specific drugs and chemicals to block specific ion currents.  As described earlier, 
one of the characteristics of ITO is that it can be blocked by 4-AP.  Relatively high 
concentrations of 4-AP, in the region of 10 mM, are required to completely block ITO, 
however, IKUR is blocked by 4-AP at much lower concentrations.  Low dose 4-AP has been 
used to isolate ITO from IKUR although the rapid activation of ITO compared to IKUR can also 
be used to separate the currents when they are measured using voltage clamp experiments. 
1.3.1.1 The role of ITO in determining the action potential duration. 
The rapid activation and inactivation of ITO means it can only contribute directly to the 
early phase of action potential repolarisation.  A reduction in the magnitude, or current 
density, of ITO should, therefore, prolong phase 1 repolarisation.  Other changes in the 
properties of ITO could also directly affect early repolarisation.  The current density could 
be affected by a change in the voltage dependency of the current.  A change in the 
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inactivation kinetics will influence the “amount” of current available to contribute to early 
repolarisation.  The rapid reactivation or recovery of ITO implies its contribution to 
repolarisation is relatively independent of stimulation rate or heart rate.  However, this may 
not be the case at the very rapid atrial rates seen in AF when changes in the reactivation 
kinetics of ITO may have the potential to significantly impact on early repolarisation. 
However, changes in early repolarisation do not necessarily alter the overall action 
potential duration.  An early study looking at the effects of 4-AP on the action potential in 
isolated human atrial myocytes showed that, at a dose of 0.5 mM, the plateau of phase 2 
repolarisation was elevated suggesting a reduction in the currents underlying phase 1 
repolarisation ie the yet uncharacterised ITO (43).  This change was associated with a 
shortening of the APD measured at 90% repolarisation (APD90).  At this dose, 4-AP would 
be expected to reduce ITO by less than 50% but significantly reduce the yet unidentified 
IKUR (33).  This in turn might be expected to prolong the APD90 and suggests that the 
interaction of currents in determining the APD is complex.  A subsequent study also 
reported that 0.5 mM 4-AP appeared to block initial repolarisation with elevation of the 
plateau height, prolonging early repolarisation but, in this case, shortening the APD90 (39).  
In isolated atrial and ventricular cells, higher doses of 4-AP, which would be expected to 
produce greater ITO block, have been shown to prolong the APD90 in addition to elevating 
the plateau (2;44).  
 
It would appear that the consequences of ITO block on APD are complex, particularly, with 
a non-specific blocker like 4-AP.  There are no specific blockers of ITO in clinical use.  
Various anti-arrhythmic drugs including quinidine, propafenone and flecainide have been 
shown to block ITO and do result in prolongation of atrial APD and atrial refractoriness. 
However, these drugs have multiple effects on different ion channels and it cannot be 
assumed that it is the ITO block which is responsible for the prolonged atrial repolarisation. 
(33;45).  Recently, several new blockers of ITO have been identified from the toxins of 
venomous creatures including scorpions, spiders, snakes and sea anemones (46).  These 
toxins can block the cell membrane proteins that are responsible for conducting ITO and 
have been used to study this current in cell lines.  There is limited evidence of the effects 
of these blockers in isolated cardiac myocytes.  The venom of the Malaysian Heteropoda 
venatoria spider contains heterpodotoxins (HpTx) which have been shown to block ITO in 
isolated rat ventricular myocytes in a voltage dependent manner.  HpTxs have been shown 
to shift the voltage dependence of ITO activation and inactivation, slow the time to peak 
activation and slow the time constant of inactivation.  They also prolong the ventricular 
APD90 providing further support for the role of ITO in determining APD (47).  The 
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phrixotoxins (PaTx) were isolated from the venom of the Chile fire tarantula Phrixotrichus 
auratus and have been shown to be specific blockers of ITO.  They also affect the voltage 
dependency of the current and kinetics of activation and inactivation.  When PaTx1 was 
injected into mice there was a significant increase in QT interval, a marker of ventricular 
repolarisation on the ECG (48).  Neither of these toxins has been used in human cardiac 
myocytes to investigate the link between ITO reduction and APD prolongation but, as 
specific ITO blockers, they could be very useful tools for confirming the effects of changes 
in ITO on late repolarisation.   
 
Computer models have been developed to study the effects of changes in ITO density on 
APD in ventricular myocytes.  In one study, reducing ITO had no effect on APD90 (49).  In 
another study, based on canine action potentials, a increase in ITO could either increase or 
decrease the APD depending on both the baseline density and degree of change (50), an 
effect largely modulated by secondary changes in ICaL.   
 
Therefore, while a reduction in ITO current density does appear to prolong early 
repolarisation, its overall effect on APD remains debatable.  Any effects of ITO reduction 
on late repolarisation may simply represent secondary changes in other ion currents 
particularly ICaL and IKUR.  Changes in other properties of ITO may also affect early and, 
possibly indirectly, late repolarisation. 
 
1.3.1.2 ITO and APD remodelling in cardiac diseases 
Remodelling of ITO occurs in AF in association with shortening of the atrial APD.  
Consistently, studies have shown reductions in human atrial ITO current density of between 
44 and 70% in cells from patients with AF (2;9;11;51).  This reduction in ITO has also been 
reported in animal models of AF and/or atrial tachycardia (52;53).  Although this reduction 
in ITO could be consistent with shortening in APD as outlined above, there is a theoretical 
expectation, and evidence to support, ITO reduction causing prolongation of APD.  The 
contribution of ITO reduction to AF-induced, APD shortening in AF remodelling is unclear 
and probably small compared to the effects of ICaL reduction and increased IK1 (4;54) 
In contrast to AF, a reduction in ITO current density in association with a prolongation of 
the APD is seen in ventricular myocytes from patients with heart failure (41;44).  In 
general, a prolongation of APD might be expected to be anti-arrhythmic and yet there is a 
strong link between heart failure and ventricular arrhythmias.  This link may well reflect 
the many other cardiac problems associated heart failure particularly ischaemic heart 
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disease.  However, when APD prolongation is very marked or associated with altered 
dispersion of repolarisation it may well be pro-arrhythmic.  In atrial cells from patients 
with heart failure secondary to left ventricular dysfunction but with no evidence of atrial 
dilation or AF, ITO current density was reported to increase in association with shortening 
of the atrial APD (55).  Why ITO should be remodelled differently in different cardiac 
chambers is unclear but these findings may help to explain the increased incidence of AF 
in patients with heart failure.  Changes in the reactivation kinetics of ITO have also been 
reported in atrial and ventricular myocytes in these studies. 
1.3.1.3 ITO and chronic β-blockade 
As discussed earlier, there is one study that has shown that a significant reduction in 
human atrial ITO current density in association with chronic β-blockade (29).  This 
reduction in ITO was associated with prolongation of atrial APD90, ERP and slowing of 
phase 1 Vmax, the maximum velocity of the downslope of phase 1 of the action potential.  
This, therefore, provides further support for a reduction in ITO density causing prolongation 
of atrial repolarisation.  To my knowledge, this is the only study that has examined the 
effects of chronic β-blockade on ITO in human cardiac myocytes and there are no similar 
animal studies.  This report did not examine the effects of chronic β-blockade on any other 
characteristics of ITO or explore any underlying mechanisms to explain the reduction in 
current density.   
There is some additional evidence to support ITO modulation by the adrenergic system.  
The only other study looking at the effects of β-blockers on human ITO examined the 
effects of carvedilol on atrial myocytes (56).  In this study, acute application of carvedilol 
also significantly and reversibly inhibited ITO current density.  This was associated with an 
increase in the activation and inactivation kinetics as measured at room temperature but not 
with any change in voltage dependency or reactivation.  Action potentials were not 
recorded in this study and there is no description of the drugs the patients were prescribed 
prior to cardiac surgery and cell isolation.  It should be noted that carvedilol is not a β1-
selective blocker as was used in the study by Workman et al 2003.  There are no direct 
reports of the effects of either acute or chronic β-blockade on ITO in animal cardiac 
myocytes.  There is one report of the effects of propranolol treatment on transgenic mice 
with dilated cardiomyopathy which showed no change in ventricular ITO although heart 
failure itself did significantly affect ITO current density (57). 
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Further support for the ability of the adrenergic system to modify ITO and APD comes from 
a study of catecholamine depleted rats which have been shown to have reduced ventricular 
ITO current density in association with altered voltage dependency of the current and 
prolonged ventricular APD (58).  
ITO can be affected by adrenergic stimulation however, the nature of the response has not 
been fully determined.  Several studies in animals have suggested stimulation with α -
agonists reduces ITO current density (59).  There is very little data examining the effects of 
β-adrenergic stimulation on ITO.  Cultured canine myocytes have been shown to have 
reduced ITO current density compared to freshly isolated cells and this can be restored to 
normal levels with the addition of the β-adrenoceptor agonist isoproterenol (60).  Rats with 
cardiac hypertrophy secondary to treatment with isoproterenol have decreased ventricular 
ITO along with prolonged APDs but it is difficult to separate the effects of hypertrophy 
from those of direct β-adrenergic agonism in this study (61). 
1.3.2 IKI 
An inwardly rectifying current was first identified in cardiac tissue over 50 years ago in 
sheep Purkinje fibres (62).  Inward rectifiers preferentially conduct K+ inwardly rather than 
in the outward direction.  At voltages negative to EK (more negative than -90 mV) the 
resistance of the IK1 ion channel is essentially independent of voltage and the current-
voltage (IV) relationship for IK1 is a straight line, also known as an ohmic relationship.  
The conductance of the channel (the inverse of the resistance) is high at these 
hyperpolarised membrane potentials and the channel passes a large inward current.  As the 
voltage rises, however, the conductance of the channel becomes smaller and is no longer 
independent of voltage.  The IV relationship is no longer linear and the amount of outward 
current that is passed at voltages positive to EK is smaller.  The activation of IK1 depends 
on the difference between the membrane potential and EK, known as the driving force, 
rather than just the membrane potential alone.  IK1 can, therefore, be controlled by voltage 
and the extracellular K+ concentration.  It is almost time independent (62-64).  Although 
IK1 has the potential to be a much larger inward than outward current, it is the outward 
component that is of greatest physiological importance.  Normally cells are not 
hyperpolarised to voltages more negative than EK and so the inward current does not occur. 
 
The mechanism by which IK1 can switch from conducting current inwardly to outwardly 
i.e. the mechanism of inward rectification, is thought to reflect a voltage dependent 
removal of a positively charged “blocking particle” from the ion channel pore, which 
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allows K+ to be conducted out of the cell (62;64).  Intracellular divalent cations like Mg2+ 
and Ca2+ have been shown to facilitate inward rectification but do not fully replicate the 
inwardly rectifying properties of IK1 (62).  Subsequently, it was found that intracellular 
organic cations called polyamines could cause strong inward rectification similar to that 
seen with IK1 (65;66) and depletion of these cations could abolish this outward current.(67) 
 
Extracellular ions, particularly barium, have also been shown to be potent selective 
blockers of both the inward and outward components of IK1 in a voltage dependent fashion. 
(62;64)  Barium is commonly used in experimental studies to dissect out IK1 from other ion 
currents and also to test the properties of ion currents derived from over-expression of ion 
channel proteins in cell lines (37;68).  It can, however, affect other ion channels such as 
ICaL and, therefore, its effect on IK1 is not “clean” (69). 
 
1.3.2.1 The role of IK1 in determining APD. 
As described earlier, it is the outward component of IK1 that contributes to the 
repolarisation phase of the action potential.  Therefore, if this component of IK1 changes in 
size it may alter the action potential duration.  In atrial cells, both the outward and inward 
components of IK1 current density are considerably smaller than in ventricular cells and 
this helps to account for the slower phase 3 repolarisation in atrial cells (64) although it 
should be noted that the atrial APD remains shorter than the ventricular.  Application of 
barium to block IK1 has been shown to result in prolongation of cardiac APD in a canine 
ventricular wedge preparation.  There are a number of anti-arrhythmic drugs which have 
been shown to block IK1 along with multiple other ion channels and, although many of 
these drugs prolong APD, it is difficult to use them to determine the specific effects of IK1 
block on APD or the clinical consequences of changing IK1. (33).   
 
1.3.2.2 IK1 and APD remodelling in cardiac diseases 
Changes in the current density of IK1 and associated changes in cellular APD have been 
described in cardiac diseases.  Several studies have reported that IK1 is increased in isolated 
atrial cells from patients with AF (2;9;12;70).  This might be expected to increase phase 3 
repolarisation and contribute to the shortening of the APD that is seen in these cells.  It 
may also contribute to the more negative resting membrane potential reported in cells from 
AF patients (70).  The importance of IK1 in determining the APD was highlighted by a 
computer modelling study of human atrial APD remodelling in AF which suggested that 
upregulation of IK1 had a bigger role to play in APD shortening than changes in ICaL (54)  
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Animal models of AF have reported conflicting results with regards to atrial IK1, showing 
no change (52) or an increase (53).  To my knowledge, there are no studies looking at 
modification of IK1 as a treatment for AF but several studies have examined its possible 
anti-fibrillatory effects in context of ventricular fibrillation (VF) using barium, computer 
models or the selective blocker RP58866 (71-73).  Blocking IK1 may be beneficial in 
terminating or preventing VF by destabilising the high frequency rotors which are thought 
to help sustain fibrillation (64).  
 
IK1 has been reported to be altered in other animal models of cardiac disease.  A decrease 
in ventricular IK1 is reported in some animal models of myocardial infarction (74) and there 
is also a reduction in ventricular IK1 density, along with prolongation of the APD, in 
spontaneously hypertensive rats (75).  A reduction in ventricular IK1 has been reported in 
some (76;77) but not all animal models of heart failure (78). In humans, a reduction in 
ventricular IK1 has also been described in cells from patients with heart failure which also 
exhibit a prolonged APD (79).  In patients with idiopathic dilated cardiomyopathy, 
ventricular IK1 density is smaller in association with a longer APD and a lower resting 
membrane potential, when compared to patients with ischaemic cardiomyopathy (80).  
 
1.3.2.3 Potential modification of IK1 by chronic β-blockade   
There is very little evidence regarding any possible effects of chronic β-blockade on IK1.  
Workman et al 2003 showed that chronic β-blockade was associated with an increase in the 
input resistance (Ri) of isolated human atrial cells during a clamp protocol which may, in 
part, be due to a decrease in IK1(29).  Acute application of carvedilol, has been shown to 
block some K+ channels including ITO and IKR  but not IK1 in isolated rabbit cardiac 
myocytes (81;82).  Acute application of another β-blocker, tilisolol, did not affect IK1 in 
isolated guinea pig ventricular myocytes (83)  Adrenergic modulation of IK1 has been 
further supported by reports demonstrating changes in IK1 density with β-adrenergic 
stimulation.  In isolated human ventricular myocytes, application of isoproterenol, has been 
shown to reduce both the inward and outward components of IK1, an effect which was 
dependent on protein kinase A phosphorylation and reversed by the addition of the β-
blocker propranolol.  This effect was noted to be reduced in myocytes from failing hearts.  
Chronic exposure (48 hours) to isoproterenol also reduced the density of IK1 in cultured 
adult guinea pig ventricular myocytes (84).  Another study looking at sympathetic 
modulation of K+ currents used antibodies to nerve growth factor in rats to delay 
sympathetic innervation of heart and showed a reduction in IK1 density compared to hearts 
with increased sympathetic innervation (85).   
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It would appear that β-adrenergic modulation can influence IK1 density but the exact nature 
and magnitude of potential changes are unclear.  IK1 does play an important role in 
repolarisation, with a decrease in the current density being associated with an increase in 
APD.  It is also one of the currents remodelled in AF and other cardiac diseases.  It is, 
therefore, possible that a reduction in the density of IK1 may be responsible, or may 
contribute to, the prolongation of APD seen with chronic β-blockade.  However, IK1 has 
not been directly measured (by barium subtraction) in human atrial myocytes in a 
prospective study of the effects of chronic β-blockade. 
   
1.3.3 The delayed rectifiers  
The delayed rectifier currents, IK, are outward potassium currents which contribute to 
phase 3 repolarisation.  Although the name implies slow activation, the delayed rectifier 
currents are actually several distinct currents with varying activation and inactivation 
kinetics.  IK is made up of a several distinct components with varying inactivation kinetics, 
the ultra-rapid IKUR, the rapidly activating IKR and the slowly activating IKS.  The presence 
and size of these currents varies in different species and in different anatomical areas of the 
heart.   
1.3.3.1 The contribution of the delayed rectifiers to atrial action potential duration 
IKR was first detected in guinea pig ventricles (86).  It activates rapidly, albeit more slowly 
than IKUR and ITO, in a voltage dependent fashion and then inactivates rapidly as the 
membrane depolarises above 0 mV (86).  During an action potential IKR will start to 
activate but then quickly inactivate as the membrane depolarises.  It, therefore, contributes 
little, if any, current to early repolarisation.  As the membrane potential becomes more 
negative IKR can “reactivate” and therefore contribute to late repolarisation.  This 
contribution is also influenced by the time dependent aspect of its activation and, therefore, 
IKR is likely to be bigger in cells with longer APDs like ventricular cells.  In cardiac 
myocytes IKR is generally very small compared to other currents (37).  A current with 
similar, although not identical, properties to the classically described IKR has been detected 
in a sub-population of isolated human atrial myocytes in one study (87).  In this study, the 
cells with recordable IKR had different shaped action potentials with more prominent 
plateaus and a small proportion did not have ITO which is thought to be a characteristic 
feature of atrial myocytes.  In a different study, IKR was also detected in human ventricular 
cells (88).   
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IKS is a very slowly activating current which was also identified initially in guinea pig 
ventricular myocytes.  It is also voltage dependent and inactivates with different kinetics in 
different species (37).  It can be separated from IKR using specific blockers and has been 
detected in only a very small proportion of isolated human atrial cells (89). 
There are currently very few studies that have demonstrated the presence of IKR and/or IKS 
in human atrial cells.  Some studies have failed to detect either current in isolated human 
myocytes of atrial or ventricular origin (35;42) or the presence of significant numbers of 
the characteristic subpopulations of cells reported to have these currents (2;36).  It is 
possible, that these currents are very sensitive to different experimental techniques making 
them difficult to measure.  There is considerable clinical evidence to suggest these currents 
do have a significant functional role in determining human atrial APD.  Class III anti-
arrhythmic drugs like amiodarone and sotalol target IKR and IKS and, by blocking these 
channels, the drugs prolong the atrial APD and can prevent AF.  APD prolongation as a 
result of modifying IKR and IKS can have detrimental effects in the ventricle by prolonging 
the QT interval, a clinical measure of ventricular repolarisation, and predisposing to 
ventricular arrhythmias.  While APD prolongation can be beneficial in preventing re-
entrant arrhythmias, excessive prolongation or increased dispersion of repolarisation can 
be pro-arrhythmic.  
IKUR was first described in human atrial myocytes and appears to be atrial specific (90).  
This makes it an extremely interesting target for anti-arrhythmic drugs with the possibility 
of prolonging the atrial APD but avoiding ventricular arrhythmias.  IKUR activates in a 
temperature and voltage dependent fashion.  At physiological temperature its activation is 
almost instantaneous at positive membrane potentials.  It, therefore, activates at the same 
time as ITO on membrane depolarisation and, unlike the other delayed rectifiers, can 
contribute to early repolarisation.  IKUR inactivates extremely slowly and complete 
inactivation can only be appreciated in voltage clamp studies using long depolarising 
pulses.  It takes around 50 seconds for IKUR to fully inactivate and very little, if any, 
inactivation occurs during the typical duration of an action potential.  As ITO inactivates 
rapidly and the contribution of IKR and IKS are probably small, IKUR has its biggest impact 
on phase 3 repolarisation in human atrial myocytes.   
Changes in IKUR, therefore, have the potential to significantly impact on the atrial APD.  
IKUR can be difficult to study in isolation from other currents, particularly, ITO as both 
currents activate extremely rapidly upon depolarisation.  The different inactivation 
characteristics of the two currents can be exploited to isolate IKUR by using prolonged 
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depolarising pulses or partially depolarising pre-pulses to inactivate ITO.  Blockers of IKUR 
are also useful tools to help dissect out the current from others and investigate its role in 
repolarisation.  There are several blockers of IKUR which have also been shown to prolong 
atrial APD.  4-AP can be used to separate IKUR and ITO.  It blocks IKUR at low 
concentrations, with 50% block (IC50) occurring at 0.001-0.005 mM compared to an IC50 
of 1-2 mM for ITO (33;35;90).  Selective inhibition of IKUR by low dose 4-AP prolongs 
human atrial APD (90) and has also been shown to prolong atrial refractoriness in canine 
atria but, unsurprisingly, not in the ventricles (91).  IKUR is relatively insensitive to class III 
anti-arrhythmics but, along with other ion channels, can be partially blocked by other anti-
arrhythmic dugs including calcium channel blockers and class I anti-arrhythmics.  Some 
specific blockers of IKUR have been developed which have been shown to prolong atrial 
refractoriness but there is little clinical data on the efficacy of these drugs (33).  In contrast, 
a study of IKUR block in atrial trabeculae showed that low dose 4-AP shortened the APD in 
patients in sinus rhythm although it prolonged the APD in AF patients (92).  This suggests 
that the role of IKUR in determining APD is more complex in the whole heart and may 
depend on secondary changes in other ion currents.  
1.3.3.2 Remodelling of IKUR in cardiac disease 
As IKUR is an atrial specific current, its role in AF remodelling has been studied with 
interest.  Several studies have reported a reduction in the sustained outward current, IKSUS, 
and IKUR in cells from patients in AF compared to those in sinus rhythm (11;12).  IKSUS is 
the outward current measured at the end of a depolarising voltage pulse using the voltage 
clamp technique.  It is often measured as a surrogate of IKUR as it is composed mainly of 
IKUR but is possibly contaminated with other slowly inactivating outward currents.  Like 
ITO, a reduction in IKUR or IKSUS does not initially appear to be consistent with shortening of 
the atrial APD as is seen in AF.  It is probable, therefore, that changes in IKUR do not play a 
prominent role in the APD shortening in AF and other currents have a greater impact.  
Remodelling of IKUR in AF is not a consistent finding, however, with some studies 
reporting no change in this current (2;9).  Canine models of AF have also reported no 
remodelling of IKUR (52). 
There is a suggestion that IKUR may be decreased in atrial cells from patients with heart 
failure but no direct comparison has been made between patients with normal and 
abnormal left ventricular function (93). 
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1.3.3.3 Potential modification of IKUR by chronic β-blockade   
There is evidence to support adrenergic modulation of IKUR.  In isolated human atrial 
myocytes, acute β-agonist stimulation by isoproterenol increased IKUR while α-agonist 
stimulation with phenylephrine decreased it.  In dogs, a similar response was seen to β -
agonists but in this case α -agonists also increased IKUR (94).  These results would perhaps 
suggest that β-blockers might have the opposite effect and decrease IKUR which might 
explain the APD prolongation associated with chronic β-blockade.  There is very little data 
on the effects of β-blockers on IKUR.  In keeping with its known class III anti-arrhythmic 
action, sotalol does not appear to affect IKUR (95).  Acute application of carvedilol has been 
shown to reduce IKUR in isolated human atrial myocytes without affecting the voltage 
dependency of activation (56).  In contrast, chronic β-blockade with β1-selective blockers 
was not associated a change in IKSUS in a small retrospective data analysis (29).  
A decrease in IKUR current density could contribute to atrial APD prolongation.  This 
current does appear to be affected by the adrenergic system and, therefore, it is possible 
that the APD prolongation associated with chronic β-blockade could at least be partially 
explained by a decrease in IKUR current density.  At present there is limited evidence to 
suggest IKUR may not actually be involved and further work is required to clarify this. 
1.4 The structure of K+ channels 
Voltage gated ion channels carry K+ currents across the cell membrane.  These ion 
channels usually consist of pore-forming and accessory proteins.  The pore-forming 
proteins are membrane spanning proteins with a central tunnel through which ions can 
travel down their electrochemical gradients.  The structure of the pore-forming proteins 
determines the specificity of the channel for K+ and also determines the open and closing 
properties of the channel.  The accessory proteins are proteins of differing structure and 
function that can associate with the pore-forming proteins and modify their expression as 
well as altering the properties of the currents they conduct.  The different expression and 
combinations of these pore-forming and accessory proteins underlie the inter-species and 
intra-cardiac variations in ion currents.  
 
1.4.1 ITO pore-forming protein: Kv4.3  
The genes for the voltage gated potassium (Kv) pore-forming proteins were originally 
cloned from the Shaker locus in Drosophila and are divided into three homologous 
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subfamilies according to their structure: Shal, Shaw and Shab.  Similar families of pore-
forming proteins, or α-subunits, have subsequently been identified in mammals.  The 
proteins in each family are classified using the nomenclature Kvx.y where x, represents the 
subfamily and y, the number of genes within the subfamily (96;97) 
 
The Kvα-subunits are proteins consisting of six transmembrane-spanning domains (S1-6) 
with cytoplasmic amino and carboxyl termini as seen in figure 1-3 (98).  These proteins 
associate as heterozygous or homozygous tetramers to form the structure of the ion 
channel. Each protein contributes a pore-lining loop (P-loop) to form the central ion 
conducting pore.  The P-loop lies between S5 and S6 and determines the ionic specificity 
of the pore.  The voltage dependency of the channel is controlled by the positively charged 
S4 domain which moves in response to changes in the membrane potential and mediates 
channel activation.  The cytoplasmic termini play a role in channel inactivation and the 
tetramerisation domain in the amino terminus helps mediate subunit-subunit interactions.   
Domains on the cytoplasmic termini help regulate trafficking of the α-subunits to the cell 
membrane and are involved with binding to accessory proteins (96;97).  
 
Various techniques have been used to identify the pore-forming proteins responsible for 
ITO.  Several different Kvα-subunits have been cloned from mammalian cardiac tissue 
including the Shal-type genes KCND2 and 3 which encode the pore-forming proteins 
Kv4.2 and 4.3.  When these genes are expressed in cell lines they result in potassium 
currents that activate and inactivate rapidly in a voltage dependent manner, properties that 
are very suggestive of ITO.  These currents also respond in a similar fashion to ITO when 
exposed to pharmacological blocking agents like 4-AP and heteropodotoxins (96;97;99).   
 
Further support for these proteins being the pore-forming proteins for ITO has come from 
studies using genetically modified rodents.  Anti-sense oligonucleotides (AODNs) against 
Kv4.2 and 4.3 messenger ribonucleic acid (mRNA) have been used in rats to try to block 
functional expression of the genes.  They have suggested a crucial role for Kv4.2 in 
forming atrial ITO and both proteins in forming ventricular ITO, possibly by forming 
heterozygous tetramer ion channels (100;101).  Kv4.2 also seems to play an important role 
in murine ITO as indicated by the lack of ventricular ITO in transgenic mice that have had 
the Kv4.2 gene replaced by a non-functioning one.  These mice also have prolonged 
ventricular APDs and prolonged QT intervals on ECGs, further supporting the role of ITO 
in cardiac repolarisation (102).  In rat and ferret ventricles, the expression of mRNA for 
Kv4.2 varies across the ventricle wall with highest expression in the epicardium (96;103).   
This mirrors the gradient seen in ITO density.  
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Figure 1-3 Schematic representation of Kv4.3. A shows the six transmembrane domains 
S1-S6 with positively charged S4 domain and P-loop (P).  The functional ion channel with 
its tetramer structure and central pore is shown in B.   Modified (98) 
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Other Kvα-subunits can also contribute to the formation of ITO reflecting the inter-species 
variation in the characteristics of this current.  Kv1.4 is expressed in rodents, ferrets and 
rabbits and appears to mediate the slowly inactivating ITO current (ITOs) found 
predominantly in the ventricles of these species but also present in rabbit atria (97;104).  
   
In contrast to other species, only one Kvα-subunit seems to be responsible for human ITO.  
Kv4.3 mRNA is highly expressed in human brain and heart tissue and is virtually absent in 
other tissues like lung and skeletal muscle (105).  Two splice variants of Kv4.3 have been 
identified with the long variant predominantly expressed in the heart (105).  In human 
atrial cells, Kv4.3mRNA and protein are expressed at high levels but there is no Kv4.2 
expression and only Kv1.4 mRNA but not protein has been detected (104;106).  The role 
of Kv1.4 in human atrial tissue is unclear, particularly as several studies have failed to 
show the presence of ITO in human atrial myocytes (35;36).  This highlights a potential 
problem with all studies in which mRNA expression is studied, as the presence of mRNA 
does not necessarily correlate with functional protein expression.  Functional evidence for 
the role of Kv4.3 in mediating human atrial ITO is further supported by a study showing ITO 
attenuation following exposure to Kv4.3 AODNs in human atrial myocytes (104;107).  
Kv4.3 mRNA and protein, but not Kv4.2, are also expressed relatively abundantly in 
human ventricles. (97).  There are conflicting reports as to whether Kv4.3 expression 
varies across the ventricle wall and therefore could be responsible for the transmural 
gradient in ITO current density (108-110).  These studies have suggested that other proteins 
(accessory proteins) are important for replicating ITO in a physiological setting.  This is 
also supported by the fact that the expression of Kv4.3 and other Kvα-subunits in cell lines 
do not result in currents which completely replicate all the features of cardiac ITO (96;97).  
 
1.4.1.1  Altered Kv4.3 expression modifies ITO in cardiac disease  
Various disease states and other physiological variables have been shown to result in 
changes in ITO density in association with changes in the expression of the Kvα-subunits 
responsible for ITO in the species studied.  
 
Several studies have reported a reduction in both Kv4.3 mRNA and protein in patients with 
AF which may well explain the reduction in ITO current density seen in these patients. 
(111;112).  Similar reductions in Kv4.3, 4.2 and/or 1.4 have been reported in various 
animal models of AF and atrial tachycardia, again mirroring the reductions in ITO current 
density (52;113;114).  Kv4.3 expression has also been demonstrated to be reduced, in 
association with reductions in ventricular ITO, in patients with heart failure (108;115;116).  
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In one of these studies the reduction in Kv4.3 protein expression was demonstrated in both 
epicardial and endocardial myocytes, maintaining the transmural gradient of Kv4.3 
expression in the failing heart (108).  Cardiac hypertrophy in animal models has also been 
demonstrated to be associated with parallel reductions in ventricular ITO and Kv4.3 and 4.2 
mRNA however, this is not found in all such models (99).   
 
1.4.1.2 Can chronic β-blockade modify Kv4.3 expression? 
There is good evidence to support the link between Kv4.3 expression and ITO current 
density.  It is possible that any changes in ITO current density secondary to chronic β-
blockade may be explained by changes in Kv4.3 expression.  Although there is very little 
data regarding a possible role for the adrenergic system in modulating Kv4.3 expression, 
there is one study to support it.  In adrenalectomised and catecholamine-depleted rats a 
reduction in Kv4.2 and 4.3 mRNA expression has been shown in association with a 
reduction in ventricular ITO current density (58).  No studies have looked at the effects of 
chronic β-blockade on Kv4.3 expression in animals or humans.    
 
In most of the studies described in the previous section, Kv4.3 expression is determined by 
examining mRNA and/or protein expression.  Detection of mRNA does not necessarily 
equate to functional protein expression but clearly, one mechanism for altering protein 
expression would be to increase or decrease gene transcription and translation.  Even 
detection of the protein itself does not necessarily equate to functional ion channel 
expression as these proteins are subject to post-translational modifications and then have to 
travel to the cell membrane.  If chronic β-blockade alters the expression of functional 
Kv4.3 it may do so at any of these stages, however, measuring tissue levels of this protein 
would seem to be a reasonable starting point when looking for potential changes in the 
functional expression of this ion channel.   
 
1.4.2 Modulation of Kv4.3 by accessory proteins 
Another possibility is that chronic β-blockade may affect ITO by modifying the expression 
or function of the accessory proteins which associate with Kv4.3.  This may result in 
changes in ITO current destiny but also changes in the kinetics and voltage dependent 
properties of the current.  A number of accessory proteins have been identified in the last 
few years which have the potential to modify Kv4.3 and hence ITO. 
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1.4.2.1 KChIP2 
The Kv channel-interacting proteins (KChIPs) are cytoplasmic proteins belonging to the 
recoverin-neuronal Ca2+ sensor (NCS) superfamily.  They have a conserved carboxy 
terminus with calcium binding domains and a unique amino terminus that interacts with 
the Kv4.x α subunits (96).  Four KChIP proteins have been identified, encoded by the 
genes KCNIP1-4 but only KChIP2 seems to be expressed in the heart (97).  It is expressed 
in both the atria and ventricles of adult human heart and has multiple splice variants 
(97;117).   
 
The KChIP proteins are thought to interact specifically with Kv4 α-subunits in a 4:4 
stoichiometry (97).  They were originally described in rat brain tissue where they have 
been shown to co-localise with Kv4.2 and 4.3 using immunolocalisation and co-
immunoprecipitation studies (118).  Subsequent studies expressing KChIPs with Kv4.2 and 
4.3 in cell lines have shown that these accessory proteins increase the cell surface 
expression of the α-subunits and so, significantly, increase the current density of ITO 
(96;97).  The KChIPs are thought to be important in trafficking Kv4 α-subunits to the cell 
membrane.  When COS cells are transfected with Kv4.2 alone, the protein remains in the 
endoplasmic reticulum but when the cells are co-transfected with KChIP2, both proteins 
are present in the Golgi apparatus and at the cell surface (96).  KChIP2 has also been 
shown to affect Kv4 channel gating and kinetics in expression systems by slowing 
inactivation, increasing the speed of recovery and shifting the voltage dependency of 
activation in a hyperpolarising direction.  It is thought that different regions of the KChIP 
proteins may be responsible for the different modulatory effects on the Kv4 subunits 
(96;97). 
 
The physiological importance of KChIP2 to cardiac ITO has been demonstrated in a number 
of human and animal studies.  Homozygous KChIP2 knock-out mice completely lack ITO 
in isolated ventricular myocytes compared to wild type mice, with the heterozygous knock-
outs demonstrating a 50% reduction in ITO current density.  These mice also have a 
prolonged ventricular APD and are susceptible to ventricular arrhythmias but have little in 
the way of ECG changes (119).  In both humans and dogs, KChIP2 mRNA and protein 
expression exists in a gradient across the ventricular wall and is thought to help contribute 
to the transmural gradient in ITO current density.  ITO is largest in epicardial myocytes but 
not all studies have demonstrated that Kv4.3 is expressed more highly in these cells to 
account for this (108;120).  In several, but not all studies, KChIP2 mRNA and protein have 
been shown to be higher in epicardial cells than in the midmyocardium and endocardium 
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(108;110;120;121).  Remodelling of ventricular KChIP2 mRNA has been described in one 
study of human heart failure (116) which, along with a reduction in Kv4.3 expression, was 
thought to contribute to the reduction in ITO current density.  However, this finding was not 
replicated in another study which looked at KChIP2 mRNA and protein in dogs and 
KChIP2 protein in humans and found no change in expression associated with heart failure 
(108).  There appears to be only one study which has looked at KChIP2 gene expression in 
patients with AF and it did not report any change in expression (122).   
 
It would, therefore, appear that alterations in KChIP2 expression can have a physiological 
impact on ITO current density although the evidence that it is involved in pathological 
remodelling of the ion current in cardiac diseases is sparse.  It is possible that changing 
KChIP2 could also have a physiological impact on the other properties of ITO.  There is no 
evidence to date that KChIP2 expression can be modulated by the adrenergic system and 
no studies have examined the effects of chronic β-blockade on KChIP2 expression.   
 
1.4.2.2 Kvβ1-3  
The Kvβ-subunits are another family of cytosolic accessory proteins which have been 
shown to interact with Kv4.3 and hence modify ITO.  There are three highly homologous β-
subunits that have been identified, Kvβ1-3, with a variety of splice variants all encoded by 
the KCNAB genes.  Like the KChIPs, each β-subunit has a conserved carboxy terminus 
and unique amino terminus (96;123).  Both Kvβ1 and 3 genes have been demonstrated to 
be expressed in human hearts with Kvβ3 mRNA expression being higher in the ventricles 
(122;124;125).  
 
The Kvβ subunits are thought to act as chaperone proteins to promote or stabilise cell 
surface expression of Kv channels as well as having the potential to alter channel kinetics. 
When expressed in cell lines with Kv4.3, Kvβ1 and 2 have been shown to increase the 
density of the current conducted by Kv4.3 in association with an increased expression of 
Kv4.3 protein.  These subunits did not affect the voltage dependence or kinetic properties 
of Kv4.3 (126).  Co-expression of Kvβ3 and Kv4.3 in a cell line also resulted in an 
increase in current density in addition to slowing of reactivation and a shift in voltage 
dependence of inactivation in a hyperpolarising direction (127).  The Kvβ-subunits can 
also interact with other Kvα-subunits including the Kv1 subunits. (96). 
 
There is very little evidence examining the physiological role of Kvβ-subunits in the 
remodelling of ITO in cardiac disease and none looking at the possible modulation of these 
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subunits by drugs or the adrenergic system.  In one study of gene expression comparing 
patients with valvular heart disease in AF or SR, Kvβ1 was found to be upregulated but 
Kv4.3 downregulated in the AF patients (122).  This study identified significant changes in 
at least 12 ion channel related genes and there are likely to be complex interactions 
between these changes, not all of which necessarily have a functional significance.  It 
remains a possibility, however, that changes in the expression of Kvβ subunits could have 
a functional impact on ITO and altered expression of this subunit may contribute to any 
change in ITO found in association with chronic β-blockade. 
   
1.4.2.3 KChAP 
The Kv channel–associated protein, KChAP, is another cytoplasmic accessory protein 
about which there is limited information.  It is a member of the protein inhibitor of the 
activated STAT family of proteins which can interact with a variety of transcription factors 
and play a role in programmed cell death. (96;97).  Originally it was described in rats, with 
the mRNA detected in a variety of tissues including the heart (128).  When expressed in 
cell lines, KChAP interacts transiently with the amino termini of Kvα-subunits (1.x, 2.1 
and 4.3) and increases their expression without changing the channel gating or kinetics, 
suggesting it is a true chaperone.  KChAP has also been shown to interact with Kvβ 
subunits (129).  
 
The functional role of KChAP in human hearts is currently unknown but it is possible that 
it may have a functional role in the modulation of ITO. 
 
1.4.2.4 minK and MiRPs  
The KCNE1-5 genes encode a group of five small proteins with a single transmembrane 
domain that associate with various K+ channels.  The first protein to be identified was 
minK (KCNE1) initially thought to be minimal protein to form a K+ channel which 
associates with KvLQT1 (to form IKS) in expression systems and affects current density 
and gating kinetics (130).  It has also been shown to associate with various other Kvα-
subunits in expression systems including hERG1 and Kv4.3 although the functional 
significance of these interactions is unclear (130).  When expressed with Kv4.3 in cell lines 
there is an increase in Kv4.3 current density with no change in the IV relationship.  There 
is also significant slowing of the current kinetics (127).  Different mutations in human 
KCNE1 result in different types of long QT syndrome (LQTS) including Jervell Lange-
Neilson and Romano-Ward syndromes, therefore, it does have a functionally important 
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role in the human heart (97;130;131).  MinK mRNA has also been shown to be 
upregulated in patients with AF and valvular heart disease (122) although this does not 
clearly correlate with a change in ion current.   
 
The other proteins encoded by KCNE 2-5 are known as the minK related peptides (MiRPs 
1-4).  Originally thought to form part of a functional hERG channel, MiRP1 has 
subsequently been shown to associate with various Kvα-subunits in expression systems 
and modify their properties and/or cell surface expression (130).  Co-expression of MirP1 
with Kv4.3 in a cell line results in increased current density with no change in the IV 
relationship and modest slowing of rate of inactivation (127).  Similarly to KCNE1 
(minK), mutations in KCNE2 are also associated with forms of LQTS and, therefore, this 
gene does appear to have a functionally important role in the human heart (97;130).  
Mutations in KCNE2 have also been found in cases of familial AF although it is unclear 
whether the expression of this gene is associated with functional ion current remodelling in 
AF (131). 
 
The main physiological output of both mink and MiRP1 appears to be to the delayed 
rectifier currents.  Although they have the potential to modify Kv4.3 and hence ITO, it is 
unclear whether this has any functional significance. 
 
1.4.2.5 Other accessory proteins 
Frequenin, also known as NCS-1 (neuronal calcium sensor protein-1), belongs to the same 
superfamily as the KChIP proteins.  The protein is expressed in adult mouse ventricles and 
co-immunoprecipitates with Kv4.3.  When expressed with Kv4.2 or 4.3 in an expression 
system, it increases the current density and decreases the rate of inactivation.  It is also 
associated with increased expression of Kv4.3 at the cell membrane (132). One study has 
showed very low expression of mRNA in human heart tissue compared to other tissues 
and, like many of the accessory proteins, its physiological role remains unclear (133).   
 
DPP6, also known as DPPX, belongs to a family of non-classical serine proteases although 
it has no enzyme activity itself.  It is an integral membrane protein which has been detected 
in the human heart (97;134).  When it is expressed in cell lines along with Kv4.3 and 
KChIP2, it results in a current which resembles human ventricular ITO more closely than 
the current generated by any other combination of these proteins.  When DPP6 is 
expressed with Kv4.3, it increases current amplitude but also affects inactivation and 
reactivation kinetics and voltage dependency (134).  DPP6 is thought to enhance 
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trafficking of Kv4.3 to the cell membrane (135).  There is as yet no evidence to link it to 
changes in ITO remodelling in cardiac disease.  
 
1.4.3 IK1 pore-forming proteins 
In addition to the Kvα-subunits family, other K+ channel, pore-forming proteins have been 
identified. The Kirα-subunits are a family of pore-forming proteins encoded by the 
KCNJ1-15 genes.  They have two transmembrane domains which are homologous to the 
S5 and S6 domains of the Kv channels and one P loop with a signature G-Y-G sequence 
that confers K+ selectivity to the channel (see figure 1.4A) (62;64;97). Like Kvα-subunits, 
Kirα-subunits assemble as tetramers to form functional channels.     
 
When the KCNJ genes are expressed in cell lines they are found to conduct strongly 
inwardly rectifying currents and it is, therefore, thought that this family encode the proteins 
responsible for IK1.  The properties of the Kir2 α-subunits, in particular Kir2.1 (originally 
called IRK-1), most closely match the properties of endogenous IK1 (62;97).  AODNs 
against Kir2.1 mRNA have been shown to significantly reduce IK1 in rats but not eliminate  
it, suggesting that other α-subunits may contribute to IK1 (136).  This has been further 
supported by a study looking at the barium sensitivity of Kir2 channels which found that 
heteromeric Kir2 channels more closely resemble native IK1 than homomeric channels 
(68).  The importance of heteromeric complexes to the formation of functional IK1 may 
contribute to the varying severity of Andersens’s syndrome in which Kir2.1 mutations can  
result in a range of cardiac pathologies ranging from asymptomatic LQTS, through to 
lethal ventricular arrhythmias (64).  
 
There are three Kir2 channels which are expressed in the human heart (Kir1-3). Kir2.1 is 
more highly expressed in the ventricles than the atria and Kir2.2 and 2.3 are more highly 
expressed in the atria (137).  This may help explain the variation in IK1 current density 
between the atria and ventricles although the abundance of these ion channels relative to 
each other is not known.  
 
There are few studies that have looked for altered expression of Kir2 subunits in non- 
familial cardiac disease as a possible explanation for altered IK1 current density.  In one 
study of human AF, Kir2.1 mRNA was shown to be upregulated in association with 
increased IK1 (51).  In a rabbit model of heart failure ventricular Kir2.1mRNA was 
downregulated in conjunction with a decrease in IK1(138).  In contrast, a human study of 
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Figure 1-4 Schematic diagram of Kir2 channel with two transmembrane domains (M1 and 
2) and P loop (A). Schematic diagram of TWIK-1 with four transmembrane domains (M1-
4) eand two P loops is shown in B.  Modified (98). 
 
 A 
B 
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ion channel expression in heart failure did not find any change in ventricular Kir2.1 mRNA 
expression when they had previously detected a reduction in IK1 current density (115).  
They did not examine Kir2.1 protein expression or look at the expression of other Kir2.1 
subunits.  This lack of change in ventricular Kir2.1 mRNA expression in human heart 
failure was supported by another study which also showed no change in Kir2.2, 2.3 or in 
TWIK-1 mRNA (137).   
 
Another family of potassium pore-forming subunits has been identified. These proteins 
have four transmembrane domains and two pore regions and are known as 2P or K2P 
channels (see figure 1-4B).  TWIK-1 (KCNK1) is a member of a large family of these 2P 
channels that forms homodimers with four P domains.  It is a weak inward rectifier.  The 
TWIK channels have a wide tissue distribution and TWIK-1 is expressed strongly in the 
heart with higher expression in the ventricles than atria (137;139).  When it is expressed in 
cell lines, TWIK-1 generates a time independent current which is blocked by barium (139).  
It does not mimic the rectification profile of IK1 and it is unclear whether TWIK-1 does 
contribute to IK1 or whether it is contributes to background K+ membrane conductance 
(64;139). 
 
There is evidence that modification of Kir2.1 can influence IK1 current density but whether 
the adrenergic system can alter the expression of Kir2.1 is unknown.  If chronic β-blockade 
results in a change in atrial IK1, the altered expression of Kir2.1 and possibly other pore-
forming proteins including Kir2.2, 2.3 and perhaps even TWIK-1 could be responsible. 
 
1.4.4 Kv1.5: the pore forming channel for IKUR 
The Kv1 α-subunits were the first of the voltage-gated, K+ channel, pore-forming proteins 
originally cloned from the Shaker locus in Drosophila (97).  Ion channels related to the 
Kv1 Shaker family have been cloned from human and animal hearts and found to conduct 
currents with similar activation and inactivation profiles to IKUR when expressed in cell 
lines (90;94).  Of these proteins, Kv1.5 has the most similar pharmacological profile to 
IKUR.  Further evidence to support Kv1.5 as the molecular correlate of IKUR comes from the 
use of  AODNs to Kv1.5 which have been shown to attenuate IKUR in isolated human atrial 
myocytes (140).  Kv1.5 mRNA has also been shown to be very highly expressed in human 
atria compared to the ventricles, a pattern which fits with the atrial specific nature of IKUR.  
In chronic AF, Kv1.5 protein and mRNA has been shown to be reduced, which is thought 
to explain the reduction in IKUR current density (12;141).  Interestingly, a mutation in 
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Kv1.5 has been identified in a familial case of AF.  Expression of this mutation results in a 
loss of functional protein and IKUR, along with prolongation of the APD and potentially 
pro-arrhythmic, early after-depolarisations (142).  It is unclear whether any accessory 
proteins associate with Kv1.5 and modify IKUR. 
 
While the other delayed rectifier currents IKR and IKS have not been consistently detected in 
human atrial myocytes, the pore forming proteins thought to be responsible for these 
currents have been.  The KCNH2 gene forms part of an additional subfamily of the Kvα 
genes and encodes hERG1, thought to be the pore-forming protein responsible for IKR 
(86;97).  The accessory protein MirP1 has been shown to interact with hERG and modify 
its function (86;97).  Although hERG1 mRNA and protein are expressed in human atria 
their expression is much higher in the ventricles (143).  As with KCNQ1, the gene 
encoding IKS, mutations in KCNH2 are associated with inherited LQTS in which patients 
are prone to ventricular arrhythmias (97).  The functional roles of IKR and IKS in atrial 
repolarisation remain unclear, however, there are mutations in KCNQ1 which have been 
linked to familial AF (144).  Remodelling of both KCNH2 and KCNQ1 in AF has been 
reported in some, but not all, studies although the functional significance of this is unclear 
as there is no corresponding current data (51).  
 
Initial evidence has not suggested that IKUR is remodelled by chronic β-blockade but this 
has not been examined in a large prospective study (29).  Given the evidence that Kv1.5 
expression directly determines the density of IKUR, if this current were altered by chronic β-
blockade, a reduction in Kv1.5 expression would be a possible explanation.  No studies 
have examined the effects of β-adrenergic modulation of Kv1.5. Due to the difficulties in 
recording atrial IKR and IKS the physiological effects of any change in the expression of 
their pore-forming proteins by chronic β-blockade would be uncertain. 
 
1.5 Hypothesis and Aims 
The hypothesis of this thesis is that the potentially anti-arrhythmic prolongation of human 
atrial cell action potentials by β-adrenoceptor antagonist therapy involves altered density, 
time and voltage dependency of the K+ currents ITO and IK1, associated with changes in 
atrial tissue levels of the underlying K+ channel pore-forming and accessory proteins. 
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The aims of the thesis are: 
1. To measure density, time and voltage dependency of ITO in isolated human atrial 
myocytes using the whole cell patch clamp technique. These variables would be 
compared in cells from patients taking or not taking β-blockers, as part of a 
prospective study. 
2. To measure the density of IKI and IKUR in isolated human atrial myocytes and 
compare these variables in cells from patients taking or not taking β-blockers as 
part of a prospective study. 
3. To measure the atrial mRNA levels of pore-forming and accessory ion channel 
proteins that contribute to the various K+ current characteristics which are altered in 
association with chronic β-blockade, by using real time RT-PCR.  The levels of ion 
channel mRNA would be expressed relative to housekeeping genes and compared 
in tissue from patients taking or not taking β-blockers. 
4. To measure the atrial tissue levels of pore-forming and accessory ion channel 
proteins that contribute to the various K+ current characteristics which are altered in 
association with chronic β-blockade, by using Western blotting.  The levels of ion 
channel proteins would be expressed relative to a control protein and compared in 
tissue from patients taking or not taking β-blockers. 
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CHAPTER 2  
 
EFFECTS OF CHRONIC β-BLOCKADE ON HUMAN 
ATRIAL REPOLARISING POTASSIUM CURRENTS.
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2.1 Introduction 
The transient outward potassium current ITO is mainly responsible for early cardiac 
repolarisation.  The atrial specific, ultra-rapid, delayed rectifier current IKUR and the 
outward component of the inwardly rectifying current IK1 contribute to late 
repolarisation.  Changes in any or all of these currents therefore have the potential to 
alter the atrial action potential.  Prolongation of atrial APD may in turn have anti-
arrhythmic effect in preventing atrial fibrillation, the most common cardiac arrhythmia. 
β-blockers are amongst the most widely used cardiac drugs for conditions including 
angina, myocardial infarction, hypertension and heart failure.  Although commonly used 
in atrial fibrillation to control ventricular rate, they are also known to have an anti-
arrhythmic action in preventing recurrence of this arrhythmia (19). Several studies have 
shown that chronic use of β-blockers is associated with prolongation of atrial APD, an 
effect that may partially explain the anti-arrhythmic action of these drugs (28;29).  
The mechanisms underlying the prolongation of atrial APD by chronic β-blockade are 
unclear.  One study has suggested this may be due to a reduction in ITO density but it is 
not known whether other properties of the current are affected (29).  A reduction in ITO 
density at a given voltage and/or stimulation rate may reflect changes in the voltage 
dependency of the current or its recovery from inactivation. A reduction in the 
contribution of ITO to early repolarisation may occur either because the current density 
is reduced or because it inactivates more rapidly.  Determining the effects of chronic β-
blockade on the current characteristics of ITO may help to clarify the contribution of any 
current change to APD prolongation and may give some insight into the mechanism by 
which these current changes occur.  
The effects of chronic β-blockade on IKUR and IK1 current densities are unclear.  One 
study has suggested IKUR may not be affected by chronic β-blockade and IK1 may be 
reduced but there are very limited data to support this (29).   
2.2 Aims 
The particular aims of the experiments described in this chapter were: 
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• To compare ITO density in isolated human atrial myocytes from patients treated 
or not treated with β-blockers. 
• To establish whether any patient characteristics other than chronic β-blockade 
may be influencing ITO density. 
• To test the potential effects of phrixotoxin block of ITO in human atrial myocytes 
with a view to trying to mimic any reduction in ITO density associated with 
chronic β-blockade and measure the resulting change in atrial APD in cells from 
non β-blocked patients. 
• To compare the voltage dependency, time dependent inactivation, reactivation 
and rate dependence of ITO in cells from patients treated or not treated with β-
blockers. 
• To assess IKSUS block by low dose 4-AP to see whether this could be used as a 
technique for isolating ITO from IKSUS. 
• To compare IKSUS density in isolated human atrial myocytes from patients 
treated or not treated with β-blockers. 
• To compare IK1 density using barium subtraction in isolated human atrial 
myocytes from patients treated or not treated with β-blockers. 
2.3 Methods 
2.3.1 Principles of whole cell patch clamping 
The whole cell patch clamp technique is an adaptation of technique originally described 
by Neher and Sakmann to measure ion currents within living cells (145).  Using this 
technique, a glass micropipette containing an “internal” electrolyte solution and silver 
chloride wire is gently lowered onto the surface of an isolated cardiac myocyte 
maintained in an “external” electrolyte solution.  Using gentle suction, the pipette 
attaches to the cell and forms a tight, high resistance “seal” with a patch of membrane 
known as a gigaseal.  This allows the flow of ions through channels in the patch of cell 
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membrane into the interior of the micropipette where they are converted into electrical 
current at the surface of the electrode wire by the reversible conversion of Cl- + Ag ↔ 
AgCl + e-.  The patch of membrane can then be ruptured by further application of gentle 
suction allowing low resistance access to the whole cell and enables the measurement of 
ion currents flowing across the whole cell membrane.  This is known as the whole cell 
configuration.  Measurements of these ion currents can be made using a single electrode 
voltage clamp technique.  Using this technique, the cell membrane potential is 
controlled by use of an amplifier which both measures the membrane potential and can 
change it to a preset command potential by injection of the necessary amount of charge.  
The magnitude of this charge represents the size of the current that flows at the 
command potential and is measured using the same electrode.  A simplified diagram of 
this circuit is shown in figure 2-1.  The duration and rate at which the cell membrane 
potential is changed can also be controlled using this technique which allows different 
properties of ion currents to be studied. 
 
2.3.2 Obtaining atrial tissue 
In these experiments ion currents were measured in human, isolated, right atrial 
appendage cells.  These cells were isolated from right atrial appendage tissue obtained 
from adult patients undergoing cardiac surgery for coronary artery bypass grafting 
and/or valve replacement.  During these operations, the right atrial appendage and aorta 
are cannulated in order to allow the patients circulating blood volume to be diverted 
away from the heart via a bypass machine.  Tissue can be excised from the right atrial 
appendage in order to gain access for the bypass cannula without detriment to the 
patient and it was this tissue that was used in all the experiments described in this thesis.  
All the procedures followed were approved by the institutional research ethics 
committee and informed consent was obtained from each patient by either myself, 
Professor Rankin or Drs Cormack, Jackson, Motherwell, Myles or Nisbet using the 
form shown in figure 2-2.  The investigation conformed to the principles outlined in the 
Declaration of Helsinki (146).   
No patients with a documented history of AF were included in this study.  All patients 
were in sinus rhythm the day before surgery as confirmed by their pre-operative ECG. 
All the β-blocked patients were taking β1-selective blockers for ≥ 4 weeks prior to 
surgery unless otherwise stated.  All patient characteristics were obtained from case    
Gillian E. Marshall 2008  42 
 
 
 
 
Figure 2-1 Whole cell patch clamping of an isolated atrial myocyte in a bath of salt 
solution. The flow of ion currents e.g. K+ currents through ion channels in the cell 
membrane can be controlled and detected using a microelectrode and amplifier in 
contact with the interior of the cell via a ruptured patch in the membrane. 
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Right atrial appendage 
Glasgow Royal Infirmary University N.H.S. Trust 
PATIENT INFORMATION AND CONSENT FORM 
 
Title of Project: Electrophysiological and molecular properties of isolated human cardiac 
myocytes. 
 
Summary: You are shortly to undergo a heart operation. The reasons for this, and the type of 
operation to be performed, will have been discussed with you by your cardiologist and by the 
heart surgeon. 
 
We are undertaking research into why some patients have abnormal heart rhythms and how 
these cardiac arrhythmias affect the heart cells. In order to understand the biological properties 
of heart cells we would like to obtain a small sample of your heart muscle.  
During the operation, the surgeon routinely makes a small cut in the heart to allow the operation 
to proceed. Many surgeons perform this by removing a small piece of heart tissue (about the 
size of a pea), which would normally be discarded. Some surgeons do not routinely remove this 
piece of tissue, but are willing to do so, since they know that such a procedure would not do you 
any harm. We are asking for your consent to use this small piece of the heart to obtain heart 
cells for our study. Part of the tissue will be studied directly for electrical activity and then 
discarded, and the remainder will be deep-frozen at the hospital for future analysis of molecular 
activity, after which it will be destroyed. Participation in our study will not change the operation 
or result in additional risk or discomfort to you. 
In addition, we would ask your permission to obtain details of your condition from your medical 
records. These details will be kept confidential and your identity will be concealed by the use of 
a coding system. Such information will be retained for comparison with the results of the tissue 
analysis, and will not be disclosed to anyone outside the hospital. 
This research project will not be of direct benefit to you, but the results may help other patients 
in the future. If you are unwilling to take part, you are entirely at liberty to refuse permission. 
This would not affect your medical treatment in any way. 
Consent: 
I, (Name) ………………………………………………………………………………. 
of (Address) …………………………………………………………………………… 
agree to take part in the Research Project described above. 
Dr …………………………………………….. has explained to me what is involved, how it might 
affect me and the purpose of the Research Project. 
Signed …………………………………………………………… Date …………….. 
Witness….…………………………………………………………Date……………..  
Figure 2-2 Example of patient consent form for obtaining right atrial tissue. 
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notes and stored in a database by Julie Russell and are described in the results section.  
2.3.3 Cell isolation 
The right atrial appendage tissue was transported to the laboratory for processing within 
approximately 5 minutes of excision in 50 ml of oxygenated solution A (see table 2-1).  
Atrial myocytes were isolated enzymatically using a modification of the chunk method 
(147-149).   Excised tissue (0.2 - 1 g) was sliced into approximately 1 mm3 chunks and 
washed three times, for 3 minutes per wash, in Ca2+-free solution B (see table 2-1).  
Each wash was performed in an incubation bath at 37ºC, under oxygen and shaken at 
130 strokes/minutes.  After the final wash, the chunks were removed from solution B 
and incubated in 15 ml of solution C (see table 2-1) containing protease (Type XXIV, 
Sigma, 4 U/ml).  This solution was shaken for a further 45 minutes at 37ºC under 
oxygen.  It was then filtered through a nylon gauze filter and the chunks incubated in a 
similar fashion in 12 ml of solution C containing collagenase (Type 1, Worthington, 400 
U/ ml).  The chunks were incubated for 15 minutes in this collagenase solution and then 
filtered again through nylon gauze.  The partially digested tissue was incubated again in 
the collagenase solution for 15 and then 20 minutes.  The filtrates of isolated atrial 
myocytes were collected after each of the three incubations and centrifuged at 40 g for 2 
minutes.  The supernatants were removed and the cells resuspended in 1ml of solution 
D to wash off residual enzyme.  This solution was replaced with a low Ca2+ solution E 
following repeat centrifugation (40 g, 2min) and the cell suspension stored in Petri 
dishes for up to 8 hours at room temperature. 
2.3.4 Measuring currents by whole cell patch clamping 
2.3.4.1 Preparing the patch clamp equipment  
The arrangement of equipment can be seen in the photograph in figure 2-3.  The 
microscope, perfusion chamber, microelectrodes and micromanipulator were mounted 
on an air table in order to minimise vibration and were all earthed to eliminate electrical 
noise.  The reservoirs for external solution were mounted above the level of the 
perfusion chamber on the wire cage.  A suction bottle was located on the floor beneath 
the perfusion chamber to remove external solution.  The amplifier, oscilloscope and  
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Table 2-1 Composition of solutions for cell isolation.  All concentrations are expressed 
in mM.  All chemicals were obtained from Sigma except for MgCl2, MgSO4 and 
KH2PO4 which were obtained from AnalaR BDH. 
 
 
 
 
 A 
 
B C D E 
NaCl  150 120 120  130 
KCl 5.4 5.4 5.4 40 4 
KOH    70  
KH2PO4    20  
MgCl2 1.2   3 1 
MgSO4  5 5   
CaCl2 1  0.05  0.2 
EGTA    0.5  
Glucose 10 20 20 10 10 
L-Glutamic 
acid 
   50  
HEPES 5 10 10 10 10 
Pyruvate  5 5   
Nitrilotriacetic 
acid 
 5    
Taurine  20 20 20  
pH with HCl pH7.4     
pH with NaOH  pH 6.95 pH 6.95  pH 7.35 
pH with KOH    pH 7.2  
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Figure 2-3 Picture of patch clamp equipment. The perfusion chamber and 
microelectrodes were located on the microscope stage. 
Air table 
Wire cage 
Micromanipulator 
Digital 
thermometer 
In-line heater 
Reservoirs 
Microscope 
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computer, programmed to generate stimulus protocols and acquire data, were all placed 
in a tower beside the vibration table. 
2.3.4.2 Perfusion chamber 
Once the myocytes were isolated, a small aliquot of cell suspension was placed in a 200 
µl perfusion chamber (RC-24E fast exchange perfusion chamber, Warner) mounted on 
the stage of a microscope (Nikon TMS).  The myocytes were allowed to adhere to a 
glass coverslip that formed the bottom of well 1 of the perfusion chamber illustrated in 
figure 2-4.  External solution (see table 2-2) flowed into well 1 from a reservoir 
mounted at a higher level than the perfusion chamber at a rate of approximately 2 
ml/minute.  Before the external solution entered the well it flowed through an in-line 
heater (Warner Instrument Corporation Model SH-27A Inline Heater) which heated the 
solution to 36ºC.  The temperature was recorded using a temperature probe placed in 
well 1.  Well 1 connected to well 2 by means of a small channel which allowed 
equalisation of the volumes of solution between the two wells.  Well 2 also connected to 
the suction device that allowed a constant flow of external solution through the 
perfusion chamber.  Well 3 was filled with a 3 M KCl solution into which the earth 
electrode was placed.  The electrical circuit between the earth electrode and the 
recording electrode in well 1 was completed using an agar bridge linking wells 2 and 3.  
The role of the agar bridge was to keep the Cl- concentration around the earth electrode 
constant, as fluctuations in the concentration of Cl- between wells 1 and 3 would have 
resulted in an offset voltage between the earth and recording electrode.  The agar 
bridges were made by heating short lengths of borosilicate glass capillaries without
inner filaments (Clark electromedical instruments) into “U” shapes that were filled by 
emersion in agar solution and then stored in the 3 M KCl solution. 
 
2.3.4.2.1 Microelectrodes 
 
The micropipettes were made from 15 cm long, 1.5 mm outer diameter x 1.17 mm inner 
diameter, borosilicate glass capillaries with inner filaments (Clark electromedical 
instruments).  These were cut in two lengths, 7 cm long, using a diamond cutter and 
each length used to make two microelectrodes using a vertical puller (Narishige PP-83).  
Each microelectrode was pulled in two steps, the first at 12 A and the second at 9 A.   
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Figure 2-4  Diagram of perfusion chamber.  See text for details of components.  
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Table 2-2 Composition of external and internal solutions.  All concentrations are 
expressed in mM.  All chemicals were obtained from Sigma except for MgCl2 which 
was obtained from AnalaR BDH. 
 External Solution Internal Solution 
NaCl 130  
KCl 4 20 
MgCl2 1 1 
CaCl2 2  
CdCl2  0.2  
Glucose 10  
HEPES 10 5 
EGTA  0.15 
L-aspartic acid  110 
Na2ATP  4 
Na2GTP  0.4 
pH with NaOH pH 7.35  
pH with KOH  pH 7.3 
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The tip of each microelectrode was then fire polished to remove any imperfections that 
might damage the cell membrane and prevent the formation of the high resistance seal.  
The micropipette was then back-filled with an internal electrolyte solution with the 
same osmolarity as the cytoplasm of the cell (see table 2-2).  A silver-chloride wire was 
placed into the micropipette and connected to the amplifier.  Before each experiment, 
both this wire and the wire used as the earth electrode, were cleaned and chlorinated 
using electrolysis and a chloride containing solution.   
 
The electrical resistance of a number of microelectrodes was measured to enable 
adjustments to be made in the pulling process.  This enabled the microelectrode 
resistance to be kept low relative to the cell seal resistance and, therefore, minimise the 
leakage current when patching the cells.  The resistance was measured before patching a 
cell by applying a 1 mV voltage pulse once the electrode was lowered into the external 
solution.  The current generated across the electrode tip by the voltage step was 
measured and the resistance calculated using Ohms Law (R=V/I).  The median 
microelectrode resistance was 2.8 MΩ (n=138). 
 
2.3.4.3 The use of amplifier to record currents and adjust for errors in the voltage 
clamp mode 
An Axopatch-1D amplifier (Axon Instruments) was used in voltage clamp mode in 
conjunction with the software programme WinWCP (J Dempster, Strathclyde 
University) to record ion currents.  The cell membrane potential was measured and 
fixed to a preset command by injection of current using a single microelectrode in a 
whole cell patch clamp configuration.  The same microelectrode was used to measure 
the resulting currents across the cell membrane activated at the preset membrane 
potential.  Using this technique, there are various sources of error which can affect the 
current recordings and can be compensated for either prior to, or during, recordings 
using the amplifier. 
 
Once the cells were placed in the perfusion chamber and superfused with heated 
external solution the microelectrode was lowered carefully into the external solution.  
At this point various offset potentials occur, including a current which flows between 
the internal and external solutions, that contain different concentrations of K+, known as 
the liquid junction potential.  Adjusting the "junction null" control on the amplifier 
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compensates for all these effects.  However, when the electrode is in contact with the 
inside of the cell and the cytoplasm has dialysed with the pipette solution, the liquid 
junction potential no longer exists, as the internal solution of the electrode is the same 
as the interior of the cell.  This means that the voltage measured by the electrode will 
differ from the true voltage by the size of the liquid junction potential.  To correct for 
this the electrode is nulled “a priori” at a predetermined voltage that is the same size but 
opposite polarity to that of the liquid junction potential (150).  Previous work in our lab 
has established that the liquid junction potential correction when using the external 
solution and internal solution was -7 mV.  
 
Following adjustment of the “junction null” a square voltage pulse was applied from a 
holding potential of zero to -1mV in order to measure the electrode resistance.  The 
electrode was then lowered onto the cell membrane of a single, elongated, striated 
myocyte using a micromanipulator (Narishige) and gentle suction applied in order to 
obtain a gigaseal.  At this point, a second voltage pulse was applied, from a holding 
potential of -40 with a step to -50 mV, in order to visualise the capacity transients of the 
electrode which could then be nullified with the “fast magnitude” control on the 
amplifier.  Further gentle suction was then applied in order to rupture the patch of cell 
membrane at the tip of the electrode and gain access to the interior of the cell.  This 
generates further larger currents transients as the voltage pulse charges the cell 
membrane capacitance.  These were compensated for by adjusting the “whole cell 
capacitance” and “series resistance” controls on the amplitude.   The final setting on the 
whole cell capacitance control is a measure of the capacitance of the cell which is 
proportional to its surface area and this was recorded for all cells patch clamped.  The 
final setting on the series resistance control is a measure of the combined resistance of 
the electrode tip and the open patch in the membrane.  This resistance was kept to a 
minimum by ensuring only low resistance electrodes were used and only cells in which 
a high resistance seal was initially achieved.  However, even with low series resistance, 
large currents can result in a significant voltage error whereby the voltage recorded by 
the amplifier is different from that actually occurring at the cell membrane.  The voltage 
error was minimised by using series resistance compensation.  Series resistance 
compensation of 64-72% was used in 75% of cells to keep the average voltage error less 
than 5mV.   
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Once the current transients were compensated for, various voltage pulse protocols, 
designed using the WinWCP software, were applied in order to measure currents.   
2.3.4.4 Isolating currents  
When the whole cell patch clamp technique is used to record currents it records the net 
effect of all currents flowing at a particular membrane potential rather than the 
individual current components.  There are several methods that can be used to isolate a 
particular current of interest.  Some voltage dependent currents have different activation 
and inactivation profiles and this can be exploited in order to separate individual 
currents.  For example, INa activates and inactivates rapidly at more negative potentials 
than ITO and IKUR and, by avoiding hyperpolarising the cell to these potentials during 
recordings of these two currents, the effects of INa activation can be prevented.  Some 
currents including ITO, IKUR and ICaL activate over a similar voltage range and, in this 
case, other techniques can be used to block the effects of unwanted currents.  One 
method is to add drugs to the external solution to block particular ion currents.  In these 
experiments cadmium chloride was added to the external solution at a concentration of 
0.2 mM in order to block ICaL (33).   
Several methods can be used to separate ITO and IKUR.  One is to exploit the difference 
in the inactivation profiles of ITO and IKUR.  ITO inactivates very quickly and IKUR 
extremely slowly in comparison.  The current trace obtained using a relatively long 
voltage pulse to activate both these currents will, therefore, consist of IKUR at the end of 
the trace, “the end-pulse current”, while the peak current will consist of both ITO and 
IKUR.  ITO can, therefore, be represented by the peak minus the end pulse current and this 
was the method used to measure ITO in the experiments described in this chapter.  It 
should be considered that there are other currents that may also be activated along with 
ITO and IKUR including the other delayed rectifier currents which are more likely to have 
a greater impact on the end pulse current due to their slow activation.  For this reason 
the end pulse current was labelled as IKSUS (the sustained outward potassium current) 
which consists predominantly of IKUR. 
Drugs can also be used to separate ITO from IKUR, in particular, 4-AP, which can block 
both of these currents at different concentrations.  The possible use of low dose 4-AP to 
block IKUR but not ITO was investigated in some preliminary experiments, the results of 
which are described in 2.4.9.  External solution was prepared containing no 4-AP, 0.05, 
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0.1 or 2 mM 4-AP.  Patched atrial myocytes were then perfused with these external 
solutions in turn, starting with the solution without 4-AP.  After 90 seconds to allow the 
drug to equilibrate within the well, a square voltage pulse of 100 ms duration from a 
holding potential of -50 mV to +60 mV was applied and the resulting currents recorded. 
ITO and IKUR were measured using the end-pulse method and compared with recordings 
made after exposure to the various concentrations of 4-AP.  
 
The potential use of phrixotoxins to specifically block ITO in isolated human atrial 
myocytes was also investigated in preliminary experiments with a view to possibly 
using this toxin to investigate the effects of ITO block on APD.  Phrixotoxin-2 (PaTx2) 
was purchased from Calbiochem.  The PaTx2 was dissolved in external solution 
containing 0.1% BSA and used at concentrations of 100 and 200 nM.  ITO was recorded 
using a series of square voltage pulses of 100 ms duration from -50 to +60 mV repeated 
at three second intervals.  ITO was initially recorded using external solution without 
PaTx2.  This was then stopped by closing the tap from the reservoir of external solution 
and replaced with external solution containing PaTx2 from a separate reservoir.  ITO was 
continually recorded until the cell died, the seal was lost or recordings were electively 
stopped after a wash out period.  In some cells, the PaTx2 containing external solution 
was replaced with external solution without PaTx2 and further recordings made after 90 
seconds of the start of this wash out phase.  All the cells used for these experiments 
were isolated from tissue from non β-blocked patients and experiments were carried out 
at 36 ºC. 
 
IK1 was separated from other currents on the basis of its sensitivity to barium.  Currents 
were recorded using external solution and again after 90 seconds exposure to external 
solution containing 0.5 mM barium chloride.  IK1 was determined by subtracting the end 
pulse current recorded with barium from that recorded without barium. 
2.3.4.5 Voltage pulse protocols 
2.3.4.5.1 ITO and IKSUS activation, ITO voltage dependence and time dependent 
inactivation 
 
A protocol consisting of a series of square voltage pulses of 100ms duration was used to 
record peak activation, voltage dependent activation and time dependent inactivation of 
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ITO.  This protocol along with an example of the resulting current trace is shown in 
figure 2-5.  There was a three second interval between each pulse when the cell 
membrane was clamped to the holding potential of -50 mV.  The first pulse was a flat 
pulse at the holding potential of -50 mV.  Each subsequent pulse increased in 10 mV 
increments from -50 to +60 mV, returning to the holding potential of -50 mV at the end 
of the pulse.   
 
Peak ITO and peak IKSUS were measured using only the step from -50 to +60 mV, as was 
ITO time dependent inactivation.  
 
2.3.4.5.2 ITO voltage dependent inactivation 
 
A protocol consisting of a series of two square voltage pulses of different durations was 
used to record the voltage dependence of ITO inactivation.  Part of this protocol is shown 
in figure 2-6 along with an example of a current trace.  Pulse one was 1000 ms long and 
was immediately followed by pulse two which was 100 ms in duration.  Pulse one 
stepped from the holding potential of -50 mV to -90 mV and pulse two from -90 to + 60 
mV before returning to the holding potential again.  After pulse two, there was a three 
second interval when the cell membrane was clamped to the holding potential of -50 
mV.  In subsequent series of pulses, pulse one increased in 10 mV intervals from -90 to 
+60 mV whereas pulse two remained a constant step to +60 mV from the voltage 
achieved at the end of pulse one.  The holding potential remained at -50 mV throughout. 
   
2.3.4.5.3 ITO reactivation 
 
A protocol consisting of a series of two identical square voltage pulses was used to 
record reactivation of ITO.  This protocol is shown in figure 2-7 along with an example 
of a current trace.  Each pulse was of 100 ms duration and stepped from -50 to +60 mV.  
The time interval between the end of pulse one and the start of pulse two (interpulse 
interval) was varied.  The initial interpulse interval was 500 ms.  There were then seven 
subsequent series of pulses in which the interpulse intervals reduced by 50 ms each time 
until it reached 150 ms.  After this, the interpulse interval was sequentially reduced by 
10 ms for a further fourteen series of pulses reaching a final interpulse interval of 10 ms.  
There was a three second interval between each pair of pulses when the cell membrane 
was clamped to the holding potential of -50 mV.   
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Figure 2-5 Voltage pulse protocol for determining peak ITO and IKSUS activation, ITO 
voltage dependence and time dependent inactivation (A).  An example of the resulting 
current trace is shown in B. 
+ 60 mV 
- 50 mV 
A 
25 ms 
500 pA 
B 
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Figure 2-6 Voltage pulse protocol for ITO voltage dependent inactivation (A).  An 
example of the resulting current trace is shown in B. 
+ 60 mV 
    
 - 50 mV 
25 ms 
    - 90 mV 
A 
500 pA 
B 
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Figure 2-7 Two pulse voltage pulse protocol for ITO reactivation (A) with example of 
resulting current trace (B). 
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2.3.4.5.4 ITO rate dependence  
 
A protocol consisting of six trains of square voltage pulses with eight identical pulses in 
each train was used to record ITO rate dependence.  A selection of trains of pulses from 
this protocol is shown in figure 2-8 along with examples of current traces.  Each pulse 
was of 100 ms duration and stepped from a holding potential of -50 mV to +60 mV 
before returning to the holding potential again at the end of each pulse.  The interpulse 
intervals varied from one train to the next but, within each train of pulses, the interpulse 
intervals remained constant.  In the first train of eight pulses the interpulse interval was 
700 ms, corresponding to a stimulation rate of 75 beats/minute or frequency of 1.25 Hz.  
The second train of eight pulses had an interpulse interval of 300 ms (150 beats/minute, 
2.5 Hz).  The interpulse intervals in subsequent trains of pulses were 100, 33 and 20 ms 
corresponding to stimulation rates of 300, 400 and 500 beats/minute and frequencies of 
5, 6.7 and 8.3 Hz respectively.  A final train was then repeated at a stimulation rate of 
75 beats/minute.  There was a three second interval between each train of pulses when 
the cell membrane was clamped to the holding potential of -50 mV.   
 
2.3.4.5.5 IK1 voltage dependent activation 
 
A protocol consisting of a series of square voltage pulses of 500 ms duration was used 
to record IK1 voltage dependent activation.  This protocol is shown in figure 2-9 with an 
example of the resulting current traces using external solution with and without barium.  
There was a three second interval between each pulse when the cell membrane was 
clamped to the holding potential of -50 mV.  The first pulse was stepped from the 
holding potential of -50 mV to -120 mV and then back to the holding potential again.  
Each subsequent pulse increased in 10 mV increments from -120 to +60 mV returning 
to the holding potential of -50 mV at the end of each pulse.   
2.3.5 Data analysis 
2.3.5.1 Calculating conductance and the reversal potential 
Conductance (g) was calculated from the current (I) elicited by each voltage pulse using 
the equation described below. 
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Figure 2-8 Voltage pulse protocol for ITO rate dependence at 75 (A), 300 (B) and 500 
(C) beats/minute with corresponding current traces. 
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Figure 2-9 Voltage pulse protocol for IK1 activation (A) with resulting current traces 
recorded using external solution without (B) and with (C) 0.5 mM barium chloride. 
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g = I/(Vt−Vrev) 
 
 where Vt is the test potential and Vrev is the reversal potential or EK.   
 
EK was not measured but calculated from the Nernst equation using the K+ 
concentrations from the internal and external solutions.  
 
EK= RT/F In[K+]o/[K+]I 
 
where T is the absolute temperature of the external solution, R is the universal gas 
constant and F is Faraday’s constant.  EK was calculated as -92.7mV. 
 
2.3.5.2 Curve fitting 
All non linear regression analysis was performed using GraphPad Prism.  In order to fit 
curves to the time course of inactivation of ITO, all the data from each current trace was 
exported from WCP into a Microsoft Excel spreadsheet.  The ITO density at every time 
point was calculated by subtracting the end pulse current from the total outward current. 
The maximum ITO density for each cell was termed “the peak ITO density at time zero” 
and this data point, along all subsequent data points until the end of the voltage pulse, 
were exported to GraphPad Prism for curve fitting analysis. 
 
The following equations were used for mono-exponential, bi-exponential associations, 
mono-exponential decay and Boltzmann curve fits. 
  
Mono-exponential association: I(t)= I(1−exp-t/τ)  
 
where I describes the maximum plateau of the current, t is recovery period or time and τ is 
the time constant. 
 
Bi-exponential association:   I(t)= I1(1−exp-t/τ1)+ I2(1−exp-t/τ2)  
 
where τ1 and τ2 are the fast and slow time constants for the relative amplitudes of the fast 
and slow current components I1 and I2.  
Gillian E. Marshall 2008  62 
 
 
Mono-exponential decay:   I(t) = I+exp-t/τ  
 
where I describes the starting current value, t the time and τ the time constant. 
 
Boltzmann curve fit for activation:  g(t)=1/1+exp [(V0.5−Vt)/k]  
 
where Vt is the test potential, V0.5 is the voltage of half-maximal activation and k is the 
slope factor. 
 
Boltzmann curve fit for inactivation:  I(t)=1/1+exp [(Vt −V0.5)/k]  
 
where Vt is the test potential, V0.5 is the voltage of half-maximal inactivation and k is the 
slope factor. 
 
The goodness of fit for all curves was assessed by examining several parameters, the most 
important of which was whether the computer programme was able to converge on a fit.  
The width of the confidence intervals, R2 value and runs tests were also examined.  The 
comparison of fits to two different equations was performed as part of the GraphPad Prism 
analysis programme using an F test  The equation with fewer variables was chosen as the 
best fitting equation unless p<0.05. 
 
2.3.5.3 Other statistical analysis 
All other statistical analyses were performed using GraphPad Prism unless stated 
otherwise. 
 
The distribution of ITO current densities was examined visually but was also tested for the 
degree of deviation from a Gaussian distribution using the Kolmogorov-Smirnov test.  
Given the relatively small sizes of the non β-blocked and β-blocked patient groups (<100), 
p>0.05 was not taken to be conclusive of a Gaussian distribution but to indicate that the 
distribution was not inconsistent with a Gaussian distribution. 
 
Comparisons between mean current values in each group of patients or cells were done 
using a Student’s t-test.  P<0.05 was taken to be statistically significant. Comparisons 
between the numbers of patients with particular characteristics in the β-blocked or non β-
Gillian E. Marshall 2008  63 
 
blocked groups were done using a Fisher’s exact t-test.  P<0.05 was taken to statistically 
significant. 
 
The relationship between heart rate and ITO was assessed using correlation analysis and 
linear regression analysis was used to investigate the relationship between atenolol dose 
and ITO.   
 
Multiple linear regression was used to examine the association of multiple variables with 
ITO.  This was performed by Pardeep Jhund.  Initially β-blocker use was entered into the 
model as the primary variable of interest and secondly age and sex were also entered to 
adjust for these variables. Age was entered as a continuous variable while β-blocker use 
and sex were added as binary variables, where no β-blocker use and female sex were used 
as the referent categories. Statistical significance was taken at the 5% level (P<0.05). 
Regression analyses were carried out using Stata Version 10 (Stata Corp., College Stations, 
Texas, USA). 
 
2.4 Results 
2.4.1 The effects of chronic β blockade on ITO current density  
ITO was measured in isolated human atrial cells using the voltage clamp protocol described 
in the methods section of this chapter.  An example of the current traces obtained from 
representative cells from a non β-blocked and a β-blocked patient are shown in figure 2-10.  
In these traces ITO (measured as the peak current minus the end pulse current) is 
represented by the triangular portion of the current trace.  In both traces it can be seen that 
ITO activates in a voltage dependent fashion, increasing in magnitude as the voltage step 
increases in magnitude.  ITO is, therefore, largest when activated by the -50 to +60 mV 
voltage step and is not present with voltage steps of -50 to 0 mV or less.  When the two 
current traces are compared, it can be seen that ITO is smaller in the cell from the β-blocked 
patient at each voltage step.   
 
Figure 2-11 shows the ITO current-voltage relationship for each cell in the two patient 
groups.  Current densities were measured across the voltage range of -50 to +60 mV in 32 
cells from 14 non β-blocked patients (BB No) and 30 cells from 15 β-blocked patients (BB 
Yes).  These current-voltage relationships show a normally distributed range of current 
densities for cells in each patient group.  Statistical analysis of the current densities at +60  
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Figure 2-10 Current traces showing ITO voltage dependent activation in atrial cells of 
similar capacitance isolated from a non β-blocked (A) and β-blocked (B) patient. 
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BB Yes BB No 
A B 
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Figure 2-11  Individual voltage current relationships for ITO in all cells isolated from non β- 
blocked (A) and β-blocked (B) patients  
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Figure 2-12  Mean ITO current-voltage relationship (A) and mean peak ITO density at +60 
mV (B)  for all cells from non β-blocked (  ) and β-blocked patients ( ).  Mean patient 
data are shown in C and D.  * indicates p<0.05, Student’s t-test.  
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mV confirms the distribution is not inconsistent with a Gaussian distribution (K-S 
distances of 0.09 and 0.11, p>0.1 for BB No and BB Yes cells, respectively).  This figure 
also suggests that the ITO current densities in the cells from the β-blocked patients are 
smaller than those from the non β-blocked patients and this was examined by plotting the 
mean current-voltage relationships for each group of cells as seen in figure 2-12. 
 
The mean ITO current density, at each voltage step to voltages ≥ +10 mV, was significantly 
smaller in the cells from the β-blocked patients (Student’s t-test, p<0.05) as shown in 
figure 2-12A.  At peak ITO activation, achieved with the voltage step from -50 to +60 mV, 
chronic β-blockade was associated with a 34% reduction in the ITO current density.  The 
mean current densities at +60 mV were 15.0 ± 1.1 pa/pF in the cells from non β-blocked 
patients and 9.9 ± 0.7 pA/pF in the cells from β-blocked patients as shown in figure 2-12B, 
p= 0.0001.  This reduction in ITO current density was maintained when the data was 
meaned for patient rather than cell numbers as illustrated in figures 2-12C and D. 
 
2.4.2 Effects of patient characteristics on ITO current density 
The characteristics of both the cells and patients in the non β-blocked and β-blocked 
patient groups were examined, to try to determine whether any other factors may be 
contributing to the difference in ITO density demonstrated between these two groups.   
 
2.4.2.1 Cell characteristics 
Table 2-3 shows the mean electrophysiological properties of the cells in each patient 
group.  The distribution of each variable was not inconsistent with that of a Gaussian 
distribution. There was no significant difference in any of the electrophysiological 
properties of the cells in either group.   
 
Any difference in cell capacity between the two groups of cells which might have 
contributed to the magnitude of ITO had already been corrected for by calculating the 
current densities.  It should be noted that the cells in each group were already depolarised 
prior to voltage clamping which is not an unusual finding when using human atrial cells 
isolated in this fashion (151).  It might be expected that the voltage error (post series 
resistance compensation) would be smaller in the BB Yes cells given ITO is smaller in these 
cells.  Series resistance compensation was not applied during the first nine experiments in 
order to avoid additional difficulties when learning the technique of patch clamping.  Of  
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Table 2-3 Electrophysiological characteristics of cells from patients treated (BB Yes) or 
not treated (BB No) with β-blockers prior to cardiac surgery (mean ± sem).  Series 
resistance was recorded before series resistance compensation was applied1.  Voltage error 
was calculated after series resistance compensation applied2 
 
Cell characteristics 
 
BB No cells 
 
 
 
BB Yes cells 
 
 
 
Capacitance (pF) 
 
Resting membrane 
potential (mV) 
 
Series resistance (MΩ)1 
 
Voltage error (mV) 2 
 
          74.0 ± 2.8 
 
        −20.3 ± 1.8 
 
 
            5.9 ± 0.3 
 
            3.7 ± 0.3 
 
          69.3 ± 3.3 
 
        −23.6 ± 2.2 
 
 
            6.3 ±0.4  
 
            4.2 ± 0.5 
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these experiments seven were done using BB Yes cells and this might have resulted in a 
net increase in the mean voltage error for the entire BB Yes group relative to the BB No 
group.  However, this does not result in any significant difference in mean voltage error 
(post series resistance compensation) between the two groups and, therefore, is unlikely to 
have any influence on the difference in ITO density. 
 
2.4.2.2 Patient characteristics 
Table 2-4 shows the patient characteristics for the cells in which ITO was recorded.  No 
attempt was made to match patients during the period in which tissue samples were 
collected.  The patients in each group are of a similar age and sex but there are a number of 
differences including heart rate, pre-operative drugs and pre-operative diseases which may, 
possibly, contribute to the difference in ITO density between the groups.   
 
To examine the effects of other patient characteristics on ITO current density, multiple 
linear regression analysis was performed by Dr Pardeep Jhund.  There were only enough 
patients in the study to examine the effects of three variables including β-blockade, based 
on the need to have a minimum of 10 patients per variable studied. An analysis was 
therefore performed using the standard co-variables of age and sex. The results of this 
analysis along with single linear regression analysis for chronic β-blockade are shown in 
table 2-5. 
 
The effects of various patient characteristics on ITO were then considered individually as 
described in the following sections.   
 
2.4.2.3 Effects of heart rate on ITO density 
β-blockers slow the heart rate.  It is possible that heart rate, rather than specifically β-
blocker use, determines ITO current density and that the reduction in ITO density seen in the 
β-blocked patient group was due directly to the slower heart rate in that group (see table 2-
4).  However, within each group of cells there was no correlation between peak ITO density 
and heart rate as shown in figure 2-13. 
 
2.4.2.4 Effects of pre-operative drugs on ITO density 
All of the non β-blocked patients in this study were taking β1-selective blockers with 15 
out of 17 patients taking atenolol and the remaining two patients taking bisoprolol (see
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No. of patients 
Male patients 
Mean age (yrs) 
Mean heart rate 
(beats/min) 
  
Surgery:  
CABG 
AVR alone 
CABG + AVR 
CABG + MVR 
 
Pre-op drugs: 
β-blockers 
    - atenolol 
    - bisoprolol 
ACE inhibitors 
CCBs 
Nicorandil 
Statins 
Digoxin 
Amiodarone 
 
Pre-op disease: 
MI 
Angina 
LVSD 
    - mild 
    - moderate 
    - severe 
 
 
15 
13 (86.7) 
62.0 ± 2.8 
73.8 ± 3.5 
 
 
 
10 (66.7) 
3 (20) 
1 (6.7) 
1 (6.7) 
 
 
0 (0) 
0 (0) 
0 (0) 
4 (26.7) 
8 (53.3) 
7 (46.7) 
11 (73.3) 
0 (0) 
0 (0) 
 
 
1 (6.7) 
12 (80) 
2 (13.3) 
2 (13.3) 
0 (0) 
0 (0) 
 
 
17 
12 (70.6) 
65.7 ± 2.7 
53.4 ± 1.4* 
 
 
 
17 (100)τ
 
0 (0) 
0 (0) 
0 (0) 
 
 
17 (100) 
15 (88.2) 
2 (11.8) 
10 (58.8) 
3 (17.6) 
4 (23.5) 
17 (100) τ
 
0 (0) 
0 (0) 
 
 
5 (29.4) 
17 (100) 
1 (5.9) 
0 (0) 
1 (5.9) 
0 (0) 
 
 
32 
25 (78.1) 
- 
- 
 
 
 
27 (84.4) 
3 (9.4) 
1 (3.4) 
1 (3.4) 
 
 
17 (53.1) 
15 (46.9) 
2 (6.3) 
14 (43.8) 
11 (34.4) 
11 (34.4) 
28 (87.5) 
0 (0) 
0 (0) 
 
 
6 (18.8) 
29 (90.6) 
3 (9.4) 
2 (6.3) 
1 (3.1) 
0 (0) 
 
Patient 
Characteristics 
Non β-blocked 
patients               
(BB No) n(%)            
β-blocked patients 
                                  
(BB Yes) n(%)            
Total patients 
n(%) 
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Table 2-4 Patient characteristics of cells in which ITO was recorded   
 
CABG = coronary artery bypass graft, MVR = mitral valve replacement, AVR = aortic 
valve replacement, Pre-op = before surgery, ACE = angiotensin converting enzyme, 
CCB = calcium channel blocker, MI= myocardial infarction, LVSD =left ventricular 
systolic dysfunction. * indicates a significant difference from BB No (p<0.05, Students 
t-test). τ a significant difference from BB No (p<0.05, Fishers exact test ).
 
Hypertension 
Diabetes 
Post-op AF 
 
10 (66.7) 
3 (20) 
4 (26.7) 
 
11 (64.7) 
2 (11.8) 
4 (23.5) 
 
21 (65.6) 
5 (15.6) 
8 (25) 
Gillian E. Marshall 2008  72 
 
 
 
 
 
 
 
 
Table 2-5  Single (A) and multiple (B) linear regression analysis of ITO current density 
for patient co-variables listed.   Total number of patients is 32. 
 
Clinical factor Change in ITO 
(pA/pF) 
95% Confidence 
Interval 
P value 
 
β-blockade 
 
-4.14 
 
-7.50 to -0.77 
 
0.02 
Clinical factor Change in ITO 
(pA/pF) 
95% Confidence 
Interval 
P value 
 
β-blockade 
 
-3.57 
 
-6.93 to -0.21 
 
0.04 
 
Age 
 
0.02 
 
-0.15 to 0.19 
 
0.82 
 
Sex 
 
4.00 
 
-0.56 to 8.58 
 
0.08 
A 
B 
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Figure 2-13 Patient heart rate Vs peak ITO density in cells from non β-blocked (A) 
patients and β-blocked (B) patients.  r2 was calculated from the correlation coefficient. 
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table 2-4).  Clearly too few patients were taking β1-selective blockers other than 
atenolol to test whether the reduction in ITO density was a class effect of this type of 
drug or whether it  was specific to atenolol.  The inclusion of two patients taking 
bisoprolol did not have any affect the on the mean ITO density for the entire β-blocked 
patient group as shown in table 2-6.  
 
If β-blockers have a direct action on ITO it might be expected that they would exert a 
dose dependent effect on ITO density.  Figure 2-14 shows the total daily dose of atenolol 
each patient was taking and the ITO densities for all the cells from those patients.  Linear 
regression analysis showed there to be no relationship between these data (r2=0.00).  
 
Many cardiac drugs are known to or have the potential to affect cardiac 
electrophysiology.  Of these drugs, the ones taken prior to cardiac surgery by patients in 
this study are shown in table 2-4 along with the number of patients taking each drug.  
Multiple linear regression analysis of the effects of drug therapy on ITO density could 
not be performed but the comparison of ITO densities between the non β-blocked and β-
blocked patients was repeated when patients taking different types of cardiac drugs were 
excluded.  Table 2-6 shows both the patient and cell mean ITO densities when patients 
taking calcium channel blockers, ACE inhibitors, nicorandil or statins were excluded 
individually.  There remained a significant reduction in ITO density in the β-blocked 
patients when those patients taking either nicorandil or statins are excluded.  When 
patients taking calcium channel blockers or ACE inhibitors were excluded, the number 
of patients in each group was considerably smaller and, perhaps not surprisingly, the 
difference in the mean patient ITO was not statistically significant.  There remained, 
however, a significant reduction in ITO density in the β-blocked patients when the cell 
means were compared.   
 
2.4.2.5 Effects of patient pre-op pathology on ITO density 
The effects of various pre-operative cardiovascular morbidities on ITO density were not 
examined directly but, again, the mean ITO densities of the non β-blocked and β-blocked 
patients were compared when various patient groups were excluded from the analysis.  
The reduction in ITO density associated with chronic β-blockade was maintained when 
patients without a previous myocardial infarction, with left ventricular dysfunction or 
with diabetes were individually excluded (see table 2-6).   
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Figure 2-14 Total daily dose of atenolol given to the β-blocked patients Vs  peak ITO 
density in cells from those patients with the regression line and 95% confidence 
intervals. 
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Patients 
excluded 
 
BB No ITO density         
mean ± sem 
 
BB Yes ITO density         
mean ± sem  
 
None 
 
 
Females 
 
 
Valve surgery 
 
 
Pre-op drugs: 
Bisoprolol 
   
    
CCBs 
    
    
ACE inhibitors 
    
    
Nicorandil 
    
    
Statins 
    
Pre-op disease: 
    
No previous MI 
    
 
LV dysfunction 
    
 
14.4 ± 1.4 (n=15 patients) 
[15.0 ± 1.1 (n=35 cells)] 
 
15.7 ± 1.3 (13) 
[16.4 ± 1.0 (30)] 
 
16.3 ± 1.5 (10) 
[17.0 ± 1.2 (23)] 
 
 
14.4 ± 1.4 (15) 
[15.0 ± 1.1 (35)] 
 
13.7 ±  1.6 (7) 
[14.7 ± 1.2 (19)] 
 
13.0 ± 1.4 (11) 
[13.2 ± 1.1 (25)] 
 
14.1 ± 1.4 (8) 
[14.7 ± 1.1 (19)] 
 
15.2 ± 1.7 (11) 
[16.0 ± 1.8 (25)] 
 
 
14.0 ± 1.5 (14) 
[14.7 ± 1.1 (33)] 
 
14.1 ± 1.6 (13) 
[14.8 ± 1.2 (31)] 
 
10.2 ± 0.9 (n=17 patients) * 
[9.9 ± 0.7 (n=39 cells)] * 
 
10.5 ± 1.1 (12) * 
[9.8 ± 0.9 (26)] * 
 
10.2 ± 0.9 (17) * 
[9.9 ± 0.7 (39)] * 
 
 
10.5 ± 1.0 (15) * 
[9.9 ± 0.7 (35)] * 
 
10.6 ± 1.0 (14) 
[10.1 ± 0.8 (31)] * 
 
10.1 ± 1.3 (7) 
[9.9 ± 1.0 (16)] * 
 
10.1 ± 1.0 (13) * 
[9.9 ± 0.7 (30)] * 
 
10.2 ± 0.9 (17) * 
[9.9 ± 0.7 (39)] * 
 
 
9.8 ± 1.6 (9) * 
[8.8 ± 1.1 (19)] * 
 
10.6 ± 0.9 (16) * 
[10.4 ± 0.7 (36)] * 
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Diabetes 
 
 
 
14.0 ± 1.4 (12) 
[14.6 ± 1.0 (28)] 
 
10.1 ± 1.0 (15) * 
[9.7 ± 0.8 (32)] * 
 
 
Table 2-6 Mean ± sem peak ITO densities (pA/pF), in non β-blocked (BB No) and β-
blocked patients (BB Yes) when patients with characteristics listed in the left column 
were excluded from analysis.  Mean ITO densities for all remaining cells in each group 
are shown in square brackets.  * indicates significant difference from non β-blocked 
patients or cells (p<0.05, Student’s t-test).  
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2.4.3 Effects of phrixotoxin-2 on ITO density 
The results of application of either 100 or 200 nM phrixotoxin 2 on four and two cells 
respectively are shown in figure 2-15.   ITO density was plotted at approximately twenty 
seconds intervals for these graphs.  The application of either 100 or 200 nM of PaTx2 
had no significant effect on the atrial ITO current density.  The two cells with wash 
recording in figure 2-15A were from the same non β-blocked patient as those in figure 
2-15B and, in all four of these cells, the ITO density is significantly smaller than the 
mean current density for this patient group.  The ITO densities from the other two cells in 
figure 2-15A were from a different non β-blocked patient.  They have more 
representative values for this patient group but were also unaffected by PaTx2.  
 
Higher concentrations of PaTx2 were not used due to prohibitive cost and the lack of 
effect at concentrations previously shown to significantly reduce ITO in cellular 
recordings.  The use of this blocker of ITO was not investigated further.  
 
2.4.4 Effects of chronic β-blockade on time dependent inactivation 
of ITO 
The time dependent inactivation of ITO was found to fit a bi-exponential function.  
When a comparison was made between mono-exponential and bi-exponential curve fits 
to the raw data from individual cell, 100 % of the non β-blocked and 93% of the β-
blocked cells best fitted a bi-exponential relationship.  The mean fast rate constants (the 
inverse of the fast time constants) were 0.15 ± 0.008 for the non β-blocked cells (n = 27 
cells, 15 patients) and 0.16 ± 0.012 for the β-blocked cells (n = 22 cells, 13 patients), p 
= 0.38.  The slow rate constants were 0.035 ± 0.009 and 0.033 ± 0.005 respectively, p = 
0.87.  These data are shown in figure 2-16B.  Cells were excluded from the analysis if 
they did not best fit a bi-exponential function.  A few cells (5 non β-blocked and 4 β-
blocked) also had very small rate constants with very large standard deviations 
incorporating negative values.  These cells were also excluded from analysis on the 
basis that they did not well fit a bi-exponential function.  Bi-exponential curves fits to 
the mean current densities in both groups of cells are shown in figure 2-16A.  It can be 
seen from these curves that ITO inactivated rapidly with approximately 80% of the 
current inactivating within the first 20 ms.   
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Figure 2-15 Effects of phrixotoxin 2 on peak ITO current density at +60 mV Vs time.  
100 nM phrixotoxin 2 was applied to four cells represented by the different symbols in 
A.  In B, 200 nM of phrixotoxin was applied to two different cells. 
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Figure 2-16 Time dependent inactivation of ITO at +60mV.  A shows bi-exponential 
curve fits to mean ITO density (pA/pF) normalised to the ITO density at time zero Vs 
time, for cells from non β-blocked and β-blocked patients.  The mean ± sem fast and 
slow rate constants (K) for each group of cells are shown in B.
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2.4.5 Effects of chronic β-blockade on voltage dependence of ITO 
The mean conductance values for voltage dependent activation and the mean current 
density values for inactivation of ITO in cells from non β-blocked and β-blocked cells are 
shown in figure 2-17.  The values were normalised to the corresponding maximal 
conductance/density and Boltzmann curve fits were superimposed on each data set.  It 
can be seen that there was no difference between these curves in either groups of cells 
for either activation or inactivation.  The mean voltage of half maximal activation (V0.5), 
obtained from Boltzmann curve fits to the individual cells, was 23.8 ± 0.5 mV for the 
non β-blocked cells (32 cells, 14 patients) and 25.1 ± 
 
0.7 mV for the β-blocked cells (29 
cells, 15 patients), p = 0.15.  The corresponding slope factors were 8.6 ± 0.2 mV and 8.5 
± 0.3 mV respectively, p = 0.78.  The mean voltage of half maximal inactivation was        
-19.5 ± 0.6 mV for the non β-blocked cells (32 cells, 15 patients) and -19.0 ± 1.0 mV 
for the β-blocked cells (29 cells, 13 patients), p = 0.61.  The corresponding slope factors 
were 4.7 ± 0.3 mV and 5.3 ± 0.3 mV respectively, p = 0.13.  Figure 2-17C shows the 
mean curves for voltage dependent activation and inactivation for the non β-blocked 
and β-blocked cells.  In both groups of cells, inactivation was fully developed at 
potentials positive to 0 mV and activation did not commence at potentials negative to 0 
mV.  There was, therefore, no window current.  
 
2.4.6 Effects of chronic β-blockade on reactivation of ITO 
The effects of chronic β-blockade on ITO reactivation are shown in figure 2-18.  The 
mean ITO densities elicited by the second pulse (P2) of the protocol, which occurred at 
varying interpulse intervals, are shown in figure 2-18A for the cells from the non β-
blocked patients (31 cells, 14 patients) and β-blocked patients (30 cells, 13 patients).   
Initially, at the longer interpulse pulse intervals (≥ 200 ms) ITO density remained 
relatively constant in both groups of cells, albeit smaller in the β-blocked cells, 
indicating that ITO recovers quickly from inactivation.  At the shorter interpulse intervals 
(<150 ms), ITO density was reduced in both groups of cells.  This reduction in ITO 
density at very short interpulse intervals occurred, to the same extent, in both the non β-
blocked and β-blocked cells.  This can be seen in figure 2-18B when the mean densities 
elicited by P2 were normalised to the first, post-rest P1 of the voltage pulse protocol.  In 
this figure the mean data points for both the non β-blocked and β-blocked cells 
superimpose.  The reactivation data best fit mono-exponential curves.  A comparison of  
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Figure 2-17 Voltage dependence of ITO.  A shows the voltage dependency of activation 
of ITO with mean normalised ITO conductance Vs membrane voltage along with 
Boltzmann curve fits to cells from non β-blocked (  ) and β-blocked (    ) 
patients.  B shows the voltage dependency of inactivation of ITO with mean normalised 
ITO densities Vs membrane potential for non β-blocked (  ) and β-blocked (   
) cells and corresponding Boltzmann curve fits. The same activation and 
inactivation curve fits for both groups of cells are shown in C.  
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Figure 2-18  ITO reactivation. A shows the mean ITO densities elicited by pulse 2 of the 
protocol Vs the time interval between pulses one and two, in cells from non β-blocked 
(  ) and β-blocked ( ) patients.  In B the ITO densities are normalised to those elicited 
by the first post-rest pulse one in each group of cells. 
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mono-exponential and bi-exponential curve fits for each individual cell showed that 
93% of the non β-blocked cells (28 cells, 13 patients) and 80% of the β-blocked cells 
(24 cells, 12 patients) best fitted mono-exponential curves.  The mean data for these 
cells along with their curve fits are shown in figure 2-19.  It can be seen that the curve 
fits for both groups of cells superimpose even at the short interpulse intervals.  The 
mean time constants for reactivation derived from the curve fits to the individual cells 
were no different in non β-blocked cells at 31.3 ± 1.9 ms compared to  33.5 ± 2.6 ms for 
the β-blocked cells, p = 0.14.  
 
2.4.7 Effects of chronic β-blockade on rate dependence of ITO 
The rapid recovery of ITO suggests it is relatively rate independent except at extremely 
rapid stimulation rates.  However, the effects of incremental shortening of interpulse 
intervals, as used to determine ITO reactivation, do not necessarily replicate the effects 
of repetitive rapid stimulation.  This can be seen using the eight pulse protocols 
illustrated in figure 2-8 of the methods, in which, at rapid rates, the first, post–rest ITO 
recording is larger than the subsequent pulses in the train at rates above 75 bpm.  The 
effects of changing stimulation rate on ITO ie the rate dependence stimulation of ITO are 
shown in figure 2-20.  
 
The mean steady state ITO densities in cells from non β-blocked (27 cells, 11 patients) 
and β-blocked (17 cells, 6 patients) patients are shown in figure 2.20A.  In both groups 
of cells ITO was reduced significantly at rates ≥ 300 beats/minute.  This reduction was 
not due to run down of ITO as it reversed when the stimulation rate returned to75 
beats/minute.  Even at the most rapid stimulation rates, the ITO density in the cells from 
the β-blocked patients was smaller compared to that of the non β-blocked cells.  This 
reflects the fact that the degree of reduction in ITO density due to increasing stimulation 
rate was the same in the β-blocked and non β-blocked cells.  This is seen in figure 2.20B 
when the mean densities for each group of cells superimposed after they were 
normalised to their respective values at 75 beats/minute.   
 
2.4.8 Effects of chronic β-blockade on IKSUS density 
Peak IKSUS was measured as the end pulse current elicited by the voltage step from -50 
to +60 mV.  IKSUS measurements were made from current recordings used to measure 
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Figure 2-19  ITO reactivation.  The main graph shows the mean normalised ITO densities 
Vs interpulse intervals for all non β-blocked (  ) and β-blocked (  ) cells with 
the best fitting the mono-exponential curves.  The inset graph shows part of the main 
graph expanded at the shortest interpulse intervals. 
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Figure 2-20 Rate dependence of ITO. A shows the mean, steady state (8th pulse) ITO 
density Vs stimulation rate for cells from non β-blocked ( ) and β-blocked ( ) 
patients.  The current densities normalised to their respective values at the initial 
stimulation rate of 75 beats/minute are shown in B.  
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ITO density however, IKSUS was not measured in every cell in which ITO was recorded.  
The patient characteristics for the cells in which IKSUS was recorded are shown in table 
2-7.  For each patient group the distribution of the peak IKSUS densities were not 
inconsistent with a Gaussian distribution (KS distances of 0.17 and 0.12, p > 0.1 for BB 
No and Yes cells respectively). The mean peak IKSUS in cells from non β-blocked 
patients was 11.4 ± 1.1 pA/pF (n = 33 cells, 13 patients) compared to 9.7 ± 0.7 pA/pF in 
the cells from β-blocked patients (n = 31cells, 13 patients).  There was no significant 
difference between mean peak IKSUS in these two groups as shown in figure 2-21, p = 
0.21 Students t-test.  IKSUS density was not formally evaluated at other voltages. 
2.4.9 Assessing block of IKSUS by 4-AP 
Preliminary experiments were performed to assess the degree of block of IKSUS using 
low dose 4-AP to determine whether this could be used as an alternative method for 
separating ITO from IKSUS.  These experiments were performed in cells from non β-
blocked patients.  ITO and IKSUS were measured as the peak minus end pulse current and 
end pulse current respectively using a voltage step from -50 to + 60 mV.  The effects of 
different concentrations of 4-AP on current traces from the same cell can be seen in 
figure 2-22.  It can be seen that, in this cell, there was not complete “wash reversal” of 
4-AP.  Figure 2-23A shows the effects of varying concentrations of 4-AP on the mean 
peak IKSUS current density in all cells exposed to 4-AP.  Statistical analysis was not 
performed on these data as the small numbers of paired data may have lead to 
misleading results however, the graph does suggest that IKSUS was reduced by all 
concentrations of 4-AP.  The use of  4-AP as a blocker of IKSUS is only effective if a 
high level of IKSUS block can be achieved without affecting ITO density.  At the highest 
concentration of 4-AP used, 2 mM, approximately 50 % block of IKSUS did appear to be 
achieved.  However, at this concentration there also appeared to be some block of ITO 
when compared to ITO recorded without 4-AP and after wash out of 4-AP as shown in 
figure 2-23B.  Again, statistical analysis was not performed due to low n.  
 
2.4.10 Effects of chronic β-blockade on IK1 density 
The effects of chronic β-blockade on IK1 are shown in figure 2-24.  It can be seen that 
IK1 was significantly reduced at -120 mV with a mean density of -2.5 ± 0.2 pA/pF in 
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Patient  
characteristics 
IKSUS 
BB No n(%) 
IKSUS 
BB Yes n(%) 
IK1 
BB No n(%) 
IK1 
BB Yes n(%) 
No of patients 13 13 12 11 
Male patients 11 (84.6) 8 (61.5) 12 (100) 9 (81.8)) 
Mean age (yrs) 63.4 ± 3.0 66.9 ± 3.1 61.3 ± 2.2 62.8 ± 3.7 
Mean heart rate 
(beats/min) 
74.1 ± 3.9 52.6 ± 1.6* 75.2 ± 4.1 54.4 ± 1.8* 
Surgery:         
CABG               
AVR alone    
CABG + AVR              
CABG + MVR 
                           
9 (69.2)                                   
3 (23.1)                            
1 (7.7)                      
0 (0) 
                
13 (100)           
0 (0)                          
0 (0)                           
0 (0) 
                    
10 (83.3)                    
2 (16.7)                           
0 (0)                       
0 (0) 
                     
11 (100)                 
0 (0)                                      
0 (0)                                          
0 (0) 
Pre-op drugs:       
β-blockers            
-atenolol                   
-bisoprolol     
ACE inhibitors 
CCBs      
Nicorandil  
Statins        
Digoxin     
Amiodarone 
                         
0 (0)                            
0 (0)                    
0 (0)                       
3 (23.1)                    
7 (53.8)                  
7 (53.8)                                  
10 (76.9)                
0 (0)                   
0 (0) 
                          
13 (100)                          
12 (92.3)                           
1 (7.7)                  
7 (53.8)                                     
2 (15.4)                             
4 (30.8)                                       
13                                                                    
0 (0)                                 
0 (0) 
                        
0 (0)                                           
0 (0)                                         
0 (0)                                                  
3 (25)      
7 (58.3)                            
6 (50)
10 (83.3)       
0 (0)                                                   
0 (0) 
                  
11 (100)    
10 (90.9)          
1 (9.1)
5 (45.4)                     
1 (9.1)               
5 (45.4)                                           
11 (100)            
0 (0)                  
0 (0) 
Pre-op disease:  
MI                 
Angina                
LVSD                    
                    
1 (7.7)                                  
11 (84.6)                                   
2 (15.4)       
                          
3 (23.1)                                                 
13 (100)                                           
1 (7.7)         
                      
2 (16.7)                                                     
11 (91.7)
2 (16.7)        
                     
4 (36.4)
11 (100)                       
1 (9.1)         
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-mild                         
-moderate                  
-severe       
Hypertension      
Diabetes           
Post op AF         
2 (15.4)                
0 (0)                                                                  
0 (0)                                            
8 (61.5)                
3 (23.1)                                                                  
3 (23.1) 
0 (0)                       
1 (7.7)
0 (0)                                               
9 (69.2)                                                        
1 (7.7)                           
3 (23.1) 
2 (16.7)                  
0 (0)                                                
0 (0)                                                               
8 (66.7)                   
3 (25)                 
2 (16.7) 
0 (0)                                                                                
1 (9.1)          
0 (0)               
5 (45.4)                                                                         
0 (0)                                                                                         
1 (9.1) 
 
Table 2-7 Patient characteristics of cells in which IKSUS and IK1 were measured. 
BB No = non β-blocked patients, BB Yes = β-blocked patients, CABG = coronary 
artery bypass graft, MVR = mitral valve replacement, AVR = aortic valve replacement, 
Pre-op = before surgery, ACE = angiotensin converting enzyme, CCB = calcium 
channel blocker, MI= myocardial infarction, LVSD =left ventricular systolic 
dysfunction. * indicates a significant difference from BB No (p<0.05, Students t-test. 
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Figure 2-21  Mean peak IKSUS density at + 60 mV for cells (n) from non β-blocked (  ) 
and β-blocked patients (  ). 
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Figure 2-22 Effect of 4-AP on ITO and IKSUS.  The voltage pulse is shown in A and 
representative current traces from the same cell exposed to external solution containing 
varying concentrations of 4-AP. [  = no 4-AP,  = 0.05 mM 4-AP,  = 0.1mM 4-AP, 
 = 2mM 4-AP,  = no 4-AP (wash)] are shown in B. 
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Figure 2-23  Mean current density of IKSUS  (A) and ITO (B) at +60 mV after application of 
varying concentrations of 4-AP. when n(x) indicates the number of cells (n) and patients 
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Figure 2-24 Effects of chronic β-blockade on IK1. A shows the mean current voltage 
relationship for IK1 in cells from non β-blocked (  ) and β-blocked patients (  ).  The 
inset graph shows part of the main graph expanded for small the outward current densities 
between -80 and -20 mV. Mean peak IK1 density at -120 mV is shown in B.  * indicates 
p<0.05, Student’s t-test. 
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cells from non β-blocked patients (n = 31 cells, 12 patients) and -1.7 ± 0.0 pA/pF in cells 
from β-blocked patients (n = 21 cells, 11 patients).  However, there was no significant 
difference in current density at voltages less negative than -120 mV in particular, there was 
no difference in the small outward portion of the current between -90 and -30 mV.  This is 
the portion of the current that would be expected to contribute to terminal repolarisation.  
There was no current at -90 mV in keeping with the equilibrium potential for K+.  There 
was also no net current at around -30 mV as a result of the negative slope conductance of 
IK1 which may help explain why the cells in this study were depolarised to around this 
voltage (62).  
 
2.5 Discussion 
The experiments in this chapter describe the effects of chronic treatment of patients with 
β1-selective blockers on repolarising K+ currents in isolated, right atrial appendage 
myocytes.  There was a significant reduction in the density of ITO without any change in 
other properties of the current, specifically its voltage, time or rate dependency.  There was 
also a significant reduction in peak IK1 density but no change in peak IKSUS. 
 
2.5.1 Chronic β-blockade and reduction in ITO density: comparison 
with other studies  
This is the first study in which the effects of chronic β-blockade on the characteristics of 
ITO have been fully studied.  A reduction in ITO current density in association with chronic 
β-blockade has already been reported in a smaller retrospective study (29).  In that study a 
37% reduction in ITO current density was reported with mean values of 13.7 ± 2.1 and 8.7 
±1.3 pA/pF in the non β-blocked (n = 8 cells) and β-blocked (10) cells respectively, p<0.05 
(29).  In this prospective study, very similar absolute values of ITO and a similar percentage 
reduction have been found in larger population of cells and patients.     
 
To my knowledge, no other studies have examined the effects of chronic β-blockade on ITO 
in human cardiac myocytes.  There are several studies which have examined the effects of 
either chronic β-blockade or chronic changes in sympathetic innervation in animal hearts.  
As discussed in chapter 1, the only study to look at the chronic effects of β-blockers on 
animals showed prolongation of the atrial and ventricular APD in whole tissue after 9 days 
of treatment with either propranolol or metoprolol (152).  That study used microelectrode 
measurements and did not isolate cardiac myocytes or measure ion currents.  In 
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catecholamine depleted rats, action potentials measured in isolated, perfused left ventricles 
were prolonged and ITO density was significantly reduced in isolated ventricular myocytes 
(153).  A reduction in sympathetic innervation of the rat heart, induced by inhibitory 
antibodies of nerve growth factor during neonatal life, also resulted in a reduction in ITO 
density and prolongation of the APD in ventricular cells (85).  None of these animal 
experiments replicate the experimental design of this study but the similarities do provide 
support for my findings. 
 
Seemingly in contrast to the results of this study, another study looking at transgenic mice 
with dilated cardiomyopathy showed no change in ITO following treatment with 
propranolol for 2 weeks (57).  However, ITO was significantly lower in both the treated and 
untreated heart failure groups than a non heart failure, untreated control.  Perhaps the 
additional complicating factor of heart failure in these animals is enough to explain the 
lack of effect of β-blocker on ITO, particularly, as very few patients in my study had heart 
failure.  Alternatively, the genetic manipulation of the mice may have altered the 
susceptibility of ITO to β-blockade.  
To further support the role of the adrenergic system as a modulator of ITO, a number of 
studies have reported that adrenoceptor agonists can affect ITO.  Cultured, canine, 
ventricular myocytes have a reduced ITO density in comparison to freshly isolated cells.  
Exposure of these cells to isoproterenol, a non selective β-adrenergic agonist, for 24 hrs 
restored ITO density to pre-culture levels (60).  This perhaps suggests that it may not be the 
direct effect of β-blockers that reduces ITO but the unopposed β-adrenergic stimulation that 
results in a greater ITO current density in the cells from patients not treated with β-blockers.   
In contrast to this, another study treated rats with isoproterenol for 7 days, in sufficient 
doses to induce cardiac hypertrophy, resulting in a reduction of ITO in isolated ventricular 
myocytes. (61).  However, in this model it is impossible to distinguish between the effects 
of the β-agonist and the possible synergist or indeed opposing effects of cardiac 
hypertrophy.  It should be noted that both studies looked at the effects of relatively chronic 
exposure to β-agonists but only ventricular tissue was studied.  In contrast, α1- adrenergic 
stimulation appears to reduce ITO in several animal models as well as humans.  This 
reduction has been shown with both acute and chronic exposure to α1 agonists in both atrial 
and ventricular myocytes.  However, there does appear to some variation in response 
between different species and even between different types of cardiac myocytes within the 
same species (99;154;155). 
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This study did not examine the effects of either β-agonists or acute application of β-
blockers on atrial ITO.  This was partly due to time constraints but primarily reflects an 
interest in understanding the electrophysiological changes occurring as a result of chronic 
drug exposure in our patients.  Most patients treated with β-blockers tend to continue the 
drugs for prolonged periods of time and the electrophysiological consequences of chronic 
drug use are important to establish in their own right, even allowing for any possible anti-
arrhythmic actions.  The patients in this study were all treated with β-blockers for at least 
four weeks prior to cardiac surgery.  During this time, the exposure to these drugs will 
have resulted in changes, not only to cardiac tissue, but to the vasculature, the sympathetic 
nervous system and other organs which, in turn, may further modify the myocardium.  
Chronic exposure to β-blockers might also be expected to change the responsiveness and 
or expression of β-adrenoceptors (156;157) which may, in turn, affect how our isolated 
cells would respond to either acute application of β-blockers or indeed β-agonists.  
Therefore, acute application of β-blockers on isolated cells would not necessarily be 
expected to replicate the effects of chronic β-blockade in patients and, what is more, any 
acute affects on cardiovascular electrophysiology would not necessarily occur via the same 
mechanisms.   
The possibility that chronic β-blockade may have different effects from acute β-blockade 
has been suggested by several studies.  Treatment of patients with oral metoprolol for five 
weeks was associated with prolongation of the ventricular action potential duration in 
electrophysiology studies whereas acute, intravenous administration of the drug had no 
effect on repolarisation (158).  The rabbits treated with oral metoprolol or propranolol in 
Vaughan Williams study did not show any change in atrial or ventricular APD until they 
had been treated for 9 days.  However, studies looking only at the effects of acute β-
blockade in humans do report varying results.  Intravenous atenolol has been shown to 
prolong the atrial but not ventricular ERP in a human electrophysiological study (159).  
Acute intravenous bisoprolol has been shown to increase human atrial FRP and 
temporarily increase ventricular ERP (160).  Low dose intravenous propranolol has been 
shown to have no significant effect on ventricular repolarisation as assessed by the QT 
interval (161) whereas, in a different study, higher doses were actually shown to reduce 
ventricular monophasic APD but have no effect on ventricular ERP (162).  The effects on 
atrial repolarisation were not examined in either study.  
 
The effects of β-blockade on cardiac repolarisation appear to vary considerably.  The 
reasons are likely to be multifactorial, reflecting variations in species, drug dosage, type of 
β-blocker and methods and site of electrophysiological measurements.  None of these 
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studies describe the effects of either acute or chronic β-blockade on isolated myocytes or 
the effects on ion currents.  It should be noted that two other β-blockers, thought to have 
additional or possibly different anti-arrhythmic activity compared to “standard”  β-
blockers, have been reported to affect repolarisation in isolated myocytes with variable 
effects on ion currents.  Sotolol, which has additional class III anti-arrhythmic effects, does 
prolong the atrial APD acutely but does not affect ITO (95) and carvedilol, which blocks 
both α1 and β-adrenoceptors, prolongs ventricular ADP and reduces rabbit ventricular ITO 
in addition to reducing ICaL and delayed rectifier K+ currents (33;81).   
 
A number of studies have, therefore, provided support for β-blockers as potential 
modulators of cardiac repolarisation and ITO.  No other studies are directly comparable 
with this work and a number of differences have been highlighted between this work and 
other study designs and results.  It would be dangerous to assume that the reduction in ITO 
density associated with chronic β-blockade in this study, applies to all human cardiac 
myocytes, all species or even to β-blockers other than atenolol.  The duration of exposure 
to β-blockade may also be critical.  It should be remembered that the behaviour of any 
isolated cardiac myocyte, even if perfectly unharmed by the removal and isolation process, 
may not be identical to that in the intact heart within a living human where it is exposed to 
all manner of other modulating conditions. 
 
2.5.2  Chronic β-blockade and reduction in ITO density: a true 
association? 
Does the association between chronic β-blockade and ITO reduction reflect a direct causal 
relationship or could there be other factors contributing to the lower ITO density in the β-
blocked patient group?  This is a particular problem when dealing with the mixed 
population of patients within this study as there are numerous patient factors which could 
not be controlled or matched for and which could potentially affect ITO.  To complicate 
matters some of these factors are linked to β-blocker use.   
 
Any of the patient characteristics in either group could potentially affect the characteristics 
of the cells in either group, thereby, affecting ITO.  Alternatively, by chance, the 
characteristics of the cells could have differed between the two patient groups, skewing the 
ITO result.  When the cell characteristics were compared, there was no significant 
difference between the two populations.   
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When studying the patient characteristics of the two groups the most obvious difference 
between the β-blocked and non β-blocked patient group is the heart rate.  It is possible, 
therefore, that the reduction in ITO was due to a reduction in heart rate rather than 
specifically to β-blocker use.  There was no correlation between resting heart rate and ITO 
in either group of cells indicating that heart rate alone could not account for the reduction 
in post-rest ITO within the β-blocked patient group.  This is at least partially supported by 
evidence from animal models in which pacing induced tachycardia, as opposed to pacing 
induced bradycardia with atrio-ventricular nodal block, is associated with a reduction in 
ventricular ITO (108;114).  It should be noted however, that chronic pacing at non 
physiological rates can have other pathological effects on the heart including causing heart 
failure which, in itself, is associated with changes in cellular electrophysiology (163). 
 
Age can influence ITO and this is most marked during neonatal life when ITO density is 
significantly smaller than in adults in both animals and humans (164-166).  Age was 
unlikely to play a role in ITO reduction in this study as all patients were adults and there 
was no significant difference in mean ages between the non β-blocked and β-blocked 
patients.  
 
It was not possible within the scope of this study to use multivariate analysis to assess the 
effects of other patient characteristics on ITO.  I was able to exclude cells from patients with 
particular characteristics and re-analyse the data to see whether there was still a significant 
reduction in ITO in the β-blocked patients.  Gender differences and pathological processes 
like left ventricular dysfunction, myocardial infarction, diabetes and valvular heart disease 
have all been shown to affect ITO in human and or animal studies (55;74;99;167-169).  
Drugs like ACE inhibitors can also influence ITO (99;167) while others may have the 
potential to do so.  Calcium channel blockers have been shown to affect ventricular ITO 
(33) although verapamil does not appear to affect atrial ITO (170) and nicorandil activates 
the K+ channel IKATP (33).  To my knowledge, statins have not been shown to affect K+ 
currents but have been reported to have anti-inflammatory actions which may affect 
cardiac remodelling and have also been shown to reduce the incidence of AF (171;172)  
However, individually, none of these factors could explain the reduction in ITO seen in this 
study.  There were, perhaps, insufficient patients once either those taking ACE inhibitors 
or calcium channel blockers had been excluded from analysis to expect there to still be a 
significant reduction in ITO in the β-blocked patients but this reduction was still seen when 
cell means were analysed.   
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It would appear that none of the patient characteristics identified in this study, other than 
chronic β-blockade, were individually responsible for the reduction in ITO density.  It 
remains possible however, that several linked factors, possibly including chronic β-
blockade, could actually be responsible for the reduction in ITO density rather than β-
blocker use alone e.g. the combination of β-blockers, ACE inhibitors and LV dysfunction.   
 
2.5.3 Chronic β-blockade and other ITO characteristics: a comparison 
with other studies  
This is the first study to examine the effects of chronic β-blockade on the characteristics of 
ITO other than just current density.  Chronic β-blockade did not affect the voltage 
dependency, time dependency of inactivation, reactivation or rate dependency of ITO.  
Changes in these characteristics potentially could have contributed to a change in ITO 
current density and could have influenced to the “amount” of current available to 
contribute to repolarisation.  
 
The current characteristics of ITO vary considerably between species but, even in humans, 
are affected by numerous factors.  These include, the type of cardiac myocytes eg atrial or 
ventricular, pathology, drugs, cardiac rhythm and experimental conditions including 
temperature, composition of solutions and methods of isolating and measuring ITO.  This 
makes it difficult to make any direct comparisons between any absolute values relating to 
ITO in this study with others.  However, it is possible to compare the current characteristics 
of ITO described in this work with the results of other human atrial studies to see if there are 
any major differences that cannot be easily accounted for and may reflect some other 
unidentified factor that may affect this current.   
 
Voltage dependent activation of ITO in human atrial cells can consistently be fitted to single 
Boltzmann equations with V0.5 values ranging from 1 to 22 mV and slope factors ranging 
from 8 to 19 mV.  Values for voltage dependent inactivation range from -14 to -40 mV for 
V0.5 and 6 to 15 mV for slope factor (9;35;39;55;164;166).  My results are in keeping with 
these ranges although the V0.5 activation in my study is slightly higher.  The variation in 
these values is likely to reflect different experimental conditions, including temperature, 
which is certainly known to accelerate ITO kinetics (35), as well as different mechanisms 
for separating ITO from other overlapping currents.   
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Rapid inactivation is one of the key characteristics of ITO in all cells.  In several studies of 
human atrial myocytes, time dependent inactivation of ITO has been described by mono-
exponential curve fits with time constants of 12 to 14 ms (9;35;36) at physiological 
temperature.  One other study in addition to this work, has reported a bi-exponential curve 
fit to ITO inactivation with fast time constant of 14 to 16ms and slow time constant of 
around 300 ms (55).  The fast inactivation of ITO reported in all of these studies is in 
keeping with the results of this study in which the mean fast rate constants approximate to 
fast time constants of 6 ms.  It is possible that the presence and value of a slow time 
constant is more influenced by differences in the actual process of curve fitting and also 
the duration of the stimulating voltage pulse. 
 
Reactivation of ITO has also been reported as being both mono-exponential 
(38;39;164;166) and bi-exponential (55) in different studies.  When mono-exponential 
reactivation is described, time constants vary from 14 to 17 ms at physiological 
temperature which is slightly faster than those of this study at around 30 ms.  However, 
this difference is relatively small and may simply reflect differing experimental conditions.  
One other study has looked at both reactivation and rate dependence of ITO in human atrial 
myocytes.  It showed no significant change in ITO density at rates from 0.1-4 Hz but did not 
examine ITO at the faster stimulation rates which resulted in reduction in ITO density in this 
study (38). 
 
2.5.4 Chronic β-blockade and IKSUS: a comparison with other studies 
In this study no change was found in IKSUS current density between the cells from the β-
blocked and non β-blocked patients.  This is the first time this has been shown in a large 
prospective study.  This result is supported by the retrospective data analysis of Workman 
et al who also showed no change in IKSUS associated with chronic β-blockade in a smaller 
patient cohort (29).  The absolute values for IKSUS density were similar between that study 
and this one.   
There is limited data to support a role of the β-adrenergic system in modulation of IKUR.  In 
contrast to the lack of effect of chronic exposure to β1-selective blockers, acute application 
of carvedilol has been shown to reduce IKUR in human atrial myocytes (56).  This may 
represent a distinct difference in the action of carvedilol as compared to other β-blockers or 
simply the difference in acute versus chronic exposure to the drug.  Acute exposure to β-
agonists has been shown to increase IKUR (173).  That study was performed at room 
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temperature although it does not seem likely this would have affected the nature of the 
current response to isoproterenol although it may have affected the magnitude and/or rate 
of change.  In vivo, particularly in the context of ischaemic heart disease, heart failure and 
cardiac surgery, there is likely to be considerable activity of both the sympathetic nervous 
system and endogenous catecholamines.  Exposure to β-blockers might be expected block 
the endogenous β-agonist mediated increase in IKUR but, under these circumstances, IKUR 
would be expected to be higher in the non β-blocked patient group which was not the case.  
It is possible that this may reflect a combination of the effects of long term exposure to 
endogenous β-agonists and/or β-blockers with possible associated changes in adrenoceptor 
receptor expression, in addition to the complicating influence of patient co-morbidities.   
In this study IKSUS was measured as the end pulse current.  This current has been shown to 
be K+ current distinct from ITO, IK1 and IK and has properties very similar to the current 
carried by Kv1.5, therefore, has been thought to represent IKUR (90).  It is remains possible 
however, that a small proportion of the end pulse current may also consist of a slowly 
inactivating component of ITO, other delayed rectifiers and other constitutively active 
background currents and, it is for this reason, this current was labelled as IKSUS and not 
IKUR in this study.  It is possible that this discrepancy between IKSUS and IKUR may explain 
the relative lack of block of the end pulse current using low dose 4-AP although too few 
cells were studied to accurately establish the degree of IKSUS block.  The lack of full 
washout also raises the possibility that the current was decaying with time.  This was not a 
feature of later experiments in which relatively long protocols were not associated with 
significant rundown of either IKSUS or ITO.  The 4-AP studies were carried out in the early 
stages of this study and it is possible that suboptimal experimental technique may have 
resulted in increased current run down.  It is also possible however, that the washout phase 
of 4-AP was simply insufficient for the current to fully recover. Although the differences 
between IKSUS and IKUR are likely to be small, some studies of IKUR have tried to eliminate 
these influences by using combinations of long voltage pulses, to eliminate any less slowly 
inactivating currents and a pre-pulse current, to inactivate ITO, before measuring the 
resulting end pulse current (90;93;174).  This may result in differences between the results 
presented here and other studies although the effects of these differences in protocols are 
likely to be minimal.  
2.5.5 Chronic β-blockade and IK1: a comparison with other studies 
In this study chronic β -blockade was shown to reduce IK1 at -120 mV but, at voltages more 
positive to this, there was no significant reduction in IK1 density.  This is the first study to 
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examine the effects of chronic β-blockade on human atrial IK1.  An earlier study by 
Workman et al measured the input resistance of human atrial myocytes as a surrogate of 
IK1 using a ramp protocol (29).  During a ramp protocol only rapidly activating and slowly 
inactivating currents contribute to the ramp current but, at negative potentials, this could 
include currents other than IK1 including the so called leak or background currents.  
Measuring IKI using a voltage pulse protocol and barium subtraction allows for 
measurement of a more defined current as well as the ability to directly measure current 
density at different voltages.  Workman et al did detect a reduction in input resistance in 
cells from patients treated with β-blockers but this could represent either a change 
predominantly at one particular voltage or across the whole range of the voltage ramp and 
is not contradictory to the results of this study.  
Two studies have examined the effects of carvedilol on IK1 in isolated rabbit ventricular 
myocytes (81;82).  One showed no effect of carvedilol across the voltage range of -100 to 
+ 50 mV using whole cell patch clamping and a square voltage pulse protocol (81).  That 
study did not define the current by using barium subtraction and did not study the current 
at voltages negative to -100 mV.  The other study looked at single IK1 currents from an 
excised inside-out patch of rabbit ventricular cell membrane, measured a room temperature 
and without barium.  It found no effect of carvedilol on IK1 channel opening (82).  These 
two studies looked at acute application of carvedilol and have suggested a direct blocking 
action of this drug within the channel pore.  This is likely to be a different mode of action 
than the effect of chronic β1-selective blockers in this work, as it is unlikely that significant 
concentrations of the drug remain in my preparations following isolation of the cells.  Both 
of these carvedilol studies differed considerably from this study in terms of experimental 
technique, protocol and type and species of cardiac myocytes used.  Crucially they did not 
study IK1 at -120 mV and so could not be expected to detect the reduction in IK1 seen in 
association with chronic β-blockade in this work.  In another study, therapeutic 
concentrations of the non selective β-blocker tilisolol were shown not to affect IK1 current 
density in isolated, guinea pig myocytes but, again, the maximum negative voltage used 
was -100 mV (83). 
Some experiments have suggested β-adrenergic stimulation may reduce IK1 which would 
seem to contradict the results of this study (84;175). In one of these studies acute 
application of isoproterenol significantly inhibited IK1, not measured by barium 
subtraction, in isolated human ventricular myocytes, across the whole voltage range from -
120 to 0 mV.  This effect was prevented by the addition of propranolol (175).  That study 
also showed that the effects of β-adrenergic stimulation on IK1 were reduced in myocytes 
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from failing hearts.  The effects of propranolol alone were not studied.  Another study 
looking at the effects of 48hrs of exposure to isoproterenol in cultured guinea pig 
ventricular myocytes, demonstrated a reduction in IK1 magnitude across a voltage range of -
100 to -70 mV but no change at voltages more positive than -70 mV (84).  Again, this 
effect was reversed by propranolol.  Both of theses studies show that IK1 can be modulated 
by the β-adrenergic system.  However, the results would suggest that, in my study, IK1 in 
cells from patients not taking β-blockers might be expected to decrease, reflecting the non 
antagonised effects of constitutively active sympathetic tone.  This is is not the case.  The 
relatively low number of patients with heart failure in this study would not explain the 
difference between this work and the results of these other studies however, it is possible 
that the influence of other patient characteristics may alter the affects of β-adrenergic 
modulation of IK1.  A number of other factors including ischaemia, left ventricular 
hypertrophy and angiotensin II activation, have all been shown to modulate IK1 
(74;75;176).  Although there is not a marked difference in some of these characteristics 
between the two patient groups in this study, it is possible that the cumulative effects are 
enough cause a difference in IK1 density, either by direct effects on the current, or by 
influencing β-adrenergic modulation.  Perhaps more importantly, it should be remembered 
that there is limited work regarding the effect of β-adrenergic modulation of IK1 and there 
are marked differences in experimental design between this study and the others described.  
To my knowledge there are no studies looking at β-adrenergic modulation in atrial 
myocytes.  The potential molecular difference in the composition of IK1 ion channels in 
atrial and ventricular myocytes may be an important factor in explaining any differences in 
either the characteristics of the current or its regulation, between theses two cardiac 
chambers (137). 
2.5.6 Chronic β-blockade and reduction in IK1 density: a 
physiologically significant change? 
This study demonstrated a reduction in IK1 current density at -120 mV in association with 
chronic β-blockade but this effect was not present at more positive voltages.  What, if 
anything, is the physiological significance of this?  By convention, IK1 is studied at 
negative voltages at which a large inward current is generated.  However, during an action 
potential the cell is not hyperpolarised to these voltages.  It is possible that even small 
changes in current density at negative voltages could affect the cell resting membrane 
potential but no significant difference in IK1 was detected at voltages positive to -100 mV.  
The resting membrane potential was similar for both groups of cells although the cells 
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were partially depolarised which prevents any direct comparison of the true resting 
membrane potential between the non β-blocked and β-blocked patient groups.   
If changes in IK1 were to explain the prolongation of the atrial APD in the cells from 
chronically β-blocked patients it would be expected that the outward component of IK1 
would be reduced in cells from these patients.  This was not seen in this study and, 
therefore, it is seems unlikely that the reduction in IK1 at -120 mV could have any direct 
effect on the APD.    
Changes in IK1 current density have been reported most frequently in the context of AF.  
Studies from patients in AF have shown a increase in IK1 that has been postulated to 
contribute to shortening of the APD, a theory that has been supported by computer 
modelling (54).  One study has suggested an increase in IK1 across a wide negative voltage 
range using a ramp protocol although only the actual difference at -100 mV was reported 
(70).  Another study, using a series of square voltage pulses but no barium, demonstrated 
an increase in IK1 but only at -120 mV (2).  A significant increase in both the outward and 
inward components of IK1 in isolated human right atrial appendage cells has only actually 
been reported in one study (9).  The results of these last two studies were used to model the 
effects of IK1 upregulation on APD duration, however only the maximal change in the 
inward portion of IK1, occurring at the most negative voltages in both studies, was applied 
across the whole voltage range of the AP model (54).  This is likely to over represent the 
true effect of any outward IK1 upregulation on the APD.  Interestingly, in another study, an 
increase in both outward and inward components of IK1 was only detected in isolated left 
atrial appendage cells in patients with AF with no change seen in right atrial appendage 
cells (12).  These somewhat inconsistent results do raise questions about whether human 
atrial IK1 is truly remodelled in a disease setting and whether the changes measured IK1 in 
isolated myocytes are likely to have any real physiological effects.  
2.5.7 Limitations of experiments 
There are several practical limitations to this work which need to be considered when 
interpreting the results.  Firstly, this was an observational rather than an interventional 
study and none of the patients from whom tissue was obtained had their treatment altered 
in any way either as a result of, or specifically for, this study.  The major difficulty with 
this was the number of confounding factors existing for each patient which could 
potentially mask or contribute to changes in cardiac electrophysiology.  The attempt to 
dissect out the true role of chronic β-blockade has already been discussed.  The advantage 
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of having an observational study is that this patient population should reflect the general 
population of patients undergoing cardiac surgery in our hospital and, therefore, these 
results should be representative of a wider “real-life” population.  However, it should be 
noted that selection of patient was not blinded or randomised due to the need to ensure 
enough non β-blocked patients could be recruited.  The very process of agreeing to 
participate in a study does select out a potentially different population.   
 
The experimental design and protocols themselves have a number of potential problems 
which need to be considered.  All of our tissue was obtained from samples of right atrial 
appendage as this is a site of access for cardio-pulmonary bypass cannulae.  There is 
evidence to suggest that ventricular ITO varies across the ventricle wall (40;177) and that 
there is some variation in ITO density in different sites of animal atria (178).  It is possible 
that human atrial ITO may also differ in different parts of the atria and therefore our results 
may not be applicable to the all cells from both atria.   
 
It is not possible to perfuse the tissue with enzymes, as can be done with animal or whole 
heart preparations and using the chunk method of cell isolation may result in damage to 
cells that may affect ion currents.  A comparison of these two methods of cell isolation for 
isolating canine atrial cells did not, however, show a significant effect on ITO although the 
delayed rectifier IK was affected (179).  Unlike animal cell isolations, the yield of healthy, 
stable and patchable cells in my study was not as high and, those that were patched had 
less negative resting membrane potentials than would be expected.  This may reflect 
damage to the cells during the isolation process and it is possible that the population of 
cells that survive are not truly representative of all right atrial appendage myocytes.    
 
In this study attempts were made to isolate ITO from other, overlapping currents in order to 
try to accurately record its characteristics.  Methods of blocking other ion currents were 
chosen to try and minimise any detrimental effect on ITO.  It is recognised that cadmium, 
which was used to block ICaL, can affect ITO by altering the voltage dependency of 
activation and inactivation (180) however, all cells were exposed to cadmium and, 
therefore, it should not account for the reduction in ITO density in the β-blocked cells.  
IKSUS was not blocked with 4-AP, as preliminary experiments showed doses of 4-AP that 
did not interfere with ITO did not even achieve 50% block of IKSUS.  If chronic β-blockade 
significantly altered the inactivation of IKSUS, it would impact on the ITO measurements in 
these cells however, given the extremely slow inactivation of IKSUS, the impact of any 
kinetic changes over the duration of the 100 ms voltage pulse would probably be small.  
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Other currents including Cl- currents and other delayed rectifier currents also contribute to 
a small degree to the end-pulse current and these currents were neither blocked nor 
measured.  It is possible that chronic β-blockade may have altered any of these currents 
which, again, would have the potential to affect ITO measurements in these cells although 
probably only to a small degree.   
 
In order to measure the voltage dependency of ITO activation, current was converted into 
conductance, which involved calculating the reversal potential for K+ under these 
experimental conditions.  It was assumed that ITO is carried by a purely K+ selective 
channel and, therefore, the reversal potential should be equal to the equilibrium potential 
for K+.  It is possible to measure the equilibrium potential by plotting the slope 
conductance of ITO.  This could be done by using a very brief voltage pulse to fully activate 
the current and then recording the tail currents as ITO inactivates to a pre-determined 
voltages.  Some studies have measured the equilibrium potential based on ITO tail currents 
and found it to be more positive than my calculated reversal potential between -65 and -70 
mV (9;181).  This might suggest that the ion channels for ITO are permeable to other ions 
but it should be noted that one of these studies was performed in ventricular myocytes and 
at room temperature which may account for some of the disparity with my results.  
 
When measuring the rate dependency of ITO, the current was not measured at rates slower 
than 75 beats/minute.  Although this is representative of the mean heart rate of the non β-
blocked patients in this study, it is faster than that of the β-blocked patients.  It is possible 
that there is a difference in the rate dependency of ITO between the two patient groups 
which is only exists over a narrow range of relatively slow stimulation rates.  The 
physiological significance of such an effect, should it exist, is unclear and it could not 
account for the reduction in steady state ITO in the β-blocked cells at higher stimulation 
rates.   
 
2.5.8 Implications of the effects of chronic β-blockade on repolarising 
potassium currents 
2.5.8.1 Can a reduction in ITO density alone explain chronic β-blocker induced APD 
prolongation?  
The potential impact of ITO reduction on APD has already been discussed in chapter 1.   A 
reduction in ITO may be expected to prolong APD purely by its contribution to early 
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repolarisation.  The reductions in ITO density in this study were significant across the whole 
voltage range of activation and not just at +60 mV.  This is important when considering the 
possible impact of this ITO reduction on APD, as atrial cells usually depolarise to between 
approximately 20 to 50 mV during the upstroke of the action potential depending on the 
rate of stimulation (2).  The reduction in ITO demonstrated in this study could therefore be 
physiologically significant in prolonging early repolarisation. 
 
In the study by Workman et al chronic β-blockade had a greater impact on APD90 than 
ADP50 which would suggest an additional and, perhaps greater, change in K+ currents 
affecting late repolarisation (29).  This was not found to be the case in this study, as IKSUS 
was not affected by chronic β-blockade and, although IK1 was reduced, its physiological 
impact on APD is likely to be minimal.  Can ITO reduction alone explain the effect of 
chronic β-blockade on APD90?  In addition to its affect on early repolarisation, any 
reduction in ITO would be expected to alter the membrane potential at the end of early 
repolarisation.  This would be expected to alter other currents including ICaL and the 
delayed rectifiers, even if none of these currents were directly affected by chronic β-
blockade.   
 
4-AP has been used to reduce ITO density by a similar degree to chronic β-blockade 
resulting in APD prolongation (29).  However, 4-AP is not a specific blocker of ITO and 
therefore cannot exactly replicate the effects of ITO reduction on APD.  It was hoped that 
phrixotoxin could be used as a specific blocker of ITO so it could be applied to cells, when 
measuring action potentials, in a dose that would mimic the degree of reduction in ITO seen 
with chronic β-blockade.  However, the lack of effect of phrixotoxin on ITO in preliminary 
experiments prevented its use for this purpose.  It is unclear why phrixotoxin did not 
reduce ITO density.  It is possible that the doses of phrixotoxin used were insufficient to 
cause a reduction in ITO and these doses only affected ITO in transfected cells because of the 
high density of Kv4.3 channels (48).  Arguing against this, is a report of similar 
concentrations of phrixotoxin significantly reducing ITO in isolated rat ventricular myocytes 
(48).  It is possible that more subtle effects of phrixotoxin on ITO in atrial myocytes may 
only have been detected if more cells were studied.  Phrixotoxin has been shown to affect 
ITO density by altering its voltage dependency of activation and has its greatest effect at 
voltages of around 20 mV whereas voltage steps to +60 mV were used in my cells.  The 
mechanism by which phrixotoxin has been reported to reduce ITO does not mimic that of 
chronic β-blockade which does not affect the voltage dependency of ITO and, therefore, 
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phrixotoxin could not have had exactly the same effects on APD even if it had reduced ITO 
density.  
 
There are other possible techniques that could be used to test the effects of a reduction in 
ITO on APD.  Computer modelling could be used to study the impact of ITO on APD.  Some 
computer modelling has already been done to assess the role of ITO in determining APD 
within the ventricle.  This has provided conflicting results, showing either no effect on 
APD (49) or prolongation of APD associated with low densities of ITO and shortening with 
high densities (50).  Atrial action potentials are different from ventricular action potentials 
mainly due to the presence of prominent atrial delayed rectifiers like IKUR (35) and it is 
possible that changes in ITO may have a more prominent impact on the atrial action 
potential due to secondary changes in these currents.  If computer modelling were to be 
used to investigate the consequences of ITO reduction on APD, the model would have to be 
representative of a human atrial action potential and, ideally, would be based on an action 
potential recorded under the same experimental conditions as described here.  Computer 
modelling may also be useful to investigate what, if any, affect IK1 reduction at only 
negative potentials might have on APD. 
 
The dynamic clamp is another technique which might be useful to further investigate the 
effects of ITO reduction on APD.  Using this technique the effects of simulated 
conductances can be tested in living cells.  During current clamping the value of the 
simulated conductance can be calculated by computer, based on the instantaneous 
membrane potential of the cell and predetermined algorithms describing the conductance.  
A corresponding current can be injected into the cell and the action potential measured.  In 
order to use this technique to “block” a current, another current of equal magnitude but 
opposite polarity can be injected into the cell.  One such study used this technique to look 
at ITO in canine ventricular  myocytes and found that “blocking” ITO reduced the notch in 
phase 1 repolarisation but did not prolong the APD (182).  It would be interesting to use 
this technique in human atrial cells. 
    
2.5.8.2 What can we tell about the mechanisms of ITO reduction by chronic β-
blockade? 
It is unclear how chronic β-blockade reduces ITO.  There are a variety of different 
mechanisms including direct channel block, alteration in ion channel protein or accessory 
protein expression or alteration in channel protein function.  It seems less likely that direct 
block of the ion pore is the mechanism involved for several reasons. Firstly, one might 
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expect β-blockade to reduce ITO in a dose dependent fashion if it were having such a direct 
action on the channel and this is not the case.  Secondly, we believe that the process of cell 
isolation removes any drugs from the environment of the cells and we would not expect 
there to be any residual β-blocker present, either bound to our cells or blocking ion 
channels.  
 
As discussed in chapter 1, ITO density and other current characteristics have been shown to 
be linked to expression of both the pore-forming channel protein Kv4.3 and various 
accessory proteins (97).  What is more, the expression of these proteins has been shown to 
change in association with changes in ITO under the influence of various cardiac drugs and 
pathologies including AF (96;99).  It is possible therefore, that chronic β-blockade may 
reduce ITO by reducing the expression of Kv4.3 or accessory proteins that influence ITO 
density and/or Kv4.3 expression.  Most accessory proteins, apart from those that are purely 
involved in Kv4.3 trafficking to the cell membrane like KCHAP, can also modify 
characteristics of ITO other than just density.  As chronic β-blockade does not alter the 
voltage, time or rate dependency of ITO, it suggests that modification of accessory proteins 
that alter these characteristics is not involved.  However, the functions of many accessory 
proteins have only been studied in expression systems and it may be their functions are 
different or more limited in a physiological setting, therefore, not ruling out their 
involvement.   
 
Chronic β-blockade may alter the expression of Kv4.3 or accessory proteins by altering 
gene expression but may also have effects further downstream, for example, by inducing 
conformational change in proteins, altering protein phosphorylation or interacting with 
other signalling pathways which result in altered expression of channel and or accessory 
proteins.  It is also possible that the actual levels of ion channel or accessory protein 
expression do not change but their functional capacity is altered such that ITO density is 
reduced.  However, it would seem a reasonable first step to examine the effects of chronic 
β-blockade on the expression of Kv4.3 and accessory proteins that are known to modify 
Kv4.3 expression in attempt to explain the reduction in ITO. 
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EFFECTS OF CHRONIC β-BLOCKADE ON ION 
CHANNEL EXPRESSION 
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3.1 Introduction  
Kv4.3 is the pore-forming protein that forms the ion channel responsible for ITO in human 
cardiac tissue (96;97).  The cell surface expression of Kv4.3 is an important factor in 
determining ITO current density.  ITO current density can also be influenced by a number of 
accessory proteins including KChIP2, KChAP, Kvβ subunits and Frequenin (96;97).  
These proteins can associate with Kv4.3 and regulate its expression and/or function thus 
potentially modifying, not only the current density, but also other current characteristics 
including time and voltage dependency.  Changes in the expression of Kv4.3 and its 
accessory proteins have been described in a number of cardiac pathologies including atrial 
fibrillation and have also been shown to be affected by a number of other factors including 
cardiac drugs (96;97;99).  It is, therefore, possible that the reduction in the ITO current 
density associated chronic β-blockade may be explained by changes in the expression of 
Kv4.3 and/or its accessory proteins.   
In this study chronic β-blockade has also been shown to reduce IK1 current density at 
negative potentials but not to affect IKUR.  There are a number of pore-forming proteins that 
form the ion channel responsible for human atrial IK1: Kir2.1; 2.2; 2.3 and possibly TWIK1 
(62;97).  The pore-forming protein for IKUR is Kv1.5 (94;97).  It is possible that the 
reduction in IK1 associated with chronic β-blockade may be secondary to a reduction in the 
expression of some, or all, of its pore-forming subunits whereas the expression of Kv1.5 
might be expected to remain unchanged. 
A previous study has shown, chronic β-blockade does not affect human atrial ICaL (29) and 
therefore would not be expected to change the expression of the pore-forming protein 
responsible for this current Cav1.2 (97).  However, a reduction in ITO current density and 
the subsequent slowing of early repolarisation (29) might be expected to influence the 
calcium entry by prolonging the duration of activation of ICaL.  This may have secondary 
effects on the cardiac sodium-calcium exchanger (NCX) which utilises the sodium gradient 
to remove excess calcium from the cell during diastole creating a net inward current (183).  
It is conceivable chronic β-blockade may affect the expression of NCX1. 
Functional changes in ion channels resulting in changes to the currents they carry may 
occur in a number of ways.  Perhaps the most basic, is a change in the absolute amount of 
one or more protein subunits, pore-forming or accessory.  The amount of a particular 
protein present within a cell can be detected by Western blotting which could be used to 
compare the abundance of ion channel proteins in tissue from non β-blocked and β-blocked 
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patients.  There are various mechanisms by which the amount of protein within a cell can 
change and one of these is by altered gene transcription and translation.  The abundance of 
mRNA encoding particular ion channel proteins can be measured as a marker of 
transcription of the corresponding genes.  This can be done using quantitative, real time, 
reverse transcriptase-PCR (RT-PCR) and, again, compared between tissue from non β-
blocked and β-blocked patients. 
3.2 Aims 
The particular aims of the experiments described in this chapter were: 
• To isolate RNA from human atrial tissue  
• To use quantitative real time RT-PCR to compare mRNA expression of ion 
channel pore-forming and accessory subunits in atrial tissue from non β-blocked 
and β-blocked patients. 
• To identify Kv4.3 protein in human atrial tissue samples by Western blotting. 
• To use Western blotting to compare Kv4.3 protein expression in atrial tissue from 
non β-blocked and β-blocked patients. 
3.3 Methods 
3.3.1 Quantification of mRNA by real time RT-PC 
3.3.1.1 Principles of quantitative polymerase chain reaction (QPCR) 
mRNA is transcribed from DNA and encodes the template from which proteins are 
synthesised or translated.   The mRNA within a cell is, therefore, a measure of genetic 
expression.  Quantifying mRNA expression can be technically difficult as it is relatively 
unstable at room temperature, extremely susceptible to destruction by ribonuclease 
enzymes and variations in pH.  Many cellular proteins are only present in relatively low 
concentrations and consequently the mRNA encoding theses proteins may also be of very 
low concentration.   Techniques to quantify mRNA therefore need to be highly sensitive, if 
low abundance mRNA is to be detected, highly specific, if only mRNA encoding pre-
specified genes is to be quantified and must maintain mRNA stability. 
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Northern blotting and RNase protection assay are two older techniques for detecting 
mRNA which can be used to some degree to quantify mRNA expression (184).  These 
techniques have various and different limitations.  One of the main problems is that both 
require the input of relatively large amounts of mRNA and, therefore, are not very useful 
for quantifying low levels of mRNA expression.  They can also be time consuming, prone 
to RNA degradation and involve the risks of radiation.    
 
Many of these problems were overcome by the development of the polymerase chain 
reaction (PCR), a highly sensitive technique which allowed the indirect detection of very 
low levels of mRNA (185).  PCR involves the exponential amplification of complimentary 
DNA (cDNA) synthesised from an mRNA template in a reverse transcription reaction 
(RT).  During this amplification process short complimentary copies of the cDNA 
(primers) bind to random or specific parts of single strand cDNA, and are then extended by 
the polymerase enzyme to make complimentary copies of the cDNA using single 
deoxynucleotide triphosphates (dNTPs).  The three steps in a PCR cycle: cDNA 
separation, primer binding or annealing and elongation occur at different temperatures and 
by continued cycling through these temperatures the steps can be repeated and the cDNA 
amplified (see figure 3-1).   
Real–time RT-PCR allows for the quantification of mRNA due to the presence of 
fluorescent reporters which generate fluorescence in direct proportion to the amount of 
cDNA product in each PCR cycle (186).  The amount of fluorescence (or amount relative 
to background levels: delta Rn) is monitored during the PCR cycles and, from this, the 
threshold cycle or Ct value for the reaction can be determined.  This indicates the cycle 
number at which the fluorescence generated by cDNA copies is detectable above 
background.  Comparing the Ct values of cDNA copies of different genes allows for the 
relative comparison of the amount of input cDNA and hence, mRNA expression within a 
tissue sample.  When investigating mRNA expression in different tissue samples, the Ct 
values of the cDNA copies have to be normalised to those of housekeeping genes which 
are expressed to the same degree in all the tissue samples.  This ensures the same amount 
of cDNA for each tissue sample was used at the start of the reaction.  Absolute 
quantification requires reference to a standard curve of fluorescence generated by a known 
number of cDNA copies. 
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Figure 3-1  Diagram of the reactions in one PCR cycle.  Each cycle can be repeated 
multiple times resulting in multiple copies of the target gene. ds = double stranded, ss = 
single stranded, primers represented by red and purple boxes. 
ds DNA 
denatured 
ss DNA 
Primers anneal to 
target gene  
Primers elongated by 
polymerase resulting in 
ds DNA copies of target 
gene 
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The high sensitivity of real time RT-PCR makes this method an ideal tool to study the 
expression of ion channels in cardiac tissue, where mRNA expression is considered to be 
low.  The methods used to compare the mRNA expression of different ion channel genes in 
tissues from β-blocked and non β-blocked patients are described in the following sections. 
3.3.1.2 Obtaining and Storing Tissue 
Right atrial appendage tissue was obtained from 16 consenting patients undergoing 
coronary artery bypass grafting.  All patients were in sinus rhythm at the time of surgery 
with no documented history of atrial fibrillation.  Eight of the patients were treated with β-
blockers for at least four weeks before surgery and were compared to eight patients who 
had not been treated with β-blockers.  Tissue was collected in operating theatres at the time 
of excision, immediately placed in RNAlater solution (Quiagen) and put on ice.  The tissue 
was cut if it exceeded approximately 0.5 cm3 thick and each section placed in 
approximately 5 ml of RNAlater.  This allowed for stabilisation of the RNA and prevented 
changes in gene expression due to induction of transcription or degradation of RNA.  The 
tissue was kept at 2ºC overnight and then stored at -20ºC as per manufacturers 
recommendations until it was transported on dry ice to the Cardiovascular Research Group 
in Manchester where the following work was carried out with the help of James Tellez 
PhD and Professor Mark Boyett. 
 
3.3.1.3 RNA Extraction 
3.3.1.3.1 Tissue Preparation 
 
 
Each piece of tissue was mounted on a cutting block using OTC Embedding Matrix 
(CellPath) and dipped in liquid nitrogen to freeze it.  The tissue was then sliced into 20 µm 
thick sections using a cryostat (LEICA CM3050S) at -22ºC.  This method yields a greater 
amount of high molecular weight RNA than powdering (J. Tellez, personal 
communication).  The cut sections were placed in cryotubes and stored overnight at -80ºC.  
Approximately 30 µg of tissue was placed in each tube.    
3.3.1.3.2 Protocol for RNA extraction using Quiagen Mini kit 
 
RNA was extracted from each tissue section using the RNeasy Mini kit (Quiagen) which 
included pre-prepared buffer solutions.  The protocol was a modified version of the 
manufacturer’s instructions (J. Tellez, personal communication).  A series of buffers and 
Gillian E Marshall 2008  116 
 
mechanical disruption were used to denature cellular proteins, including RNases, and 
break-up cell membranes in order to release the RNA which could then be extracted using 
silica columns.   
 
Firstly, the cryotubes of tissue were removed from the freezer and placed on ice.  RLT 
buffer (Quiagen) was heated to 45ºC in a waterbath and then 10 µl of β-mercaptoethanol 
(Sigma) added per 1ml of RLT.  Next, 330 µl of RLT+mercaptoethanol were added to each 
tissue sample which was immediately homogenised for 90 seconds using an Ultraturrax T8 
Homogeniser (VWR).  Then, 646 µl of molecular grade water (Sigma) was added to each 
sample followed by 19 µl of proteinase K (Quiagen).  Each sample was vortexed and 
incubated at 45ºC for 1hr or until each sample appeared clear. 
 
The contents of each cryotube were then transferred to eppendorfs and centrifuged at 
13000 rpm for 15 minutes.  The fatty deposit on the surface of each tube was discarded and 
the remaining supernatant transferred into 15 ml tubes.  By this stage the vast majority of 
proteins including RNAses should have been degraded.  1ml of RLT+mercaptoethanol was 
then added to each tube and vortexed.  This increases the salt concentration to favour RNA 
over DNA precipitation after the addition of alcohol.  Next, 1 ml of 100% ethanol (BDH) 
was added to each tube and vortexed.  This promotes binding of the RNA to the silica.  730 
µl from each tube was placed onto individual silica columns (Quiagen).  Each column was 
centrifuged at 13000 rpm for 15 seconds, the flow through discarded and a further 730 µl 
added to each column.  This was repeated until all the samples had run through their 
columns.  700 µl of RW1 buffer (Quiagen) was then added to each column to wash away 
any remaining proteinase K.  The tubes were centrifuged for 15 seconds at 13000 rpm and 
the flow through discarded.  This was repeated once more. 
 
150 µl of DNase (Quiagen) was added to 1050 µl of RDD buffer (Quiagen) and kept on 
ice.  78 µl of RDD+DNase was added carefully to cover the silica in each column and left 
for 1 hour.  This digested any residual genomic DNA which would contaminate a 
subsequent PCR reaction.  700 µl of RW1 was added to each column which was then 
centrifuged for 15 seconds at 13000 rpm and the flow through discarded.  500 µl of RPE 
buffer (Quiagen) was added to each column which was then centrifuged again for 15 
seconds at 13000 rpm and the flow through discarded.  Another 500 µl of RPE was added 
to each column, centrifuged for 2 minutes at 13000 rpm and the flow through discarded.  
The columns were spun again for 15 seconds at 13000 rpm and any flow through 
discarded.  The columns were then placed in new collecting tubes and 50 µl of molecular 
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grade water was added to elute the RNA from the silica.  This was left for 1 minute before 
centrifuging for 1 minute at 13000 rpm and the flow through collected.  This last step was 
repeated using another 50 µl of water.  9.6 µl of 3M sodium acetate (Sigma), pH 5.4, was 
added to each tube and vortexed.  Then 240 µl of ethanol and 0.5 µl of glycogen (Roche) 
were added to precipitate the RNA from the water.  The tubes were left overnight at -20ºC. 
 
Each tube was centrifuged for 30 minutes at 13000rpm at 4ºC.  The RNA forms a small 
pellet on the bottom of the tube.  The supernatant was removed from each tube and 300µl 
of 70% ethanol added carefully without disturbing the RNA pellet.  Each tube was spun for 
5 minutes at 13000 rpm at 4ºC.  The supernatants were removed, another 300 µl of ethanol 
added to each tube and the tubes centrifuged as before.  The supernatants were removed 
and each pellet left to air dry at room temperature for at least 30 minutes.  15 µl of 
molecular grade water was added to each pellet and the RNA was then stored at -80ºC 
 
3.3.1.3.3 RNA quality control and quantifying  
 
In order to achieve reliable quantitative PCR results it is necessary that high quality RNA 
is used i.e. non degraded RNA, as this will ensure good quality cDNA representative of the 
extracted RNA.  It is also important to measure the concentration of RNA extracted from 
the tissue so that equal amounts of RNA can be used as templates for generating the 
cDNA. 
 
Spectrophotometry was used to asses both the quality and quantity of extracted RNA.  The 
concentration of RNA extracted from each sample was measured using a NanoDrop ND-
1000 Spectrophotometer (260nm).  1.2 µl of each sample was placed in turn onto the 
sensor after blanking with molecular grade water.  The sensor was cleaned between each 
sample.  The quality of the RNA extracted from the tissue was assessed by first ensuring a 
clean peak absorbance at 260 nm and also by comparing the absorbance at 260 nm versus 
280 nm to look for protein impurities.    
 
Eight samples (four from non β-blocked and four from β-blocked patients) were also 
assessed by looking for 18S and 28S ribosomal RNA bands after electrophoresis on a 
formaldehyde-agarose gel.  Ribosomal RNA (rRNA) is much more abundant than mRNA 
and can therefore be more easily detected.  rRNA consists of two main components 28S 
and 18S which are 5 and 2 kb respectively.  The detection of crisp bands at these molecular 
weights is considered to be an indication of intact rRNA. 
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The gel was prepared by first heating 9mls of 10xMOPS buffer, pH7 (Eppendorf) to 55ºC 
in a waterbath.  An RNase free gel mould and comb were placed in a cold room.  0.9g of 
agarose (Nusieve) and 79 mls of deionised water were heated until the agarose dissolved. 
The solution was then placed in a water bath to cool to 55ºC. The warmed 10xMOPS and 
1620 µl of deionised 36.5% formaldehyde (Sigma) were then added, the gel poured and 
left to set in the cold room.    
 
The samples were prepared by making a master mix containing: 100 µl of deionised 
formamide (Sigma); 33.5 µl of deionised formaldehyde; 32 µl of RNase free water and 25 
µl of 10xMOPS+ethidium bromide mix [40 µl of 10xMOPS + 10 µl of 10 mg/ml ethidium 
bromide (Sigma)].  19 µl of the master mix were added to 1µl of RNA from each of the 
eight samples, vortexed and heated to 55ºC for 15 minutes.  2 µl of loading buffer (43.5 % 
glycerol, 2M EDTA, 0.02 % bromophenol blue) were added to each sample, centrifuged at 
13000 rpm for 1minute and then loaded into the wells of the gels.  One lane of the gel was 
loaded with a 0.24-9.5kb RNA ladder (Invitrogen).  
 
The gel was covered with a running buffer consisting of 70 ml of 10xMOPS, 617 ml of 
deionised water and 12.6 ml of deionised formaldehyde.  The samples were 
electrophoresed for 30 minutes at 130 mA.  The gel was then removed and the RNA bands 
visualised using a UV illuminator (BIORAd Gel Doc EQ system).  This was possible 
because the ethidium bromide intercalates with the RNA and emits fluorescence when 
exposed to UV light.  No quantification of the RNA bands was performed. 
 
3.3.1.4 Reverse transcriptase 
The RT reaction produces the first strand of cDNA from the extracted RNA.  This is then 
used as the template for the real time PCR reaction.  Errors introduced at this stage will 
result in inaccurate quantification of the mRNA content of the tissue samples and several 
steps were taken to try to reduce or eliminate errors.  The same amount of RNA from each 
tissue sample was used for the RT reaction and all samples underwent the RT reaction at 
the same time using the same master mixes of enzymes and reagents.  
 
All the reagents for the RT reaction were supplied by Invitrogen.  A master mix was made 
containing 17.9 µl of 10mM dNTPs, the building blocks for making the cDNA copy of the 
input RNA and 17.9 µl of random hexamer primers.  These random hexamer primers are 
short, 6 nucleotide, sequences of cDNA which will bind to different complementary 
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sequences of RNA and act as the starting point for the reverse transcriptase enzyme to then 
extend.  Random hexamer primers were chosen over gene specific primers as they should 
result in a copy of all the tissue mRNA which can then be used to look at the expression of 
multiple different genes.  Random hexamer primers were chosen over oligo dT primers 
which bind to the poly A tail of RNA because of the risk of producing an incomplete 
mRNA copy due to possible of degradation of the poly A tail or disruption of the copy due 
to secondary structures in the mRNA interfering with the reverse transcriptase reaction.  
Oligo dT primers would not result in a copy of the rRNA which could not then be used in 
the analysis of the PCR reaction.  A second master mix of RT enzyme and buffers 
(RT/buffer) was prepared containing: 35.8 µl of 10xRT Buffer; 71.6µl of 25m MgCl2 (co-
factor for the RT polymerase); 35.8 µl of 0.1 M DTT (Dithiothreitol); inhibits RNAse 
activity); 17.9 µl of RNAse OUT (an RNAse inhibitor) and 17.9 µl of SuperScript III 
(reverse transcriptase).  Superscript III was chosen because it is a mutated version of the 
M-MLV (Moloney-murine leukaemia virus) enzyme which has less RNase H activity, 
helping to prevent degradation of the mRNA template and increasing the cDNA yield.  It 
also has a high degree of thermal stability. 
 
Dilutions of each RNA sample were prepared using molecular grade water (2 µg of RNA 
in 8 µl of solution).  2 µl of the hexamer/dNTPs master mix were added to this, vortexed 
and briefly spun for 15 seconds at 13000 rpm.  The samples were than heated to 65ºC 
using a PCR thermo-cycler (ThermoHybaid PCR Express) in order to denature the RNA.  
The samples were then immediately put on ice for 3 minutes.  While on ice, 10 µl of the 
RT/buffer master mix was added to each sample.  The samples were then incubated at 
25ºC for 10 minutes in the PCR machine in order for the primers to anneal.  The samples 
were next incubated at 50ºC for 50 minutes during which the reverse transcriptase 
elongated the primers to make the cDNA.  A further incubated at 85ºC for 15 minutes to 
stopped the reaction and separated the cDNA from the RNA.  The samples were then 
removed from the PCR machine and a 1:10 dilution made using 3 µl of each sample to use 
as a working concentration.  This was kept at 20ºC until required while the remaining neat 
cDNA was stored at -80ºC.  
 
3.3.1.5 Quantitative Real time PCR 
3.3.1.5.1 Reagents 
 
In order to quantify the abundance of mRNA for specific ion channel subunits in each 
tissue sample, the corresponding cDNA has to identified and amplified.  This requires gene 
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specific primers, a DNA polymerase enzyme, dNTPs and the necessary co-factors.  The 
details for the primers used are shown in tables 3-1 and 3-2.  The primers for 28s and 
Kv4.3 were designed, tested and optimised by J Tellez.  All other primers were purchased 
as part of an optimised assay (QuantiTect) and had previously been used by J Tellez and 
colleagues.  KChIP2 primers [KChIP2 (2)] were also purchased from Applied Biosystems.  
The DNA polymerase used was AmpliTaq Gold (Applied Biosystems, Power SYBR Green 
PCR Master Mix).  This enzyme is a modified version of the recombinant AmpliTaq 
enzyme which is based on the naturally occurring Taq (Thermus aquaticus) enzyme.  One 
key modification of this enzyme is that it is inactive at relatively low temperatures.  This 
ensures that the elongation phase of the PCR cycle does not begin until the reaction 
conditions are optimised, resulting in increased yield, increased specificity of end product 
and allowing the reagents to be assembled at room temperature -“Hot start PCR”.  In order 
to quantify the amount of amplified cDNA produced in the PCR reaction, a fluorescent dye 
called SYBR Green was used.  Like ethidium bromide, SYBR green is a non-specific DNA 
dye which binds to DNA and only fluoresces when it is bound to double stranded (ds) 
DNA (see figure 3-2).  SYBR Green has the advantage of being much less toxic than 
ethidium bromide.  The amount of fluorescence at the end of each cycle is therefore a 
measure of the amount of ds DNA formed.  Because it is a non-specific DNA dye, SYBR 
green will bind to all newly formed ds DNA and so will measure any DNA that has been 
amplified by a non-specific primer reaction.  This can be minimised by trying to avoid any 
contamination of the cDNA samples with environmental contaminants and ensuring the 
primers have been designed to avoid non specific reactions with other genes and cross 
reactivity with each other to form primer dimers.  
3.3.1.5.2 Real time QPCR protocol 
 
A master mix was made up for each new primer containing 252 µl of Power SYBR Green 
PCR Master Mix (Applied Biosystems) which contains AmpliTaq Gold, dNTPS, MgCl2, 
SYBR Green dye and a passive reference dye in an optimised buffer.  To this, 50.4 µl of 
one the specific 10x QuantiTect primer assays was added or 20.2 µl of the forward primer 
and reverse primers for either 28S (11.25 µM) or Kv4.3 (7.5 µM).  453.6 µl of molecular 
grade water was then added to the master mix and vortexed.  For each new primer reaction, 
1µl of cDNA from each tissue sample and 9 µl of the appropriate master mix were placed 
in three separate wells (i.e. in triplicate) of a MicroAmp optical 96-well reaction plate 
(Applied Biosystems).  For each new primer reaction, 1µl of water and 9 µl of master mix 
were placed in two wells of the plate to act as the negative controls. The plates were then  
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Table 3-1 Primer details. Primers designed by J Tellez.  
 
 
 
 
 
 
 
Target 
transcript 
Accession 
number 
Primer sequence 5’-3’ Fragment 
length (bp) 
28S AF460236 GTTGTTGCCATGGTAATCCTGCT
CAGTACGTCTGACTTAGAGGCGT
TCAGTCATAATCCC 
133 
Kv4.3 NM 004980 TGGCCTTCTACGGCATCCTGCTC
GGCGTTCTCCCTCT 
84 
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Table 3-2 Primer details.  The primers were purchased as part of optimised assays 
(Quantitect). 
 
Target transcript Assay details 
hGAPDH QT01192646 
hKChIP2 (1) QT00016254 
hKChIP2 (2) Hs00752497s1 
hKChAP QT00053158 
hKvβ1 QT00031136 
hKvβ2 QT00051961 
hKvβ3 QT00056931 
hFrequenin QT00038598 
hDPP6 QT00080598 
hKv4.2 QT00006083 
hKv1.5 QT01003177 
hKir2.1 QT00001022. 
hKir2.2 QT01003296 
hTWIK-1 QT00039396 
hCav1.2 QT00053480 
hNCX1 QT00075376. 
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Figure 3-2  SYBR green reaction. SYBR green does not fluoresce when bound to single 
stranded DNA or when free (A) but does when bound to double stranded DNA (B)
SYBR green 
ss DNA 
ds DNA 
A 
B 
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spun for a 15 seconds (Mulitfuge 35 R Heraeus) and covered with an optical adhesive 
cover (Applied Biosystems). 
 
Each PCR reaction was performed using the 7900HT Fast Real-Time PCR System 
(Applied Biosytems).  Each plate was heated to 95ºC for 10 minutes to activate the 
polymerase followed by 40 cycles of 15 seconds at 95ºC and 1 minute at 60ºC to denature 
and anneal/elongate the primers.  This was followed by 15 seconds at 60ºC and 15 seconds 
at 95ºC to generate melting curves of the reaction products 
 
3.3.1.5.3 Melting curves 
 
 
SYBR Green will bind to all ds DNA, therefore, potentially, measuring any non specific 
amplified DNA including primer dimers in addition to the specific amplified target gene.  
At the end of the PCR cycles the ds DNA products in each well are denatured to generate 
melting curves and the amount of fluorescence continually measured as the temperature 
increases.  From these curves, melting peaks are automatically calculated by taking the 
first negative derivative of the melting curve.  DNA of different molecular weights and 
nucleotide compositions will melt at different temperatures.  It is possible to compare the 
melting curve of the actual DNA product with its expected melting point to check the 
identity of the actual DNA product.  However, in this study the presence of one discrete 
melting peak for each new primer reaction was taken to indicate the formation of a specific 
amplified DNA product.   
 
3.3.1.6 Analysis 
The efficiency (E) of each primer PCR reaction was determined from the fluorescence (F) 
recorded at the end of each elongation step using the following equation where n is the 
cycle number. 
E = √Fn/F-2n 
This was done for each primer reaction in each tissue sample and used to calculate the 
mean efficiency for each primer reaction.  
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The relative abundance of each primer product was calculated by first averaging the CT 
values for each tissue sample from the triplicate reactions.  The ∆CT values were then 
calculated by subtracting the average CT value for one of the tissue samples in the same 
PCR reaction from each of the other mean CT values.  The same tissue sample was used as 
the internal control or calibrator for each new primer reaction.  The abundance of each 
primer product including 28S and GAPDH was then calculated using the following 
equation;  
Abundance = E∆Ct 
The abundance of the ion channel subunit in each tissue sample (a) was expressed relative 
to the abundance of 28S or GAPDH or the mean of the abundance 28S and GADPH in the 
same tissue sample (b).   This was done using the following equation; 
Relative abundance = Ea∆Cta/Eb∆Ctb 
The mean expression of each ion channel subunit in the tissue samples from the non β-
blocked and β-blocked patients was calculated from the ∆∆Ct values and compared using 
either a Student’s t-test or Mann Whitney test depending on the distribution of the data. 
To compare the expression of ion channel subunits relative to each other, the mean Ct 
values were not expressed relative to the internal control.  The equations were thus 
modified to:   
Abundance = ECt 
Relative abundance = EbCtb/EaCta 
3.3.2 Quantification of proteins by Western blotting 
3.3.2.1 Obtaining and storing tissue 
Right atrial appendage tissue was obtained from consenting patients in sinus rhythm 
undergoing cardiac surgery.  The tissue was cut up into small chunks and homogenised 
using an Ultraturrax T8 Homogeniser (VWR) in 1 ml of protease inhibitor solution 
containing: 15 µl protease inhibitor (Sigma P8340), NaCl 150 mM, KCl 5.4 mM, MgCl2 
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1.2 mM, NaHEPES 5 mM, Glucose 10 mM, CaCl21.0 mM, pH7.4 with HCl.  The tissue 
was then stored at -80°C. 
Rabbit brain and lung tissue was obtained from a New Zealand White rabbit that was being 
sacrificed for other experiments.  The tissue was obtained with the kind assistance of Mr 
Mike Dunn.  Rat brain tissue was kindly provided by Mrs Aileen Rankin from Wistar rats 
being sacrificed for other experiments.  All animal tissue was treated in the same manner 
as the human tissue. 
3.3.2.2 Measuring protein concentration 
The concentration of protein in the tissue samples was measured using a modified version 
of the Bradford Assay.  This assay uses Coomassie blue G250 which changes from a red 
dye with an maximum absorbance of 470 nm to a blue dye with a maximum absorbance of 
590 nm when it binds to the arginyl and lysyl residues of proteins.  The increase in 
absorbance at 590 nm can be measured using a spectrophotometer and is a function of the 
protein concentration.  The concentration of protein in an unknown sample can be 
determined by comparing its absorbance with those of protein standards of known 
concentrations. 
A set of nine dilutions of standard concentrations of a bovine serum albumin (BSA) 
solution (Pierce) were prepared at 0, 25, 125, 250, 500, 750, 1000, 1500, and 2000 µg/ml 
using the protease inhibitor solution as the dilutent.  10 µl of each solution were then added 
in triplicate to a 96 well microplate.  Dilutions of each tissue sample were prepared using 
the protease inhibitor solution and added in triplicate to separate wells of the microplate.  
300 µl of Coomassie reagent (Coomassie Plus, Pierce) was added to each well starting with 
the first of every set of triplicates followed by the second and finally the third.  The 
microplate was then placed in the spectrophotometer (Thermo Labsytems Multiskan EX) 
and mixed for 30 seconds.  The absorbance of each BSA standard and the unknown protein 
dilutions were measured at 595 nm using the well containing the 0 µg/ml BSA solution as 
a blank.  The absorbance of the BSA standards versus concentration was plotted and non 
linear regression analysis performed using a polynominal fourth order equation (GraphPad 
PRISM) to generate a standard curve.  The concentrations of the tissue dilutions were then 
determined using the standard curve and a mean concentration for each tissue sample was 
calculated from the triplicate values.  
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3.3.2.3 Basic Principles of Western blotting 
Western blotting, also known as immunoblotting, is a technique which can be used for 
detection and identification of proteins and can be adapted to allow the relative 
quantification of proteins (187-189).  The technique was first described in 1979 and was 
developed following methods used to detect DNA (Southern) blotting and RNA (Northern) 
blotting (190).  The basic principles of the Western Blotting are described below and 
illustrated in figure 3-3 and I am grateful to Julie Russell for teaching me this technique. 
Western blotting makes use of sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) in which a mixture of proteins can be separated strictly on the basis of size.  
SDS is an anionic detergent which binds to proteins.  If proteins are reduced, the same 
amount of SDS will bind to them per unit of weight regardless of their amino-acid 
composition.  This ensures that all proteins will have the same amount of charge/unit of 
weight and can be separated on the basis of weight under the influence of an electric 
current. 
The proteins are loaded onto a polyacrylamide gel which is formed from polymerisation of 
acrylamide and bisacrylamide.  These gels consist of two parts, a stacking gel with large 
pore sizes which allows the proteins to concentrate into sharp bands and a separating gel. 
The relative amounts of the chemicals within the gel helps determine the size of the pores 
through which the proteins migrate and the composition of gels can be varied to allow for 
optimal separation of proteins of different weights.  The molecular weight of the proteins 
loaded onto the gels can be determined by comparison with the migration of calibration 
proteins of known molecular weights electrophoresed on the same gel.   
The separated negatively charged proteins can then be electrophoretically transferred, or 
blotted, onto nitrocellulose paper.  Blotting allows the proteins to be transferred while 
maintaining their relative positions and resolution and the use of an electric current allows 
this to be done quickly and efficiently.  The purpose of blotting is to allow the subsequent 
detection of specific proteins using molecular probes or antibodies which is difficult to do 
while the proteins remain in a gel. 
The detection of the proteins bound to the nitrocellulose paper is usually performed using a 
specific primary antibody which recognises single or multiple epitopes specific to the 
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Figure 3-3 The basic steps involved in Western Blotting. 
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protein of interest.  Before this can be done, it is necessary to block binding sites on the 
membrane to which the antibody may bind in a non-specific fashion, potentially 
overwhelming or obscuring the protein-specific reaction.  This can be done using a 
blocking solution containing an inert protein and/or non-ionic detergent. 
Once the protein-specific antibody has bound to the protein of interest on the membrane 
and any excess, unbound antibody removed or washed off, it has to be detected.  This can 
be done in a number of ways, one of which is to use a second antibody which recognises 
an epitope within the conserved portion of the primary antibody and is conjugated with an 
enzyme which can be used to indicate the location of the protein.  In these experiments any 
bound secondary antibody was detected using a chemiluminescent substrate which, when 
catalysed by the enzyme on the bound secondary antibody, emits light that could be 
detected using film.   
3.3.2.4 Protein electrophoresis and transfer 
All solutions and equipment described were purchased from Invitrogen unless otherwise 
stated. 
 
Tissue samples were thawed and diluted using ultra-filtered water.  Various dilutions of the 
tissue samples were made to allow different amounts of total protein to be loaded onto 
each gel as specified in the results.  Once diluted, 10 µl of each tissue sample were added 
to 3.75 µl of Nu PAGE LDS Sample Buffer and 1.5 µl of Nu PAGE Sample Reducing 
Agent, mixed and then heated to 70◦C for 10 minutes.  The samples were then centrifuged 
at 1000 rpm for 1 minute to allow all the contents of each eppendorf to collect at the 
bottom before loading onto either a 12 or 15 well Nu PAGE [gradient (4-12%)] Bis-Tris 
Gel.  Two molecular weight markers, 3 µl of See Blue Plus 2 Pre-stained Standard and 1 µl 
of Magic Mark Western Standard, were added to 10 µl of sample buffer and, in most 
experiments, loaded into one or more lanes of the gel.  The See Blue marker could be 
visualised on both the gel and the nitrocellulose membrane and so could be used to help 
monitor the progress and efficiency of the electrophoresis and transfer.  The Magic Mark 
marker could be visualised on the film after exposure to the chemiluminescent agent and so 
could be used to measure the molecular weight of any bands detected. 
 
Electrophoresis was performed at 200 V, 200 mA for 50 minutes using XCell Sure lock 
and PowerEase 500 Supply.  The duration of the electrophoresis was initially determined 
by the time taken for the bromophenol dye in the sample buffer to reach the bottom of the 
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gel.  The running buffer used for the electrophoresis consisted of 50 ml of Nu PAGE SDS 
MOPS Running Buffer in 950 ml of ultra-filtered water which was used to fill the outer 
well of the XCell Sure Lock.  The central well of the Xcell Sure lock was filled with 200 
ml of running buffer containing 0.5 ml of Nu PAGE Antioxidant. 
 
A nitrocellulose membrane (0.45 µm pore) in a filter paper sandwich was prepared by 
soaking for 2-3 minutes in transfer buffer.  The transfer buffer consisted of 100 ml of 
methanol, 0.5 ml of Nu PAGE Antioxidant, 50 ml of Nu PAGE Transfer Buffer and 850 
ml of ultra-filtered water.  The membrane was placed on the protein side of the gel with 
one piece of filter paper placed on top and the other underneath the gel ensuring that there 
were no air bubbles which would prevent the transfer of the proteins.  This sandwich was 
then placed between transfer pads soaked in transfer buffer and into the XCell II Blot 
Module.  The blot module was placed inside the XCell Sure Lock and then filled with 
transfer buffer.  Water was placed in the XCell Sure Lock around the outside of the blot 
module.  The protein was transferred to the membrane at 30 V, 200 mA for 75 minutes.   
 
The conditions for transfer were optimised by Julie Russell and checked by ensuring the 
transfer of the See Blue marker.  On one occasion, as part of this study, the gel was stained 
to look for residual proteins to check the efficiency of the transfer.  The gel was rinsed 
three times for 5 minutes each time in approximately 100 ml of ultra-filtered water and 
then stained by gentle shaking in Simply Blue Safe Stain for one hour at room temperature.  
The gel was washed again in 100 ml of ultra-filtered water.  No protein was detected on the 
gel.    
 
3.3.2.5 Immunodetection of Kv4.3 
3.3.2.5.1 Standard protocol for using a polyclonal anti-Kv4.3 primary antibody 
 
All solutions and antibodies used were part of the Invitrogen Western Breeze Kit unless 
otherwise specified.  All washes and incubations with blocking solution or secondary 
antibody were carried out on a rocker (Heidolph Polymax 1040) at room temperature.  The 
membrane was removed from the blot module and placed protein side up in a flat container 
approximately 10 cm2 and washed in 20 ml of ultra-filtered water for 5 minutes.  The 
membrane was then blocked for 2 hrs with 10 ml of blocking solution made up of 7 ml of 
ultra-filtered water, 2 ml of Blocker A and 1 ml of Blocker B.  The membrane was washed 
again in 20 ml water for 5 minutes before being incubated overnight at 4◦C in 10 ml of 
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polyclonal anti-Kv4.3 primary antibody (8 mg/ml, rabbit IgG, Alamone) diluted in 
blocking solution.  Various concentrations of primary antibody were used as detailed in the 
results section.  The membrane was then washed four times in 15 ml of wash solution 
diluted (1:15) in ultra-filtered water and then incubated for one hour in secondary antibody 
[anti-rabbit IgG conjugated to alkaline phosphatase (ALP)].  The membrane was then 
washed again four times in diluted wash solution and three times in ultra-filtered water.  
The membrane was placed on a transparent plastic sheet and covered with 2.5 ml of 
chemiluminescent substrate solution made up of 2.375ml of chemiluminescent substrate 
and 0.125 ml of chemiluminescent substrate enhancer for 5 minutes.  After this, excess 
substrate was blotted off with filter paper and another transparent plastic sheet placed on 
top of the membrane which was then exposed to X-ray film (Kodak BioMax Light Film, 
Sigma) in a dark room.  The films were developed using a Kodak X-OMAT 1000 
processor. 
 
3.3.2.5.2  Modified protocols for using polyclonal anti-Kv4.3 primary antibody 
 
 
The above protocol was modified in a number of ways to help determine the identity of the 
bands detected with the primary antibody. 
 
The specificity of the secondary antibody was tested by cutting the membrane in half after 
the transfer so that half of the lanes could be incubated with both primary and secondary 
antibody as indicated above and half could be incubated with secondary antibody alone.  
Each half of the membrane was blocked as described above and, while one half was 
incubated in the primary antibody diluted in blocking solution, the other half was incubated 
in fresh blocking solution.  Both halves of the membrane were incubated in secondary 
antibody and developed side by side and at the same time, using the same film.  
 
A different, more sensitive, detection system ECL-advance (Amersham) was also used 
with this primary antibody.  This detection system required the use of a different blocking 
solution of tris buffered saline (TBS: 140 mM NaCl; 20 mM Tris HCl; pH 7.6; Sigma) 
containing 0.1% Tween 20 (Sigma) and 2% blocking agent (ECL-advance, Amersham) 
The secondary antibody used was a horseradish peroxidase-conjugated anti-rabbit IgG 
(Amersham) diluted in blocking solution as specified in the results.  After incubation with 
both primary and secondary antibodies the membrane was washed once for 15 minutes and 
then three times for 5 minutes each in TBS with 0.1% Tween 20.  5 ml of the 
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chemiluminescent substrate solution (ECL-advance, Amersham) was incubated with the 
membrane for 5 minutes before the membrane was exposed to the X-ray film. 
3.3.2.5.3 Standard protocol for using a monoclonal anti-Kv4.3 primary antibody 
 
The monoclonal anti-Kv4.3 primary antibody (Neuromab) was raised in mice and so the 
only change required to the standard protocol when using this antibody was to change the 
secondary antibody to an ALP-conjugated anti-mouse IgG (Invitrogen anti-mouse Western 
Breeze Kit) 
3.3.2.5.4 Protocol for pre-incubation of primary antibody with antigen 
 
For these experiments antigenic peptide was obtained from Alomone (0.4 mg/ml).  The 
peptide was added to the primary antibody along with phosphate buffered saline (PBS: 9.1 
mM Na2HPO4; 1.7mM NaH2PO4; 150 mM NaCl; pH 7.4, Sigma) at concentrations and 
volumes detailed in the results section.  The “antibody alone” solution was made using the 
same concentration of primary antibody as for the antigenic peptide containing solution 
and an appropriate volume of PBS so that the total volumes of both solutions were the 
same.  Both solutions were then incubated on the rocker for two hours at room 
temperature.  10 ml of the blocking solution (Invitrogen Western Breeze kit) was added to 
each of these solutions.  The diluted antigen-antibody solution was then added to one half 
of a blocked membrane while the diluted antibody alone solution was added to the other 
half of the blocked membrane and both halves incubated overnight at 4ºC.  The membrane 
was then treated according to the standard protocol described in section 3.3.2.5.1. 
3.3.2.5.5 Quantification of protein concentration from Western Blots 
 
Once developed the films of the Western Blots were scanned using Fluor-S™ MultiImager 
(BIO RAD).  The digital images were then analysed using Quantity One analysis software 
(BIO RAD) in order to measure the optical density of the bands.  The optical density of 
each band was normalised to a background optical density of an identical sized area within 
each lane of the gel where there were no bands.  The optical densities for all non β-blocked 
and β-blocked tissue samples were normally distributed and the mean ± sem were 
calculated by Student’s t-test using GraphPad Prism. 
 
The molecular weights of the bands detected were calculated relative to the molecular 
weight markers by measuring the distance each band had run using Quantity One, 
calculating the relative front of each band and then plotted this against the log of molecular 
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weights of each marker to calculate the values of the unknown bands using Graph Pad 
Prism.  This was done by Julie Russell. 
 
3.4 Results 
3.4.1 Effects of chronic β-blockade on ion channel mRNA expression 
3.4.1.1 Patient characteristics  
The characteristics of all 16 patients from whom tissue samples were obtained and used for 
mRNA analysis are described in table 3-3.  It can be seen that the two patient groups were 
very similar with the exception of the mean heart rate which, as expected, was lower in the 
β-blocked patient group although this was not statistically significant.  There was one 
patient in the β-blocked patient group from whom a pre-operative heart rate was not 
obtained.  
 
3.4.1.2 Assessing the concentration and quality of extracted RNA 
The concentrations of RNA extracted from each tissue sample and measured by 
spectrophotometry are shown in table 3-4.  All the samples had a ratio of A260/A280 >1.9 
indicating a satisfactorily pure RNA sample.  The concentration of sample 1 is lower in 
comparison to the others because only the second 50 µl containing RNA eluted from the 
column was collected.  The first 50 µl was accidentally discarded.  Despite this, we felt 
there was still enough RNA to perform RT-PCR using this tissue sample. Generally the 
RNA yields were high within the other samples.  The mean RNA concentrations for the 
non β-blocked (n = 8) and β-blocked patients (n = 8) were 1268 ± 195 ng/µl and 1602 ± 
145 ng/µl respectively, p=0.19.   
 Eight of the samples of RNA were also assessed by gel electrophoresis to look at the 18S 
and 28S rRNA bands as shown in figure 3-4.  Sample 1 appears very faint partially due to 
the lower concentration of RNA but also because the gel was thick and was only imaged 
from one side.  Each of the other samples has two distinct bands corresponding to 18S and 
28S indicating that the RNA was not degraded. 
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Patient 
Characteristics 
 
Non β-blocked 
patients 
n (%) 
 
β-blocked 
patients 
n (%) 
 
Total 
patients 
n (%) 
No of patients 8 8 16 
Male patients 7 (87.5) 5 (62.5)  12 (75) 
Mean age (yrs) 64.8 ± 2.8 65.5 ± 1.6.  
Mean heart rate 
(beats/min) 
74.3 ± 4.0 65.1 ± 4.1*  
Surgery:    
CABG alone 6 (75) 7 (87.5) 13 (81.3) 
AVR alone 2 (25) 1 (12.5) 3 (18.3) 
Pre-op Drugs:    
β-blockers    
- atenolol 0 (0) 5 (62.5) 5 (31.5) 
- bisoprolol 0 (0) 2 (25) 2 (12.5) 
- carvedilol 0 (0) 1 (12.5) 1 (6.3) 
ACE inhibitors 4 (50) 5 (62.5) 9 (56.3) 
CCBs 4 (50) 3 (37.5) 7 (43.8) 
Nicorandil 6 (75) 3 (37.5) 9 (56.3) 
Statins 7 (87.5) 8 (100) 15 (93.8) 
Digoxin 1 (12.5) 0 (0) 1 (6.3) 
Amiodarone 0 (0) 0 (0) 0 (0) 
Pre-op disease    
MI 2 (25) 2 (25) 4 (25) 
Angina 8 (100) 8 (100) 16 (100) 
LVSD    
    - unknown 1 (12.5) 0 (0) 1 (6.3) 
    - mild 1 (12.5) 1 (12.5) 2 (12.5) 
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Table 3-3 Characteristics of patients treated or not treated with β-blockers prior to cardiac 
surgery in whom ion channel mRNA expression was measured.  
CABG = coronary artery bypass graft, AVR = aortic valve replacement, Pre-op = prior to 
surgery, ACE = angiotensin converting enzyme, CCB = calcium channel blocker, MI = 
myocardial infarction, LVSD = left ventricular systolic dysfunction, Post-op = within 1 to 
7 days after cardiac surgery. 
LVSD (cont)    
    - moderate 1 (12.5) 0 (0) 1 (6.3) 
    - severe 0 (0) 1 (12.5) 1 (6.3) 
  Hypertension 3 (37.5) 6 (75) 9 (56.3) 
Diabetes 2 (25) 2 (25) 4 (25) 
Post –op AF 3 (37.5) 0 (0) 3 (18.8) 
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Sample RNA concentration (ng/µl) 
 
1 214 
2 1805 
3 1608 
4 1194 
5 1059 
6 2000 
7 1204 
8 1063 
9 1551 
10 1607 
11 1439 
12 1796 
13 1632 
14 1303 
15 2443 
16 1042 
 
Table 3-4 Concentration of extracted RNA from tissue samples.  Samples 1-8 are from 
non β-blocked patients and samples 9-16 are from β-blocked patients
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Figure 3-4 Electrophoresis of RNA samples and a ladder (L) demonstrating the presence 
of 18S and 28S rRNA band 
    1         4         5        6 10        12      14       15   L   
28S 
18S 
RNA 
samples 
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3.4.1.3 Quantifying the expression of 28S rRNA and GAPDH mRNA 
The mean abundance of 28S rRNA in the tissue samples from non β-blocked (n = 6) and β 
-blocked (n = 8) patients relative to an internal standard is 0.94 ± 0.07 vs 0.83 ± 0.10 
respectively, p=0.41.  The mean relative abundance of GAPDH mRNA is 1.74 ± 0.19 vs 
1.85 ± 0.38, p=0.81.  These results are shown in figure 3-5.  28S was the most abundant of 
all the primer products measured with lower Ct values than either GAPDH or any of the 
ion channel subunits.  The change in fluorescence for each PCR cycle for 28S and GAPDH 
are shown in figure 3-6.    
When all eight of the non β-blocked tissue samples are analysed there was much greater 
variability in Ct values for 28S than within the β-blocked samples.  If the two outlier 
samples (1 and 6) were included in the analysis of 28S abundance, the data for the non β-
blocked samples became non normally distributed with a median value of 0.97 
(interquartile range 0.78 to 1.06) compared to a median of 0.80 (0.59 to 0.95) for the β-
blocked samples.  There remained no significant difference between these groups, p=0.23 
(Mann Whitney test).  The reason for these outliers is probably due to an error resulting in 
different concentrations of input cDNA for samples 1 and 6 being used at the start of the 
PCR reactions.  This effect is most obvious for the 28S PCR reaction as this is by far the 
most abundant primer product tested.  If there are significant differences in the amount of 
cDNA used at the start of PCR reaction the efficiency of the reaction may differ between 
samples making direct comparisons potentially unreliable.  For this reason samples 1 and 6 
were excluded from the analysis.  It should be noted, however, that for these samples, as 
for all of the samples there was only a single melting point for 28S and all the other primer 
products indicating the same, pure PCR DNA product was amplified from each sample 
(see figure 3-7).  Figure 3-7 also shows the melting curves for GAPDH are consistent for 
all samples but, as expected, are different from those for 28S.  In the PCR reaction for 
GAPDH, no cDNA was detected in the water controls but low levels of cDNA were 
detected in the PCR reaction for 28S, as seen in both the amplification plots and melting 
peaks.  However, the melting peaks for the water controls are different from those of 28S 
in the tissue samples and it is likely that the cDNA in the water control is the result of 
amplified primer-dimers. 
3.4.1.4 Quantifying the expression of Kv4.3 mRNA and related accessory subunits.  
The abundance of mRNA for Kv4.3 and its accessory subunits in each tissue sample was 
expressed relative to both an internal standard and the mean of the relative abundance of 
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Figure 3-5 Mean ± sem abundance of 28S rRNA and GAPDH mRNA in tissue from non 
β-blocked ( ) and β-blocked ( ) relative to an internal standard in each PCR reaction. 
P>0.05 
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Figure 3-6 Amplification plots showing the change in fluorescence per PCR cycle for all 
tissue samples and water controls using 28S (A) and GAPDH (B) primers.  The threshold 
line is shown in red.  
A 
Tissue 
Samples 
Water 
controls 
Water controls 
Tissue Samples 
B 
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Figure 3-7 Melting peaks derived from melting curve for cDNA amplified in all tissue 
samples and two water controls using 28S (A) and GAPDH (B) primers.
 Tissue 
samples 
Water 
controls 
Water 
controls 
Tissue 
samples 
A 
B 
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28S and GAPDH within the same tissue sample.  The mean relative abundances of each 
ion channel subunit for the tissue samples from non β-blocked (n = 6) and β-blocked (n = 
8) patients are shown in figure 3-8.  The mean relative abundance of Kv4.3 mRNA in the 
tissue from the non β-blocked and β-blocked patients is 2.09 ± 0.61 vs 1.83 ± 0.14 
respectively, p=0.38.  If all eight non β-blocked samples are included in the analysis there 
remains no difference in the median values for relative Kv4.3 abundance at 2.03 
(interquartile range 1.63 to 2.25) vs 1.70 (1.57 to 2.01), p=0.51.  There was no difference 
in the mean relative abundance of mRNA for the accessory subunits associated with 
Kv4.3: KChIP2 (2.23 ± 0.38 vs 2.48 ± 0.32, p=0.69); Kvβ1 (3.20 ± 0.53 vs 3.75 ± 0.20 
p=0.30); Kvβ2 (1.99 ± 0.27 vs 1.85 ± 0.15, p=0.65); KChAP (2.46 ± 0.32 vs 2.46 ± 0.15, 
p=1.0) and Frequenin (2.04 ± 0.24 vs 1.98 ± 0.15, p=0.83) n = 6 and 8 patients 
respectively.  The mean abundance mRNA for Kv4.3 and the accessory subunits did not 
differ between the tissue samples from non β-blocked or β-blocked patients when 
expressed relative to an internal standard and 28S only or an internal standard and GAPDH 
only as shown in table 3-5 
 
When PCR was first performed using KChIP2 primers from Quantitect the Ct values were 
either not identified or too high to be accurate in the majority of the tissue samples.  The 
results shown in this thesis are from a subsequent PCR reaction performed using KChIP2 
primers (Applied Biosytems) by James Tellez.  PCR was also performed using primers for 
Kv4.2, Kvβ3 and DPP6 but the Ct values were again not identified or too high to be 
accurate in the majority of the tissue samples and so further analysis for these primer 
products was not possible. 
 
The mean abundance of Kv4.3 mRNA and its accessory subunits was also calculated 
relative to 28S but not an internal control as described in the methods.  As no difference 
was demonstrated in the expression of these ion channel subunits between tissue from non 
β-blocked and β-blocked patients, the mean abundance of each subunit in all tissue 
samples was calculated.  This allows for a direct comparison between the relative 
abundance of each ion channel subunit.  It can be seen from figure 3-9 that Frequenin, 
Kv4.3 and KChAP were the most abundant of the ion channel subunits.  However, this 
method of analysis is not as accurate, as the data is not normalised to an internal standard 
and only limited conclusions should be drawn from this.  
 
Gillian E Marshall 2008  143 
 
 
 
Figure 3-8.  Mean ± sem relative abundance of mRNA of Kv4.3 and various related ion 
channel subunits in tissue from non β-blocked (  ) and β-blocked (  ) patients. 
 
0
1
2
3
4
 
m
RN
A 
ex
pr
es
si
o
n
n
o
rm
al
is
ed
 
to
28
s+
G
AP
DH
0
1
2
3
4
 
m
RN
A 
ex
pr
es
si
o
n
n
o
rm
al
is
ed
 
to
28
s+
G
AP
DH
0
1
2
3
4
 
m
RN
A 
ex
pr
es
si
o
n
n
o
rm
al
is
ed
 
to
28
s+
G
A
PD
H
0
1
2
3
4
 
m
RN
A 
ex
pr
es
si
o
n
n
o
rm
al
is
ed
 
to
28
s+
G
AP
DH
0
1
2
3
4
 
m
RN
A 
ex
pr
es
si
o
n
n
o
rm
al
is
ed
 
to
28
s+
G
AP
DH
0
1
2
3
4
 
 
m
RN
A 
ex
pr
es
si
o
n
n
o
rm
al
is
ed
 
to
28
s+
G
AP
DH
   n = 8  n = 6     n = 8   n = 6 
   n = 8  n = 6     n = 8    n = 6 
   n = 8  n = 6     n = 8   n = 6 
A  Kv4.3 B  KChIP2 
C  Kvβ1 D  Kvβ2 
E  KChAP F  Frequenin 
Gillian E Marshall 2008  144 
 
 
Table 3-5.  Mean ± sem abundance of mRNA of ion channel subunits in tissue from non β-
blocked (BB No) and β-blocked (BB Yes) patients relative to an internal standard and 
either 28S or GAPDH, n = 6 and 8 respectively..
Ion channel 
subunit 
Mean ± sem abundance 
relative to 28S  
(BB No Vs BB Yes) 
Mean ± sem abundance 
relative to GAPDH  
(BB No Vs BB Yes) 
Kv4.3 2.82 ± 0.41 vs 2.60 ± 0.14  
p=0.58 
1.54 ± 0.15 vs 1.35 ± 0.13  
p=0.36 
KChIP2 3.37± 0.63 vs 3.87 ± 0.49   
p=0.58 
1.83 ± 0.28 vs 1.95 ± 0.28  
p=0.77 
KChAP 3.60 ± 0.52 vs 3.83 ± 0.37 
p=0.79 
2.34 ± 0.54 vs 1.93 ±0.13 
p=0.84 
Kvβ1 5.12 ± 1.10 vs 5.73 ±0.34 
p=0.31 
2.81 ± 0.43 vs 2.94 ± 0.19 
p=0.33 
Kvβ2 2.60 ± 0.43 vs 2.83 ± 0.26 
p=0.85 
1.58 ± 0.24 vs 1.45 ± 0.12 
p=0.50 
Frequenin 3.00 ± 0.57 vs 3.04 ± 0.25 
p=0.96 
1.58 ± 0.14 vs 1.54 ± 0.12 
p=0.66 
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Figure 3-9 Mean ± sem abundance of mRNA for Kv4.3 and related ion channel 
subunits in all human atrial tissue samples (n = 14 patients) relative to 28S but not an 
internal standard. 
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3.4.1.5 Quantifying the mRNA expression of other ion channel subunits 
The mean abundance of Kv1.5 mRNA, relative to the mean of the abundance of 28S and 
GAPDH, in tissue from non β-blocked (n = 6) and β-blocked (n = 8) patients, was 1.28 ± 
0.10 vs 1.33 ± 0.13 respectively, p=0.75.  The relative mean abundance of Kir2.1 was 
significantly different (1.90 ± 0.21 vs 2.56 ± 0.21, p=0.05).  However, when the relative 
abundance of Kir2.1 was expressed relative to 28S (2.78 ± 0.38 vs 3.99 ± 0.45, p =0.07) or 
GAPDH alone (1.54 ± 0.16 vs 2.00 ± 0.17, p=0.08) the difference between the two groups 
just lost statistical significance.  The relative mean abundance of TWIK1 was not different 
(2.04 ± 0.29 vs 2.31 ± 0.22, p=0.47) nor were the relative mean abundances for Cav1.2 
(2.34 ± 0.38 vs 2.03 ± 0.26, p=0.50) or NCX1 (2.30 ± 0.31 vs 2.0 ± 0.18, p=0.40) when all 
were expressed relative to 28S and GAPDH.  These results are shown in figure 3-10.  With 
the exception of Kir2.1, none of the results for the other ion channels changed when the 
abundance was expressed relative to 28S or GAPDH alone.  Quantitative real time PCR 
was also performed to look at the abundance of Kir2.2 but the Ct values in five of the 
samples (three from non β-blocked and two from β-blocked patients) were too high to be 
accurate, suggesting low expression of this subunit. 
 
3.4.2 Effects of chronic β-blockade on Kv4.3 protein expression 
3.4.2.1 Patient characteristics 
The characteristics of all 20 patients from whom tissue samples were obtained for protein 
analysis are described in table 3-6.  It can be seen that there is a significantly lower heart 
rate in the β-blocked patient group as would be expected.  
3.4.2.2 Total protein concentration of all human atrial tissue samples 
The concentrations of total protein in the 20 samples of right atrial appendage tissue, as 
measured using a modified Bradford’s assay, are shown in table 3-7.  The mean protein 
concentration for the tissue from the non β-blocked patients (n = 10) was 4.25 ± 0.56 
mg/ml compared to 4.65 ± 0.37 mg/ml for the tissue from β-blocked patients (n = 10), p = 
0.56.   
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Figure 3-10 Mean ± sem relative abundance of mRNA for Kv1.5, Kir2.1, TWIK1, Cav1.2 
and NCX1 in tissue from non β-blocked ( ) and β-blocked ( ) patients.  P>0.05 for all 
except Kir2.1 when p=0.05.  
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Patient 
Characteristics 
 
Non β-blocked 
patients 
n (%) 
 
β-blocked 
patients 
n (%) 
 
Total 
patients 
n (%) 
No of patients 10 10 20 
Male patients 6 (60) 6 (60) 12 (60) 
Mean age (yrs) 66.7±3.2 66.3±2.1  
Mean heart rate 
(beats/min) 
74.3±3.6 52.9±2.7*  
Surgery:    
CABG alone 9 (90) 10 (100) 19 (95) 
AVR alone 1 (10) 0 1(5) 
Pre-op Drugs:    
Beta-blockers    
- atenolol 0 (0) 10 (100) 10 (50) 
ACE inhibitors 5 (50) 5 (50) 10 (50) 
CCBs 6 (60) 4 (40) 10 (50) 
Nicorandil 5 (50) 7 (70) 12 (60) 
Statins 10 (100) 10 (100) 20 (100) 
Digoxin 0 (0) 0 (0) 0 (0) 
Amiodarone 0 (0) 0 (0) 0 (0) 
Pre-op disease    
MI 8 (80) 4 (40) 12 (60) 
Angina 9 (90) 9 (90) 18 (90) 
LVSD    
    - unknown 0 (0) 1 (10) 1 (10) 
    - mild 4 (40) 1 (10) 5 (50) 
    - moderate 1 (10) 2 (20) 3 (30) 
    - severe 0 (0) 0 (0) 0 (0) 
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Table 3-6 Characteristics of patients treated or not treated with β-blockers prior to 
cardiac surgery in whom Kv4.3 protein expression was measured.  
CABG = coronary artery bypass graft, AVR = aortic valve replacement, Pre-op = prior 
to surgery, ACE = angiotensin converting enzyme, CCB = calcium channel blocker, MI 
= myocardial infarction, LVSD = left ventricular systolic dysfunction, Post-op = within 
1 to 7 days after cardiac surgery. * indicates a significant different from non β-blocked 
patients (p<0.05, Students t-test) 
Hypertension 5 (50) 7 (70) 12 (60) 
Diabetes 5 (50) 1 (10) 6 (30) 
Post –op AF 1 (10) 4 (40) 5 (25) 
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Sample number 
 
Total protein concentration (mg/ml) 
1 3.3 
2 6.8 
3 3.0 
4 3.4 
5 5.0 
6 4.2 
7 3.7 
8 4.0 
9 7.5 
10 1.6 
11 3.0 
12 3.4 
13 6.1 
14 6.0 
15 6.1 
16 5.0 
17 3.9 
18 5.0 
19 4.5 
20 3.5 
 
Table 3-7 Total protein concentrations of the tissue samples in which Kv4.3 was 
measured.  Samples 1-10 are from non β-blocked patients and samples 11-20 from β-
blocked patients 
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3.4.2.3 Characterisation of a polyclonal anti-Kv4.3 primary antibody 
Western blotting was performed on a human atrial tissue sample using the standard 
protocol for the polyclonal anti-Kv4.3 antibody (Alomone) on one half of a membrane and 
compared with secondary antibody alone on the other half of the membrane (see protocols 
in methods sections).  Approximately 7 µg of total protein was loaded into the four marked 
wells of the gel and the primary antibody was used at a dilution of 1:800.  The resulting 
film is shown in figure 3-11A.  It can be seen that the combination of primary and 
secondary antibodies detected a dense band between 50 and 60 kDa along with two other 
distinct bands, one just above 80 kDa and another just above 40 kDa.  The band between 
50 and 60 kDa was also detected with the secondary antibody alone indicating that some, if 
not all, of this band was the result of non-specific, secondary antibody binding i.e. the 
secondary antibody was binding to something other than the primary antibody. There are 
also several other very faint bands detected between 50 and 80 kDa.  In an attempt to help 
clarify the nature of these bands, a pre-incubation experiment was performed.  One half of 
the membrane was treated with primary antibody which had been incubated in 1ml of 
blocking solution.  The other half of the membrane was treated with primary antibody that 
had been pre-incubated in antigenic peptide made up to 1ml in blocking solution.  The final 
dilution of primary antibody used to treat both halves of the membrane was 1:533 (a 
slightly higher concentration than in figure 3-11A) and the ratio of antigen to antibody was 
10:1 (further details in the modified protocols section of methods).  10 µg of total protein 
from the same human atrial sample was loaded into each of the wells of the gel although 
this was a different tissue sample than used in figure 3-11A.  The results of this experiment 
are shown in figure 3-11B and it can be seen that pre-incubation with antigen does not 
cause any change in the bands at 80 or 50-60 kDa.  There may be a slight decrease in the 
intensity of in the bands around 40 kDa in the outer lanes of the pre-incubated half of the 
gel but it is far from convincing. 
 
A number of other experiments were performed in an attempt to clarify the nature of the 
bands detected with this primary antibody and to see whether any bands representing 
Kv4.3 were being missed from these early results due to the low concentration of this 
protein in the tissue samples.  Different concentrations of primary antibody and a different, 
more sensitive, detection system incorporating a different secondary antibody and blocker 
were used.  Figure 3-12A shows the result of using two higher concentrations of primary 
antibody to see whether any new bands could be detected.  It can be seen that there is 
clearly a double band around 40 kDa which was faintly seen on the previous films and a 
further two bands between 30 and 40kDa.  All the other bands detected on previous films  
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Figure 3-11  Western blots characterising the polyclonal anti-Kv4.3 antibody (Alomone) 
in human atrial tissue (HA).  In A, the left half of the membrane was treated with both 
primary (1ºAb) and secondary (2ºAb) antibodies and the right half with only 2ºAb 
(Invitrogen).  In B, the left half of the membrane was treated with primary antibody and the 
right half with primary antibody pre-incubated with antigenic peptide (Alomone). 
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Figure 3-12  Western blots characterising the polyclonal anti-Kv4.3 antibody (Alomone) 
in human atrial tissue (HA).  In A, the membrane was incubated with high concentrations 
of 1ºAb, 1 = 1:160 dilution, 2 = 1:100 dilution.  In B, the 1ºAb was detected using two 
dilutions of a different 2ºAb, 1 = 1:20000 and 2 = 1:10000, (Amersham) and the bands 
detected using the more sensitive chemiluminescent detection system (ECL advance, 
Amersham) 
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appear darker in this film.  Because of the high intensity of the bands in this film the 
development time was reduced to one minute.  Even at this short exposure time the bands 
still appear very intense. 
 
Other experiments were performed to test the effectiveness of different blocking agents 
including BSA and Blotto A.  These experiments were performed by Julie Russell prior to 
the work presented in this thesis and are not described here.  The most effective blockers 
for the antibodies used in this work are the ones described in the methods ie Invitrogen 
Western Breeze blockers. 
 
The results of using the same polyclonal primary anti Kv4.3 antibody at a 1:800 dilution, 
the more sensitive ECL-advance detection system along with two different concentrations 
of secondary antibody are shown in figure 3-12B.  Three distinct bands were detected for 
each antibody concentration, one at just above 40 kDa, one large band between 50 and 60 
kDa and one band just above 80 kDa.  Additional bands above 80 kDa were also clearly 
visible when using the highest concentration of secondary antibody, although, at this 
concentration, the other bands started to blur together indicating that the concentration of 
antibody was too high.  Several other concentrations of primary and secondary antibody 
were used with this detection system the results of which are not shown but this detection 
system did not seem to offer any benefits compared to the standard Invitrogen Western 
breeze system.  
 
In an attempt to establish the nature of the bands detected with this polyclonal primary 
antibody, particularly the bands around 80 and 40 kDa, a positive control was required.  It 
was not possible to purchase a pure source of recombinant Kv4.3 protein to use as a 
positive control.  Attempts to obtain a plasmid containing the cDNA for Kv4.3 in order to 
transfect cells and isolate Kv4.3 protein also proved unsuccessful.  Kv4.3 is known to be 
highly expressed in brain and its expression in lung tissue is thought to be minimal 
(105;191).  Rat and rabbit brain tissue along with rabbit lung tissue brain tissue were 
obtained and Western blots performed using these tissue and human atrial tissue and the 
resulting bands compared. The polyclonal primary antibody was reported to recognise 
Kv4.3 in these species as well as in humans (Alomone, product information).   
 
An example of Western blot of using these tissue samples is shown in figure 3-13.  One 
half of the membrane was treated with the polyclonal primary antibody (1:800 dilution) 
according to the standard protocol and the other half treated with secondary antibody alone
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Figure 3-13  Western blot comparing the polyclonal anti-Kv4.3 1ºAb (Alomone) in human 
atrial tissue (HA) with rat (rb) and rabbit brain (RB) and rabbit lung (RL).  Non specific 
bands (?) due to 2ºAb binding were demonstrated by treating half of the membrane with 
2ºAb alone (Invitrogen).  Potential bands representing Kv4.3 are labelled “?Kv4.3”. 
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(Invitrogen Western Breeze kit).  Approximately 10 µg of total protein was loaded onto the 
gel for each tissue sample.  Distinct bands can be seen in both brain samples at just above 
60 and 40 kDa which were not detected by specific primary antibody binding in the rabbit 
lung tissue.  This would suggest these bands represent Kv4.3.  However, no identical bands 
were detected in the human atrial sample.  There was a band detected around 40 kDa in a 
similar, although not identical, position to that in the positive controls which may represent 
Kv4.3.  No clear band was clearly detected around 60 kDa in the human tissue, although a 
band at this position was detected faintly in some Westerns using this antibody.  In rat 
brain tissue, another band was detected between 30 and 40 kDa which was not present in 
the rabbit brain.  In the human tissue, two bands were detected between 30 and 40 kDa, the 
darker of which is at a very similar position to the band in rat brain.  This raises the 
possibility that these bands may also represent Kv4.3.  A further band at around 80 kDa 
was detected in the human tissue which did not correspond to any band detected in the 
animal samples and the nature of this is unclear.  In rabbit brain, lung and human atrium 
there is a dense band between 50 and 60 kDa which is also present with the secondary 
antibody alone.  The identity of this band is not clear but it is unlikely that it consists only 
of Kv4.3 protein given the non-specific interaction with the secondary antibody.  There are 
numerous bands detected below 50kDa in the rabbit lung all of which are present with the 
secondary antibody alone.  In summary, the bands most likely to represent Kv4.3 in the 
brain tissue are those at 40 and just above 60 kDa and possibly one between 30 and 40 
kDa.  Of these, only the band at 40 kDa is comparable with a band detected in the human 
atrial tissue 
 
3.4.2.4 Characterisation of a monoclonal anti-Kv4.3 primary antibody 
A monoclonal antibody against Kv4.3 was obtained from Neuromab.  Figure 3-14 shows a 
Western blot of human, rat and rabbit brain and rabbit lung tissue (10 µg of total protein 
was loaded for each sample) using this primary antibody at a 1:100 dilution and compared 
to secondary antibody alone.  Using this primary antibody two very dark bands were 
detected in the human tissue, one between 50 and 60 kDa and another between 20 and 30 
kDa, both of which are detected with the secondary antibody alone.  This secondary 
antibody is different from that used with polyclonal primary antibody being anti-mouse 
IgG (Invitrogen).  In the human atrial tissue, there is also a distinct band just above 60 kDa 
which corresponds to a much darker band seen at the same molecular weight in the rat and 
rabbit brain tissue.  This band is barely visible in the rabbit lung tissue and not detected by 
the secondary antibody alone.  This monoclonal primary antibody also detects a very faint 
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Figure 3-14 Western blot characterising a monoclonal anti-Kv4.3 1ºAb (Neuromab) in 
human atrial tissue (HA), rat (rb) and rabbit brain (RB) and rabbit lung (RL).   The left half 
of the membrane was treated with both 1ºAb and an anti-mouse IgG 2ºAb (Invitrogen) 
while the right half was treated with 2ºAb alone to identify bands due to non-specific 2ºAb 
binding labelled “?”. 
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band around 40 kDa in the human atrial and animal brain tissue in addition to two very 
faint bands around 80 kDa in the human atrial tissue.  
 
If figures 3-13 and 3-14 are compared, it can be seen that both the polyclonal and 
monoclonal anti-Kv4.3 primary antibodies detect a band at the same position just above 60 
kDa in the animal brain tissue.  In an attempt to further characterise the nature of this band 
a pre-incubation experiment was planned in which the specificity of the primary antibody 
would be assessed by pre-incubation with antigenic peptide.  If a saturating concentration 
is used, the antigen should bind all of the primary antibody and, therefore, prevent the 
primary antibody from binding to any Kv4.3 on the membrane.  Unfortunately, the only 
antigenic peptide that could be obtained was from the company from which the polyclonal 
primary antibody was purchased (Alomone).  This did not contain the same epitope 
recognised by the monoclonal antibody and, unsurprisingly, an experiment in which this 
antigenic peptide was pre-incubated with the monoclonal primary antibody (Neuromab) at 
a ratio of 100:1 did not show any difference in the of the bands detected (results not 
shown).  A pre-incubation experiment was also performed using the polyclonal antibody 
and antigen in animal brain tissue.  10 µg of total protein was loaded into each well of the 
gel with duplicates for each sample.  One half of the membrane was treated with the 
polyclonal primary antibody which had been pre-incubated in 0.5ml of PBS and the other, 
treated with primary antibody that had been pre-incubated with antigenic peptide made up 
to 0.5ml in PBS.  The final dilution of primary antibody used to treat both halves of the 
membrane was 1:1600 and the ratio of antigen to antibody was 10:1.  Both halves of the 
membrane were treated identically thereafter.  The resulting film is shown in figure 3-15.  
It can be seen that pre-incubation with antigenic peptide prevented the primary antibody 
from binding to protein at 60 and also 40 kDa in the brain tissue from both the rat and 
rabbit.  
 
Based on these experiments, the band just above 60 kDa detected with the Neuromab 
monoclonal primary antibody in human atrial tissue is likely to be Kv4.3 and, when its 
position was compared to the molecular weight markers, its molecular weight was 
confirmed as being 65kDa.   
 
3.4.2.5 Characterisation of a monoclonal anti-GAPDH primary antibody  
A preliminary Western blot of varying protein loads of human atrial tissue (30, 25, 20, 15, 
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Figure 3-15  Western blot characterising the nature of the band detected at just above 60 
kDa using with the polyclonal anti-Kv4.3 1ºAb in rat (rb) and rabbit brain (RB) tissue.  
The left side of the membrane was treated with both polyclonal 1ºAb and 2ºAb whereas the 
right side was treated with an identical concentration of polyclonal 1ºAb pre-incubated 
with antigen (Ag) in addition to 2ºAb. 
Molecular weight 
markers (kDa) 
 
50 
     rb    rb   RB  RB       RB RB   rb   rb 20 
30 
40 
 
 
60 
Polyclonal Ab alone Polyclonal Ab + Ag 
Gillian E. Marshall 2008  160 
 
10, 8 and 7 µg) treated with a monoclonal anti-GAPDH primary antibody (1:1000 dilution) 
was performed in order to confirm the position of the band(s) detected with this primary 
antibody.  This was compared with a previous Western blot of the same human atrial tissue 
sample (10 µg total protein loaded in two lanes of the gel), in addition to animal tissue, 
treated with the same secondary antibody but no primary antibody.  This allowed the 
identification of any bands detected as a result of a non specific secondary antibody 
reaction.  Films of these blots are shown in figure 3-16.  It can be seen that the combination 
of primary and secondary antibodies resulted in the detection of three bands; one between 
50 and 60 kDa, one just below 40 kDa and one between 20 and 30 kDa.  There are 
additional very faint bands at 30, 40 and several around 80 kDa.  The secondary antibody 
alone detected similar bands between 50 and 60 kDa and between 20 and 30 kDa, 
suggesting the only band detected as a result of a specific primary antibody reaction is the 
band just below 40 kDa 
 
3.4.2.6 Establishing a linear relationship between optical density and total protein 
for GAPDH and Kv4.3 
In order to compare the relative amounts of Kv4.3 protein between tissue samples from 
non β-blocked and β-blocked patients, the conditions for Western blotting had to be 
optimised such that the relationship between the total protein load and optical density of 
the bands of interest was linear.  The main variables that determine band intensity are the 
amount of protein, concentration of antibodies and film exposure time.  Preliminary 
experiments comparing different films developed after different exposure times established 
that the optimum exposure was 10 minutes (results not shown) and this was used for all 
films unless stated otherwise.  The concentration of the secondary antibody remained 
constant as this antibody was supplied pre-diluted as part of the anti-mouse Invitrogen 
Western Breeze Kit.   
 
Preliminary experiments using wide ranges of total protein loads (2 - 50 µg) and different 
primary antibody dilutions helped to established the conditions at which, either no bands 
were detected, or at which, complete saturation occurred i.e. no change in optical density in 
relation to changes in protein load (results not shown).  Based on these initial experiments, 
further Western blots were performed to establish the range of protein load and primary 
antibody dilution at which a linear relationship between protein load and optical density 
occurred.  Four Western blots were performed using the same range of total protein loads 
from tissue from two non β-blocked and two β-blocked patients.  After blocking, each
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Figure 3-16  Western blot characterising the nature of the bands detected using a 
monoclonal anti-GAPDH 1ºAb in human atrial tissue (HA). In A, different total loads of 
protein were treated with monoclonal anti-GAPDH antibody (Abcam) and 2ºAb (anti-
mouse IgG Invitrogen).  In B, 2ºAb alone was used to identify non specific bands labelled 
“?”.  
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membrane was cut vertically into three sections so that the same range of protein loads 
could be incubated with three different dilutions of primary antibody as detailed in the 
legend of figure 3-17.  The three sections of each membrane were then treated identically 
and developed at the same time.  The optical densities of the bands just above 60 kDa and 
just below 40 kDa were measured in the membranes treated with either anti-Kv4.3 or anti-
GAPDH antibodies respectively.  The results of these experiments are shown in figure 3-
17.  It can be seen from figures A and B that a linear relationship between optical density 
and protein load for the GAPDH antibody only exists in loads <10 µg of total protein and, 
for both tissues, the optimal antibody dilution appears to be 1:20000.  Figures C and D 
demonstrate that a linear relationship exists over the same range of protein loads for Kv4.3 
in both tissues for all the antibody concentrations.  The exception was the 1:200 primary 
antibody dilution using tissue from the β-blocked patient, in which the bands were partially 
obscured by damage to the membrane and the optical densities could not be reliably 
measured. 
3.4.2.7 Comparing the relative amounts of Kv4.3 protein in tissue from non β-
blocked and β-blocked patients. 
All the tissue samples were pre-diluted to a concentration of 1 mg/ml, blinded and 
randomised so that two samples from non β-blocked and β-blocked patients were loaded in 
a random order on each gel.  Five Western blots were then performed using three proteins 
loads for each tissue sample of 10, 7.5 and 5 µg and a dilution of 1:20000 for the anti-
GAPDH antibody and 1:133 for the monoclonal anti-Kv4.3 antibody.  Each membrane was 
cut in half horizontally between the 40 and 50 kDa markers after the blocking stage so the 
lower half could be incubated in the anti-GAPDH antibody and the upper half in the anti-
Kv4.3 antibody.  Both halves of the membrane were then treated identically thereafter.  
The identity of each tissue sample was not known until after the optical densities of the 
bands had been measured. 
The film of one of these Western blots is shown in figure 3-18. It can be seen that the 
density of the bands for both the Kv4.3 and GAPDH bands decreased as protein load 
decreased.  There is no marked visual difference in the intensity of the bands of 
corresponding protein loads for GAPDH or Kv4.3 between the non β-blocked and β-
blocked tissue samples.  The optical densities of each of the bands in this figure are shown 
in figure 3-19 along with the ratio of the optical densities of Kv4.3 protein relative to 
GAPDH in each sample.  It can be seen from figures A and B that, in each of the samples 
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Figure 3-17 Establishing the linear range of optical density versus total protein for 
GAPDH and Kv4.3 primary antibodies.  Figures A and B show the relationship between 
optical density and total protein in tissue from a non β-blocked (A) and β-blocked (B) 
patient using different dilutions of GAPDH primary antibody (  = 1:5000, *  =1:10000  
= 1:20000).  Figures C and D show the relationship between optical density and total 
protein in tissue from a non β-blocked (C) and β-blocked (D) patient using different 
dilutions of  Kv4.3 primary antibody (  =1:100, =1:133, + =1:200). 
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Figure 3-18. Western blot of Kv4.3 and GAPDH in human atrial samples from two non β-
blocked (BBNo) and two β-blocked (BBYes) patients.   
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Figure 3-19  Optical densities of GAPDH (A) and Kv4.3 (B) at three protein loads 5, 7.5 
and 10 µg.  A best fitting straight line has been fitted to the results from two non β-blocked 
samples 1 (  ) and 2 ( ) and two β-blocked samples 1(  ) and 2 
( ).  In C, the optical densities for the Kv4.3 bands in each sample are normalised 
to the respective GAPDH optical densities. 
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for both GAPDH and Kv4.3, the optical density decreased with decreasing protein load in 
a linear fashion with the exception of Kv4.3 in β-blocked sample 2, where the optical 
density is slightly lower at the 10 µg protein load than at 7.5.  When the expression of 
Kv4.3 is normalised to that of GAPDH in figure C, the relationship between optical density 
and protein load is reversed for this one β-blocked tissue sample and the relationship is no 
longer logical.  This sample was, therefore, excluded from further analysis. 
The optical density versus protein load was plotted for both GAPDH and Kv4.3 in all the 
remaining tissue samples.  In one other β-blocked sample the bands for both GAPDH and 
Kv4.3 were too faint to analyse and, therefore, this sample also had to be excluded from 
further analysis.  There was no difference in the actual mean optical densities of GAPDH 
as measured at a protein load of 7.5 µg in the tissue from non β-blocked (n = 10) compared 
to the tissue from the β-blocked (n = 8) patients (10.66 ± 1.61 vs 9.56 ± 0.70 ODu/mm2, 
p=0.57). These results are shown in figure 3-20A.  The data was also analysed to compare 
the mean gradients of the best fitting straight lines for GAPDH optical density versus total 
protein load in each patient group and, again, there was no difference (0.78 ± 0.15 vs 0.7± 
0.10, p=0.80).  When then optical densities of the Kv4.3 bands were measured, there was 
no difference demonstrated in the mean optical densities at a total protein load of 7.5 µg in 
the tissue samples from non β-blocked (n = 10) and β-blocked (n = 8) patients (11.57 ± 
1.31 vs 11.44 ± 1.03, p=0.94) (see figure 3-20B).  Again, there was no difference when the 
mean gradients were analysed (0.99 ± 1.15 vs 1.18 ± 0.14, p=0.38).  When the optical 
density of Kv4.3 was normalised to that of GAPDH at each of the three protein loads, the 
mean optical densities at a total protein load of 7.5 µg were 1.30 ± 0.27 vs 1.24 ± 0.13, 
p=0.86 in the tissue samples from non β-blocked (n = 10) and β-blocked (n = 8) patients 
respectively.  These results are shown in figure 3-20C. The normalised mean gradients 
were no different (0.02 ± 0.006 Vs 0.03 ± 0.01, p=0.34). 
 
3.5 Discussion 
The experiments in this chapter describe the effects of chronic treatment of patients with β-
blockers on the expression of K+ ion channel pore-forming and accessory subunits.  
Despite the reduction in the current density of ITO seen in association with chronic β-
blockade, there was no change in the level of mRNA for Kv4.3, the pore-forming ion 
channel subunit responsible for conducting this current.  Nor was there any change in the  
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Figure 3-20 Mean ± sem optical densities of GAPDH (A), Kv4.3 (B) and Kv4.3 
normalised to GAPDH (C) at a protein load of 7.5µg and corrected for background, for the 
tissue samples from the non β-blocked ( ) and β-blocked (  ) patients, p>0.05. 
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level of mRNA expression for the accessory subunits KChIP2, KChAP, Kvβ1-3, or 
Frequenin, all of which can affect Kv4.3 function and/or expression.  This indicates that 
ion current remodelling in this situation is not the result of altered ion channel gene 
expression.  As expected, given the lack of change in IKSUS, there was no change in the 
mRNA expression for the pore-forming subunit for this channel, Kv1.5.  There was an 
increase in the mRNA expression for Kir2.1, one of the pore-forming ion channels 
responsible for IK1, in contrast to the reduction seen in this current associated with chronic 
β-blockade.  This reduction persisted, but was not statistically significant, in all when 
normalised to individual “housekeepers” raising some concerns about the strength of this 
result although the relatively small number of samples may partially account for this.  
Chronic β-blockade was not associated with any change in the level of Kv4.3 protein 
expression indicating that ion current remodelling was not the result of a reduction in 
translation.  
3.5.1 Ion channel mRNA expression in human atrium 
3.5.1.1 A comparison with other studies 
This study is the first to examine the effects of chronic β-blockade on ion channel 
expression in human atrial tissue.  Many of the studies looking at ion channel expression in 
human atrial tissue have been performed to look for changes in mRNA levels associated 
with cardiac disease or other patient characteristics and, therefore, it is very difficult to 
make any direct comparisons with this study.  The end product of a RT-PCR reaction is 
often not representative of the entire mRNA sequence of a gene and therefore the size or 
melting peaks of the products are not comparable between studies.  One possible area of 
comparison between this study and others, is the relative abundance of ion channel 
subunits in atrial tissue although this measurement is often not the primary aim of many 
studies including this one.  It should be remembered that the analysis of relative abundance 
of each ion channel subunit does not incorporate normalisation to an internal standard and, 
therefore, does not take into account any differences in polymerase efficiency between 
different tissue samples.   
In this study the abundance of Kv4.3, KChAP, and Frequenin mRNA were more highly 
than Kvβ2, Kvβ1 and KChIP2 which were all expressed at relatively low levels.  These 
results would appear to conflict with one study that used RT-PCR along with a slightly 
different method of analysis, specifically to look at the relative abundance of groups of ion 
channel subunits in left atrial tissue samples from donor hearts (192).  It showed found that 
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KChIP2 was highly expressed in atrial tissue and was significantly more abundant than 
either Kvβ1 or Kvβ2 with Kvβ1 being the more abundant of these β subunits.  It did not 
directly compare the abundance of Kv4.3 with these subunits.  There are several possible 
explanations for this difference.  Firstly, the methods of analysis were different and all 
samples in the study by Ordog et al were normalised to β-actin.  In that study, data was 
collected from left as opposed to right atrial appendage tissue and the clinical 
characteristics of the patients were not identical to those in this study which may result in 
different ion channel and housekeeping gene expression.  The difference in KChIP2 
expression is however is quite striking and several other studies have suggested KChIP2 
expression is relatively highly expressed.  KChIP2 mRNA has been detected in human 
cardiac tissue using less sensitive techniques than quantitative RT-PCR and there is 
sufficient protein expressed to be detectable by Western Blotting (108;110;116;117).  
KChIP2 has at least 18 splice variants (97;117;130;192).  The Quantitect primer that was 
first tested in this study detected extremely low levels of KChIP2 and, when it was 
compared to the genomic sequence of KChIP2 and that of its major splice variants, this 
primer was found not to detect the ones reported to be most abundant in human atrial tissue 
(117).  A different primer was designed (Applied Biosystems) and targeted to recognise 
regions common to the most abundant splice variants.  Higher levels of KChIP2 were 
detected with this primer and these are the results shown in figures 3-8 and 3-9 but the 
overall abundance remained low.  It is possible that some splice variants were not detected 
and the abundance of KChIP2 was underestimated.  It is, therefore, also possible that any 
possible effects of chronic β-blockade on KChIP2 expression could have been 
underestimated. 
Interestingly, this study suggests Frequenin is relatively highly expressed in human atrial 
tissue suggesting it may have quite a significant functional role.  There is very little 
information about the role or expression of Frequenin in cardiac tissue.  It has been shown 
to interact with Kv4.3 in expression systems and is structurally related to the KChIP family 
but other studies have suggested its role is not limited to modulation of ion channel 
function or expression.   It  is likely to be involved in a number of signalling and regulatory 
intracellular pathways via involvement with cAMP and phosphoinositide production (193).   
There is very little information regarding the relative expressions of KChAP and the Kvβ 
subunits in human cardiac tissue.  In this study, several other ion channel subunits 
including Kvβ3, DPP6 and Kir2.2, either could not be detected at all, or were not detected 
at a high enough level to yield reliable results.  For these subunits, this was the case within 
all the tissue samples.  There are reports of the mRNA for these subunits being detected in 
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human cardiac tissue (124;134;137;192;194) although expression of Kir2.2 has been 
shown to be relatively weak in comparison to Kir2.1(137).  The reasons for these 
discrepancies may include different methods of RNA extraction and quantification, the use 
of different primers, variable expression in different cardiac chambers, and variable 
expression according to different patient characteristics. 
3.5.1.2 RT-PCR compared to Western Blotting 
Various techniques can be used to study ion channel expression, including, microarrays to 
look at large number of genes and RT-PCR, northern blots and ribonuclease protection 
assays to look at mRNA of individual genes.  A technique like real time RT-PCR has a 
significant advantage over Western blotting in that it is much more sensitive and better 
able to measure ion channels which are often expressed at a much lower level than many 
structural or regulatory genes.  The reaction between primer and mRNA/cDNA in an RT-
PCR reaction can be manipulated to be dependent on a unique piece of genetic code, 
whereas, the reaction between antibody and protein in a Western reaction is dependent on a 
number of features including conformation shape and charge therefore, controlling 
specificity is more difficult.  The use of microplates, the speed of the PCR reaction and the 
help of Mark Boyett’s research group, who had already tested the different primers, 
allowed RT-PCR to be used to look at many more ion channel subunits than just Kv4.3.  
However, it should be remembered that Western blotting and RT-PCR are techniques that 
look at different aspects of ion channel expression.  By examining protein expression 
Western blotting comes closer to studying the functional impact.   
3.5.2 Kv4.3 protein expression in human atrial tissue   
In this study Kv4.3 protein was detected at 65 kDa in human atrial tissue using a 
monoclonal primary antibody.  To my knowledge, this is the first report of Western 
blotting using this antibody in human atrial tissue and, therefore, a number of control 
experiments were performed to confirm the nature of the bands detected by this antibody.  
The band at 65 kDa was of similar molecular weight to a band detected at a high intensity 
in rat and rabbit brain tissue which were used as positive controls because of the high 
levels of expression of Kv4.3 in these tissues (105;191).  This band was virtually absent in 
rabbit lung tissue which has minimal Kv4.3 expression and was, therefore, used as a 
negative control (105;191).  Although the structure of Kv4.3 is highly homologous 
between species and, therefore, should be of identical molecular weight in different tissues 
and species this is not necessarily the case and is a potential weakness of using these types 
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of control.  Different splice variants of Kv4.3 exist, although reports suggest that the two 
currently identified are expressed in both brain and cardiac tissue (105;191).  It is possible 
that other variations in Kv4.3 may exist between species and tissues e.g. in tertiary 
structure, glycosylation etc which may alter the molecular weight of the Kv4.3 protein.  
Non or partially reduced forms of the protein along with partially degraded forms may also 
result in different bands being detected in different species or tissues by Western Blotting 
all of which may still represent Kv4.3 protein.  The bands at 65 kDa, detected in animal 
brain tissue using the monoclonal antibody, were comparable to bands detected with the 
polyclonal antibody (Alomone) in this tissue.  Pre-incubation with antigenic peptide 
prevented the binding of the polyclonal antibody to the band at 65 kDa in animal brain 
tissue helping to confirm the specificity of the antibody-protein interaction resulting in the 
detection of this band.  This experiment could not be performed using the monoclonal 
antibody as no antigenic peptide for this antibody was available.  Ideally, a further positive 
control the monoclonal antibody and a pure source of Kv4.3 protein e.g. recombinant 
Kv4.3 would have been performed for comparison with the human atrial tissue, however, it 
was not possible to obtain any recombinant Kv4.3.   
The band detected at 65 kDa was demonstrated to be detected as a direct result of 
monoclonal primary antibody binding and was not due to non-specific secondary antibody 
binding which seemed to be responsible for two other bands detected in human atrial 
tissue, one between 50 and 60 kDa and one between 20 and 30 kDa.  The secondary 
antibody used with the monoclonal anti-Kv4.3 recognised mouse IgG and it is possible that 
it is cross-reacted with human IgG in blood within in the cardiac tissue samples.  The 
molecular weight of IgG heavy chains is 50 kDa and light chains are 25kDa, consistent 
with the bands detected by the secondary antibody alone.  It remains possible these bands 
could contain some variant of Kv4.3, in addition to IgG, and, by not including the optical 
density of these bands in the analysis, information on the expression of Kv4.3 protein may 
have been missed. 
As discussed above, it is possible to detect multiple variants of Kv4.3 by Western blotting.  
In addition to the band at 65 kDa, the monoclonal primary antibody also detected a much 
fainter band just above 40 kDa which was present in brain tissue and was not due to non-
specific secondary antibody binding.  It is possible, therefore, that this band also 
represented another variant of Kv4.3.  However, this band was not detected when Western 
Blotting was performed using all the human atrial samples because each membrane was 
cut around this position in order to detect Kv4.3 at 65 kDa and GAPDH in each tissue 
Gillian E. Marshall 2008  172 
 
sample.  Therefore, it is possible that some additional information on Kv4.3 expression 
could have been missed. 
3.5.2.1 A comparison with other studies 
There are very few reports of Western Blotting for Kv4.3 in human atrial tissue.  This may 
reflect the difficulty in obtaining human tissue for experimental work but may also reflect 
difficulties in actually detecting this protein using this technique, particularly, with 
relatively small amounts of tissue.  There are several reports of Kv4.3 protein being 
detected around 70 kDa in Western blots of human atrial tissue.  In one study Kv4.3 was 
detected in explanted human hearts using a custom made primary antibody at 74 kDa 
(104).  Under experimental conditions of that study, the position of the Kv4.3 band in 
human atrium was consistent with a band detected in rabbit atrium and rat brain and 
disappeared with pre-incubation with antigen.  That study also reported bands around 45 
kDa in both human and rabbit atrial samples when using the anti-Kv4.3 primary antibody.  
Other studies have successfully used a polyclonal primary antibody from Alomone to 
detect Kv4.3 in human cardiac tissue.  One study using this antibody describes Kv4.3 in 
human atrial tissue as a band at 72 kDa (111).  However, this study did not show whole 
membranes of the Western blots or molecular weight markers and did not mention the 
presence of any other bands detected.  What is more, they showed no evidence of positive 
or negative controls to help confirm the identity of the band they had detected with this 
antibody and no further information was provided about the primary antibody to confirm it 
was the same antibody as was used here.  Another study reported a band at 79 kDa using a 
polyclonal anti-Kv4.3 primary (Alomone) in human atrial tissue although, again, only 
partial membranes were shown with no controls and no further details about the primary 
antibody were provided (195).  
Kv4.3 protein has also been detected in human ventricular tissue by Western blotting.  In 
one study using tissue from explanted hearts, Kv4.3 was detected as a very faint band 
around 75 kD using a polyclonal primary antibody (Alomone) (108).  This band was not 
present when the antibody was pre-incubated with antigen and was comparable in 
molecular weight to a band detected using recombinant Kv4.3 isolated from transfected 
CHO cells.  Interestingly, in this positive control, a band was also detected around 43 kDa.  
Another study demonstrated a band at 76 kDa in ventricular tissue using a polyclonal anti-
Kv4.3 primary antibody (Alomone) but showed only a small section of membrane with no 
molecular weight markers although they did state that the band was not detected when the 
antibody was pre-incubated with antigen (109).  A further study using a different primary 
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antibody (Chemicon), detected Kv4.3 at 75 kDa in human ventricular tissue but at a 
slightly lower molecular weight (70kDa) in the canine tissue.  Interestingly, a study in 
rabbits, detected Kv4.3 at two molecular weights 78 and 68 kDa when using either the 
Chemicon primary antibody or a custom made antibody specific for the long splice variant 
Kv4.3 (138).  The specificity of the Neuromab and Alomone primary antibodies is not 
known. 
All the studies described above detected Kv4.3 at a slightly higher molecular weight than 
reported here using a monoclonal primary antibody.  There are several possible 
explanations for this.  Firstly, the weight of any band detected on a Western blot is 
determined by comparison with molecular weight markers.  Small variations in the weights 
of different types of markers may exist and variations in the type of gel, buffers, and 
electrophoresis protocol may also influence how both the markers and samples migrate 
through a gel.  When three other molecular markers were compared, the weight of this 
band was found to be 62kDa (Amersham ECL marker, RPN2107), 67 kDa (Sigma, 
M0671) and 80 kDa (Pierce Blue Ranger, 26651), results not shown (Julie Russell, 
personal communication).  Secondly, different antibodies detect different epitopes of 
Kv4.3.  If several “variants” of Kv4.3 of different molecular weight can exist, as suggested 
by some of these studies and indeed my own work, then different antibodies may recognise 
different variants of Kv4.3.  At least two of the studies support the possibility that the band 
detected just above 40 kDa with the monoclonal primary antibody may also be Kv4.3.  The 
reported molecular weight of Kv4.3 can therefore only be used as a guide to identifying the 
protein on a Western blot and evaluation of the whole membrane along with controls is 
important.  
 
When using the polyclonal anti-Kv4.3 antibody (Alomone) in the initial experiments 
outline in this chapter, two bands were detected relatively near to the molecular weight of 
Kv4.3 as reported by other studies using this antibody.   In figure 3-11A there is a faint 
band just above 60 kDa.  This band was not clearly visible when either high concentrations 
of the primary antibody or a more sensitive detection system were used as shown in figure 
3-12.  The band was not clearly present in the human atrial sample that was compared 
correspond the animal brain positive controls in figure 3-13.  The polyclonal antibody also 
detected a band at just above 80 kDa, however, this band also did not correspond to any 
bands detected in animal brain tissue.  Neither band disappeared with when the primary 
antibody was pre-incubated with antigen as shown in figure 3-11B.  It may be that the ratio 
of antigen-antibody was too low and there was insufficient antigen to bind all the antibody 
although this ratio of antigen:antibody did seem to prevent binding of the primary antibody 
Gillian E. Marshall 2008  174 
 
to animal brain tissue.  Another possibility is that the antigenic peptide only bound a 
subpopulation of the polyclonal antibody leaving the remaining subpopulations, which 
recognised different epitopes of Kv4.3, able to bind to the human protein.  This lack of 
specificity for just one epitope of an antigen is the hallmark of a polyclonal antibody.  This 
means this type of antibody can detect the many possible variants of this protein which 
may exist and can be separated by gel electrophoresis.  It is possible, therefore, that both 
the bands at 65 kDa and 80 kDa detected with the polyclonal antibody could both be 
variants of Kv4.3, however, the difficult in confirming the nature of these bands led to this 
antibody being abandoned in favour of the monoclonal primary (Neuromab). 
3.5.3 The role of normalisation in analysis of Western Blots and 
quantitative RT-PCR. 
In both Western blot analysis and quantitative RT-PCR, the expression of the ion channel 
subunits was normalised to the expression of GAPDH.  In the Western Blots this is meant 
to correct for any variation in the amount of total protein loaded into different wells of the 
gel from different tissue samples.  This may arise from inaccurate assessment of the total 
protein content of the tissue samples or pipetting errors in making the sample dilutions or 
in actually loading the gels.  Normalising to GAPDH in this way is only valid if the 
expression of this protein does not vary between the tissues from the non β-blocked and β-
blocked patients.  This was shown to be the case.  The mRNA expression of GAPDH was 
also shown to be similar between these groups although this was measured in tissue from 
different patients. 
In the quantitative real time RT-PCR experiments two types of normalisation were used.  
Firstly, the Ct values for each primer product were normalised to one sample to correct for 
any variations in the efficiencies of the reaction between the different tissue samples or 
pipetting variations in distributing the master mix between samples.  Secondly, each primer 
product was normalised to the mean of two “normalisation markers” of total cellular 
content from the same sample to account for any differences in the amount of RNA used at 
the start of the RT-PCR reaction.  RT-PCR is an extremely sensitive technique that can 
detect very small differences in gene expression therefore any variables in the expression 
of the “normalising marker” can have a much bigger impact than it might in Western 
Blotting.  The expression of so called reference or housekeeper genes like GAPDH are not 
always stable and can be influenced by a number of factors including heart failure which 
could potentially skew any data normalised to this gene alone (196).  Another common 
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method of normalisation is to normalise to total RNA, in which usually a marker of rRNA, 
either 18S or 28S, is used.  This is not without its problems as it cannot control for any 
errors introduced at the RT step of the PCR reaction and also assumes the rRNA:mRNA is 
the same for all samples.  By normalising to the mean expression of 28S and GAPDH there 
is less chance of a systematic bias but it cannot remove this possibility completely. 
In this study the expression of neither 28S nor GAPDH was significantly different between 
the tissue samples from non β-blocked or β-blocked patients.  There was however, greater 
variability in the expression of 28S when all eight of the non β-blocked tissue samples 
were analysed.  The two tissue samples responsible for this were samples 1 and 6 which 
had lower and higher amounts of 28S product respectively than the other samples from the 
non β-blocked patients.  In order to accurate compare the end products of the PCR 
reactions equal amounts of cDNA from each sample should have been used at the start of 
the PCR reaction.  For all the primer products, least product was consistently found in 
sample 1 and most in sample 6.  This suggests the concentrations of cDNA in the stock 
solutions of these samples were different to that of the other tissue samples although a 
genuine difference in the amount of 28S relative to other the primer products in these 
samples cannot be completely excluded.  An error could have occurred at a number of 
stages.  It was known that a lower concentration of RNA was obtained from sample 1 as 
some of this sample was accidentally discarded during the RNA isolation step.  It is 
possible, therefore, that the measurement of RNA concentration in this sample was less 
accurate potentially affecting the subsequent dilutions of RNA and cDNA.  For sample 6, 
the results of both the spectrophotometry and gel analysis of RNA concentration were 
consistent making it more likely that an error may have occurred in either the calculation 
or pipetting steps involved in making the RNA and/or cDNA dilutions.   For these reasons 
samples 1 and 6 were excluded from all analyses.  
3.5.4 What do mRNA and protein expression actually tell us about 
functional ion channels?  
In this study both Kv4.3 mRNA and protein expression were measured whereas only 
mRNA was measured for Kv4.3 accessory subunits and other ion channels.  By measuring 
mRNA levels for different ion channel subunits it is possible to compare the levels of gene 
expression of these subunits in different tissue samples.  Increased mRNA should indicate 
increased transcription of the corresponding gene and would suggest increased translation 
resulting in increased protein levels.  However, this is not necessarily the case.  While 
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translation of mRNA generally occurs at a constant rate, considerable processing of mRNA 
occurs.  This can result in different splice variants of a protein which may vary 
considerably in structure and function.  Alternations in mRNA levels do not just indicate 
altered gene transcription but may also reflect variations in the stability of the mRNA.  
Increased mRNA degradation under the influence of cAMP has been shown to result in 
decreased expression of the ion channel protein Kv1.1 in a cell line (197).  Two different 
mRNA transcripts with different stabilities have also been detected for another ion channel 
Kv1.4 (197).  
Changes in mRNA expression are not the only way in which protein expression can 
change.  Proteins undergo further processing including structural modifications that may 
include folding, glycosylation, phosphorylation, and association with other proteins 
including accessory proteins to form a functional ion channel.  Any or all of these steps 
may be necessary to produce not only a functional protein but also to prevent protein 
degradation.  While some of the accessory proteins measured in this study can alter the 
functional properties of Kv4.3 some, in particular KChAP, can also modify trafficking of 
Kv4.3 and therefore modify the expression of expression of Kv4.3 at the cell membrane.  It 
should be remembered that simply measuring the amount of Kv4.3 in a cell does not 
necessarily provide information on whether that protein is functional.  
This study shows that chronic β-blockade does not affect the expression of Kv4.3 mRNA 
or protein but what it cannot do is show whether the Kv4.3 expressed in the tissue from 
each group of patients is functionally identical.  It should also be remembered that the 
mRNA and protein for Kv4.3 were not measured in tissue from the same patients due to 
the different requirements for storage and processing of the atrial tissue.  While the 
characteristics of the two patients groups are similar in both the protein and mRNA 
experiments, they are not identical and various patient characteristics including sex, age, 
drugs, heart failure and myocardial ischaemia have been shown to affect ion channel 
expression.  It is possible that small variations in the patient characteristics both between 
the non β-blocked and β-blocked groups and also between the protein and mRNA 
experiments may mask any influence of chronic β-blockade on ion channel expression.  
This study also shows no change in the mRNA expression of various Kv4.3 related 
accessory subunits and several other ion channel pore forming subunits.  As outlined above 
this does not necessarily mean chronic β-blockade does not affect protein expression of 
these subunits.  There was a significant difference in mRNA expression of Kir2.1 with 
higher expression in the tissue from β-blocked patients compared to non β-blocked 
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patients.  This could suggest chronic β-blockade may increases Kir2.1 gene expression or 
change the stability of the mRNA.  It does not necessarily mean that there is increased 
functional Kir2.1 protein expression.  There are several instances of changes in ion channel 
mRNA expression that have not been accompanied by changes in protein expression 
(111;198). 
3.5.5 Can the adrenergic system influence ion channel expression? 
There is very little evidence looking at the effects of β-blockers or the adrenergic system in 
general, on ion channel expression.  To my knowledge the only direct evidence that the 
adrenergic system may play a role in the regulation of potassium ion channel expression is 
from a study in adrenalectomised and catecholamine-depleted rats in which there is a 
decrease in Kv4.2 and 4.3 mRNA (58).  This is clearly a different scenario than that of 
chronic treatment of patients with β-blockers and it is perhaps not surprising, that the 
results of this study do not support my findings.  There is some evidence to suggest β-
blockers can modify the expression of calcium handling proteins.  The treatment of heart 
failure patients with β-blockers has been shown to increase the expression of sarcoplasmic-
reticulum calcium ATPase (SERCA) and phospholamban (199;200).  One of these studies 
also looked at NCX expression and found it unchanged which is in keeping with the results 
of this study although clearly the patient populations are different (199).  There is also 
evidence to suggest β-adrenergic stimulation can increase the expression of Cav1.2 in 
cultured cardiac myocytes and this can be prevented by use of a β-blocker (201;202).  It is 
difficult, however, to make any direct comparisons between these findings and the lack of 
any change in Cav1.2 mRNA expression associated with chronic β-blockade. 
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GENERAL DISCUSSION
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4.1 Electrophysiological and molecular effects of chronic β-
blockade on human atrial potassium currents 
In this work, the electrophysiological and molecular consequences of chronic β-
adrenoceptor antagonist therapy on potassium currents in human atrial tissue were 
examined.  Chronic treatment of patients with β-blockers was found to be associated with a 
reduction in ITO current density in isolated atrial myocytes, but IKSUS density remained 
unchanged.  A reduction in IK1 current density was also demonstrated but only at -120 mV 
and the physiological significance of this change is likely to be minimal.  The reduction in 
ITO density was not due to any changes in its voltage dependency and was not accompanied 
by any change in the time dependent inactivation of the current.  This reduction may 
contribute to the prolongation of the human atrial action potential duration seen in patients 
chronically treated with β-blockers.  The preservation of the ITO reduction even at rapid 
stimulation rates may be an important contributing factor to the ability of β-blockers to 
prevent AF.  The mechanism underlying the reduction in ITO current density associated 
with chronic β-blockade remains unclear. Unlike other examples of ion current 
remodelling, in this case, the reduction in ITO was not due to a reduction in Kv4.3 protein 
or mRNA, nor was it due to changes in expression of mRNA encoding accessory proteins 
known to modify Kv4.3 expression and/or function.  
4.2 Do ion current changes always mirror changes in ion 
channel expression? 
Remodelling of ion currents associated with altered ion channel expression is described in 
a number of different cardiac pathologies including AF, myocardial infarction, hypertrophy 
and heart failure (97;99;203). However, it does not necessarily follow that changes in ion 
currents always reflect a change in expression of ion channel components.  Not all studies 
of these cardiac diseases have demonstrated remodelling of ion channels.  Some studies of 
AF remodelling have not consistently demonstrated changes in IKUR current and ion 
channel expression (2;12;111;112)  while others do not report changes in the expression of 
the main ICaL pore-forming subunit (204;205), despite evidence indicating ICaL remodelling 
(2;9).  In heart failure, remodelling of IK1 does appear to occur but reports of corresponding 
remodelling of IK1 ion channel expression are variable (115;137;138;203;203).  Some 
studies have looked only at ion channel expression and therefore it is not clear whether the 
lack of remodelling of ion channels is accompanied by alterations in ion currents.  There 
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are often many differences between studies of electrophysiological remodelling in cardiac 
disease including the type and species of cardiac myocytes studied, the pathological 
process underlying the cardiac disease along with methodological differences in 
experimental protocols used to study ion currents and ion channel expression.  It can be 
argued that these reasons may account for any discrepancies in ion current or channel 
remodelling between studies.  In general, however, most studies of electrophysiological 
remodelling in cardiac disease do support ion current remodelling as a result of altered ion 
channel expression.  In particular, changes in either pore forming or accessory subunit 
expression are consistently described in situations where there is remodelling of ITO.  
No other studies have looked at β-blocker induced ion current remodelling but at least one 
study has shown involvement of the sympathetic nervous system or endogenous 
catecholamines in potassium current and channel remodelling.  This study suggested 
reduced expression of Kv4.3 and 4.2 was the underlying mechanism responsible for the 
reduction in ITO current density in this setting (58).  
4.3 What is the mechanism underlying β-blocker induced ITO 
reduction? 
There are several possible explanations for the reduction in ITO current density seen in the 
cells from patients chronically treated with β-blockers.  Direct channel block by the drug is 
one possible mechanism although, as discussed in chapter 2, it seems unlikely that drug is 
still present and actively blocking channels after isolation of the cells from atrial 
appendage tissue.  Testing the acute effects of β-blocker application on isolated atrial 
myocytes from non β-blocked patients may give some idea of whether acute channel block 
is possible however, this would not be representative of the situation of a chronically 
treated patient.  As discussed in chapter 3, another possibility is that there is altered 
accessory subunit expression at a protein level reflecting changes in translation rather than 
gene transcription.  There are also a number of ways in which the function of either the 
pore-forming or accessory proteins could be modified within the cell without altering their 
level of expression.  
Direct binding of a ligand, ion or other protein to an ion channel either on the intracellular 
or extracellular side may directly influence the function and activity of the channel.  Some 
potassium channels are modulated by direct ligand interaction eg IKATP and IKACH which are 
non voltage dependent potassium currents that can contribute to repolarisation.  The former 
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is inhibited by the binding of intracellular ATP while the latter is activated by 
acetylcholine binding to coupled G proteins.  However, there is no real evidence to support 
the role of a binding ligand as necessary for the function of Kv4.3 distinct from its 
accessory proteins.  ITO1, as studied in this work, is a calcium independent current and 
therefore not directly modulated by the binding of calcium ions as are some channels 
particularly in non excitable cells.  However, it is possible that calcium ions may influence 
ITO by binding to accessory proteins like KChIP and frequenin which have calcium binding 
motifs (96).  The effects of calcium on the function of these accessory proteins and the 
resultant effect on ITO are unclear although the ability of frequenin to increase ITO density 
appears, in expression systems, to be calcium dependent (206).  
Other common mechanisms by which the function of proteins, including ion channel 
proteins, can be altered or regulated are through changes in pH, intracellular redox state 
and by post-translation modification.  A reduction in ITO density has been shown in animal 
ventricular myocytes in association with inhibition of major redox pathways which 
correlated with decreased Kv4.2 mRNA expression (207).  Exposure to TNFα has also 
been shown to reduce ITO via down-regulation of Kv4.2 expression.  This effect was 
thought to be mediated via the induction of inducible nitric oxide synthase and the 
generation of reactive oxidant species (208). The generation of reactive oxidant species is a 
common feature of many pathological disease states including myocardial ischaemia, 
infarction and heart failure (209) however the incidence of these diseases in this study was 
similar between the β-blocked and non β-blocked patient groups.  It is possible that the 
levels of circulating free catecholamines may have been affected by the chronic use of β-
blockers and excess catecholamines have been shown to undergo auto-oxidation to 
produce free radicals (209).  However, it is unlikely an altered intracellular redox state is 
the underlying mechanism accounting for the chronic β-blocker induced ITO reduction 
since modulation of ITO via oxidant species seems to involve altered expression of ion 
channel genes which was not found to be the case in this study.  
4.3.1 Post-translational modification 
Common mechanisms of post-translational modification of proteins include palmitoylation 
(attachment of fatty acids to cysteine residues of a protein), glycosylation and 
phosphorylation.  These processes can help determine protein folding, transport, 
localisation and turnover at the cell membrane and therefore may directly affect the 
function of pore-forming and or accessory proteins.  Post-translation modification of ion 
channel proteins may be important in determining their localisation to lipid rafts or 
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microdomains within the cell membrane where they can cluster and interact with other cell 
membrane-bound proteins, receptors, signalling molecules and intracellular anchoring 
proteins (210).  Post-translational modification of Kv4.3 has not been studied in great 
detail.  Palmitoylation of KChIP has been reported and may be an important factor in 
determining localisation of KChIP:Kv4.3 complexes to the cell membrane (96;211).  There 
is not much evidence to support an important role for glycosylation in modifying Kv4.3.  
Kv4.x channels do not appear to have the structural motifs for attachments of N-linked 
oligosaccharides and there are no known structural motifs for O-linked glycosylation.  
However, one study has suggested that the removal of a negatively charged sugar residue 
from ventricular myocytes results in a reduction in ITO (96).  
Post translational modification of Kv4.3 by the addition of sugar or fatty acid residues 
could significantly affect its molecular weight and therefore affect detection by techniques 
like Western blotting.  If chronic β-blockade altered the degree of post-translational 
modification of Kv4.3 this would not necessarily have been detected by experiments 
performed in this study.  Further experiments perhaps designed to look at all the bands 
detected by the anti-Kv4.3 antibodies and or the presence of additional structural elements 
within the bands detected could be considered in addition to looking at the expression of 
accessory proteins. Studies could also be performed to look for possible differences in the 
location of Kv4.3 protein within cells from β-blocked and non β–blocked patients perhaps 
using confocal microscopy of cells stained with fluorescent labelled antibodies.  This could 
help determine both the extent of cell surface expression of the Kv4.3 in addition to its co-
localisation with other accessory proteins, and perhaps β-adrenoceptors.  
4.3.1.1 Phosphorylation 
The most common and widely studied mechanism for regulating protein function is that of 
phosphorylation.  The addition or removal of phosphate from amino-acids tyrosine, serine 
and threonine are performed by kinase and phosphatase enzymes respectively.  There is 
considerable evidence indicating ion channel activity can be modulated by protein kinases 
and phosphatases involving either (de)phosphorylation of the channel itself or of second 
messenger systems involved in regulating channel function.  Altered phosphatase activity 
has been proposed as an alternative mechanism to ion channel remodelling to account for 
ICaL remodelling in AF(212).  Phosphorylation also seems to be an important regulatory 
mechanism of ITO.  The long splice variant of human Kv4.3 contains an amino acid 
sequence suitable for interaction and phosphorylation by protein tyrosine kinase C (PKC) 
(191) and activation of PKC has been shown to reduce the current density when this splice 
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variant was expressed in a cell line (154).  Both Kv4.2 and Kv4.3 have sites for interaction 
with other protein kinases and there is experimental evidence that interaction with these 
enzymes can also have functional effects on ITO.  Activation of protein kinase A (PKA) has 
also been shown to reduce ITO by affecting Kv4.2 channel opening in neurons and it is 
thought this effect is mediated via other protein kinases belonging to the ERK/MAPK 
(mitogen activated protein kinase) signalling cascade rather than via direct action of PKA 
on the ion channel.  Modulation of ITO by Kv4.2 phosphorylation via this pathway is 
dependent on the interaction of Kv4.2 with KChIP subunits (213).   
The calcium-calmodulin dependent protein kinase type II (CaMKII) is a calcium activated 
kinase that is highly expressed in heart tissue and plays an important regulatory role in 
intracellular calcium handling and excitation contraction coupling (214).  CaMKII has also 
been shown to be an important modulator of ion channels (215).  CaMKII can alter 
inactivation of ITO and inhibiting this enzyme has been shown to increase the rate of ITO 
inactivation in both cell lines and human atrial myocytes (216;217).  Increasing the rate of 
ITO inactivation would reduce the amount of current available for repolarisation and 
potentially prolong APD. However, in this work no change in ITO inactivation was 
demonstrated.  In contrast, another study in rat myocytes showed increased ITO density 
associated with chronic CaMKII inhibition which might suggest CaMKII activation could 
reduce ITO. (218).  That study did not examine other changes in current characteristics but 
did note that the change in ITO was not associated with any significant increase in ion 
channel associated genes or proteins.  The increase in ITO resulted in net shortening of APD 
despite the increase in ICaL that also occurred.   
While activation of protein kinases has been shown to be important in the regulation of 
gene expression, including recently KChIP2, (219) it is a distinct possibility that direct 
phosphorylation of either Kv4.3 or a related accessory protein by these enzymes could 
underlie the reduction of ITO in this study.  The detection of phosphate residues within 
Kv4.3 bands detected by Western blotting may be possible.  Antibodies to phosphorylated 
Kv4.2 have been used in brain tissue to look for distribution of phosphorylated Kv4.2 and 
it may well be feasible to use similar antibodies for Kv4.3 to look either at sectioned atrial 
appendage tissue or isolated cells.  However, if phosphorylation of Kv4.3 or its accessory 
proteins is the mechanism by which ITO is reduced in this study how does this link with 
chronic β-blockade? 
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4.3.1.2 Phosphorylation and β-adrenoceptors 
There are three types of β-adrenoceptors (β-ARs) with β-AR1 and β-AR2 being the 
predominant subtypes expressed in the human heart.  The ratio of β-AR1:β-AR2 in human 
atrial tissue is approximately 70:30 (220).  The β-ARs are seven transmembrane spanning 
G-protein coupled receptors.  Stimulation of these receptors leads to activation of 
stimulatory G-proteins resulting in production of cyclic adenosine 3’5’ monophosphate 
(cAMP) (221).  CAMP-dependent PKA then phosphorylates a variety of downstream, 
target proteins that can affect myocyte excitation and contraction.  However, the signalling 
mechanisms resulting from activation of β-ARs are more complex than this simple linear 
signalling pathway.  β-ARs can associate with multiple G-proteins and/or other signalling 
pathways particularly when the receptors are chronically activated.  Chronic activation of 
β-AR1 results in desensitisation of cAMP-PKA signalling and activation of CaMKII.  In 
contrast, chronic stimulation of β-AR2 results in a cAMP-PKA dependent switch from 
stimulatory to inhibitory G-protein coupling which can result in activation of a 
phosphoinositide 3-kinase (PI3K) signalling pathway, the ERK branch of the MAPK 
pathway and can inhibit PKA mediated phosphorylation.  In contrast to β-AR signalling, 
agonist activation of α-adrenoceptors (α-ARs) results in the production of inositol 
triphosphate and activation of PKC (221).  
 
In chronically β-blocked patients treated with β1 selective blockers there will be residual 
activation of β-AR2 receptors and α-ARs by endogenous catecholamines.  This potentially 
will result in activation of PKC and ERK (although not via PKA activation) via chronic 
activation of these receptors.  This could therefore result in a reduction in ITO in this patient 
group.  However, in the non β-blocked patients this reduction in ITO might be expected to 
be enhanced by CaMKII activation via chronic β-AR1 stimulation although, to my 
knowledge, there is no direct evidence that CaMKII activation would have this effect.  
 
The signalling pathways involved in β-AR signalling are extremely complex and there is 
interaction at several levels between different pathways from both the same and different 
receptor subtypes.  Clearly there is scope for different signalling pathways to be activated 
in both acute and chronic stimulation and these pathways have the potential to result in the 
direct phosphorylation of Kv4.3, and possibly other accessory proteins which can affect 
ITO.  These processes may be further complicated by the possible downregulation of β-AR 
expression as a consequence of chronic exposure to catecholamines in cardiac disease 
(220).  Linking the reduction in ITO seen in the cells from chronically β-blocked patients in 
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this study to a specific and single signalling pathways is difficult and probably an over 
simplification.  
 
4.3.2 β-adrenoceptors, ITO and calcium 
The reduction in ITO demonstrated in this work may well be the end result of numerous 
interacting factors within the cell which may affect protein trafficking, localisation on the 
cell membrane, phosphorylation and could still reflect changes in the expression of 
accessory genes which have yet to be discovered.  It is likely however that, regardless of 
the mechanism, there is a strong link between the regulation of ITO and calcium handling 
within the cell.  A reduction in ITO would be expected to increase the net influx of calcium 
ions during an action potential due to prolonged activation of ICaL.  This will then have 
knock on effects on intracellular calcium handling including activation of calcium 
dependent enzymes like CaMKII which, in addition to helping regulate ITO, also modulates 
calcium release and re-uptake from the sarcoplasmic reticulum.  This in turn helps 
determine the activity of the sodium calcium exchanger with the resulting current 
contributing directly to terminal repolarisation and therefore APD.  β-ARs can potentially 
interact with this chain at a number of points.  While they may directly affect ITO as already 
discussed it has been long recognised that they play a crucial role in modulating 
intracellular calcium.  This occurs in a number of ways most classically via cAMP-PKA 
mediated phosphorylation of the L-type calcium channel resulting in increased Ca2+ entry.  
Although ICaL current density has been shown not to change in the setting of chronic β-
blockade (29;151) β-AR signalling does affect both calcium related enzymes and the 
expression of calcium handling proteins like SERCA (199).  What comes first, β-AR 
signalling or its block, changes in intracellular calcium or ITO is unclear and very difficult 
to dissect in a human model.   
 
4.4 A clinical perspective 
The mechanism of action of ITO reduction associated with chronic β-blockade may remain 
unclear but this does not detract from the clinical usefulness of this class of drug.  Another 
question that remains unanswered is to what extent the electrophysiological changes 
demonstrated in this work explain the anti-arrhythmic action of β-blockers in preventing 
AF and how might this be exploited?  
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This work has shown that chronic β-blockade can reduce ITO over a range of stimulation 
rates including those equivalent to the rapid atrial rates achieved in atrial fibrillation.  This 
occurs both at steady state in the rate dependency experiments outlined in chapter 2 but 
also following a post rest current as demonstrated during the reactivation experiments.  If 
this ITO reduction results in prolongation of the atrial action potential and ERP at all rates, 
it would result in an increase in the minimal wavelength for re-entry and should be anti-
arrhythmic.  Potentially this could help prevent persistent AF from occurring secondary to 
either short bursts of paroxysmal AF or following pulmonary vein ectopics.  This may help 
to explain the benefits of β-blockers in preventing recurrence or initiation of AF. 
 
The potential anti-arrhythmic effects of β-blocker induced ITO reduction and APD 
prolongation initially seem to be at odds with the pro-arrhythmic, electrophysiological 
remodelling that occurs in AF where a reduction in ITO is associated with shortening of the 
APD.  The key lies in the changes that occur to other ion currents in AF, in particular, the  
reduction in ICaL and increase in IK1 (2;9) which have not been convincingly demonstrated 
in the setting of chronic β-blockade.  This study has not examined the effects of chronic β-
blockade on ion currents or indeed action potentials from patients in AF.  It would be 
interesting to see whether β-blockers counteract the electrophysiological remodelling of 
AF in any way.  This might be over optimistic given that the clinical efficacy of β-blockers 
is to prevent AF or its recurrence rather than cardioverting persistent or permanent AF 
(19). 
 
Another aspect to consider is that APD prolongation is not always anti-arrhythmic.  APD 
prolongation is seen in both heart failure and long QT syndromes which are associated 
with increased risk of ventricular (and sometimes atrial) arrhythmias.  APD prolongation 
can result in early after-depolarisations which can produce premature impulses increasing 
the risk of developing re-entrant arrhythmias.  
 
It is likely that ITO reduction and APD prolongation are not the only anti-arrhythmic 
mechanisms of β-blockers.  By blocking the actions of endogenous catecholamines on β-
adrenoceptors, β-blockers can prevent their potentially pro-arrhythmic actions including 
enhanced automaticity, shortening of the action potential, increased heterogeneity of 
repolarisation, calcium overload, cardiac cell death, fibrosis and ischaemia (222).  The 
contribution of β-blocker induced APD prolongation to the prevention of AF is therefore 
likely to depend on the individual patient, their clinical condition and risk factors for 
developing AF.  This perhaps explains why pre-operative changes in electrophysiology in 
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β-blocked patients are not associated with a reduction in the incidence of AF following 
cardiac surgery despite β-blockers being protective against AF in this setting (151).  High 
levels of endogenous catecholamines due to the stress of surgery, acute cardiac ischaemia 
and the use of inotropic drugs are likely to be the major risk factors for post-operative AF 
and probably outweigh any potential benefit from pre-operative APD prolongation.  It 
should also be remembered that β-blockers only have a modest anti-arrhythmic effect in 
preventing AF and so ITO reduction and APD prolongation must have, at best, a modest 
role to play in the management of AF.  However, it remains important to establish the long 
term electrophysiological consequences of such a commonly administered drug.    
 
I suspect that exploitation of ITO reduction as an anti-arrhythmic treatment for AF is 
therefore a long way from becoming reality.  Its anti-arrhythmic contribution in a real 
world setting is uncertain.  It is far from clear whether ITO reduction is indeed the crucial 
step in the interaction between chronic β-blockade and APD prolongation.  It is possible 
that it simply reflects or is secondary to, yet unrecognised changes in other currents or 
perhaps calcium handling.  Atrial myocytes do not exist in isolation out with an 
electrophysiology experiment and the net effects of both ITO reduction and chronic β-
blockade on whole chamber and indeed whole hearts are unknown.  However, the burden 
of AF to both patients and doctors is significant and is set to increase in the future and only 
by increasing our understanding of both the mechanisms of this arrhythmia and the actions 
of anti-arrhythmic drugs can we hope to impact on this. 
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